SIGN 149 • Risk estimation and the prevention of cardiovascular disease A national clinical guideline June 2017 Evidence KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias High-quality systematic reviews of case-control or cohort studies 2++ High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the 2+ relationship is causal 2- Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion RECOMMENDATIONS Some recommendations can be made with more certainty than others. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the ‘strength’ of the recommendation). The ‘strength’ of a recommendation takes into account the quality (level) of the evidence. Although higher-quality evidence is more likely to be associated with strong recommendations than lower-quality evidence, a particular level of quality does not automatically lead to a particular strength of recommendation. Other factors that are taken into account when forming recommendations include: relevance to the NHS in Scotland; applicability of published evidence to the target population; consistency of the body of evidence, and the balance of benefits and harms of the options. For ‘strong’ recommendations on interventions that ‘should’ be used, the guideline development group is confident that, for the vast majority of people, the intervention (or interventions) will do more good than harm. For ‘strong’ recommendations on R interventions that ‘should not’ be used, the guideline development group is confident that, for the vast majority of people, the intervention (or interventions) will do more harm than good. For ‘conditional’ recommendations on interventions that should be ‘considered’, the guideline development group is confident that the intervention will do more good than harm for most patients. The choice of intervention is therefore more likely to vary R depending on a person’s values and preferences, and so the healthcare professional should spend more time discussing the options with the patient. GOOD-PRACTICE POINTS  Recommended best practice based on the clinical experience of the guideline development group. NICE has accredited the process used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 31 March 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2015 edition (www.sign.ac.uk/sign-50.html More information on accreditation can be viewed at www.nice.org.uk/accreditation Healthcare Improvement Scotland (HIS) is committed to equality and diversity and assesses all its publications for likely impact on the six equality groups defined by age, disability, gender, race, religion/belief and sexual orientation. SIGN guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality aims are addressed in every guideline. This methodology is set out in the current version of SIGN 50, our guideline manual, which can be found at www.sign.ac.uk/sign-50.html The EQIA assessment of the manual can be seen at www.sign.ac.uk/pdf/sign50eqia.pdf The full report in paper form and/or alternative format is available on request from the Healthcare Improvement Scotland Equality and Diversity Officer. Every care is taken to ensure that this publication is correct in every detail at the time of publication. However, in the event of errors or omissions corrections will be published in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk This document is produced from elemental chlorine-free material and is sourced from sustainable forests. Scottish Intercollegiate Guidelines Network Risk estimation and the prevention of cardiovascular disease A national clinical guideline July 2017 Risk estimation and the prevention of cardiovascular disease Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published July 2017 ISBN 978 1 909103 52 8 Citation text Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2017. (SIGN publication no. 149). [July 2017]. Available from URL: http://www.sign.ac.uk SIGN consents to the photocopying of this guideline for the purpose of implementation in NHSScotland. Contents Contents 1Introduction.......................................................................................................................................................................1 1.1 The need for a guideline....................................................................................................................................................................... 1 1.2 Remit of the guideline........................................................................................................................................................................... 2 1.3 Risk estimation.......................................................................................................................................................................................... 4 1.4 Statement of intent................................................................................................................................................................................. 5 2 Key recommendations.....................................................................................................................................................7 2.1 Estimating cardiovascular risk............................................................................................................................................................. 7 2.2Diet................................................................................................................................................................................................................ 7 2.3 Physical activity........................................................................................................................................................................................ 7 2.4Smoking...................................................................................................................................................................................................... 7 2.5 Antiplatelet therapy................................................................................................................................................................................ 7 2.6 Lipid lowering........................................................................................................................................................................................... 7 3 Cardiovascular risk...........................................................................................................................................................8 3.1 Risk factors................................................................................................................................................................................................. 8 3.2 The concept of risk and why it matters............................................................................................................................................ 8 3.3 Risk scoring systems............................................................................................................................................................................... 9 3.4 What is meant by high risk?................................................................................................................................................................. 9 4 Estimating cardiovascular risk.......................................................................................................................................11 4.1 Assessing risk............................................................................................................................................................................................. 11 4.2 Recording risk factor information ..................................................................................................................................................... 11 4.3 Using risk assessment tools.................................................................................................................................................................. 14 4.4 How to determine cardiovascular risk.............................................................................................................................................. 14 5Diet......................................................................................................................................................................................16 5.1 Altering dietary fat intake..................................................................................................................................................................... 16 5.2 Reducing dietary salt ............................................................................................................................................................................. 17 5.3 Fruit and vegetable intake.................................................................................................................................................................... 17 5.4 Effect of specific minor dietary components................................................................................................................................. 17 5.5 Dietary patterns........................................................................................................................................................................................ 19 5.6 Giving dietary advice.............................................................................................................................................................................. 20 5.7 Weight reduction and cardiovascular risk...................................................................................................................................... 20 5.8 Metabolic syndrome............................................................................................................................................................................... 21 6 Physical activity.................................................................................................................................................................22 6.1Definitions.................................................................................................................................................................................................. 22 6.2 Physical activity and cardiovascular risk.......................................................................................................................................... 22 7Smoking..............................................................................................................................................................................26 7.1 Tobacco exposure and cardiovascular risk..................................................................................................................................... 26 7.2 Smoking cessation interventions....................................................................................................................................................... 27 8Alcohol................................................................................................................................................................................32 8.1 Alcohol and cardiovascular risk.......................................................................................................................................................... 32 9 Antiplatelet therapy......................................................................................................................................... 35 9.1 Antiplatelet agents for people with established cardiovascular disease............................................................................ 35 9.2 Antiplatelet agents for people without cardiovascular disease............................................................................................. 36 9.3 Antiplatelet agents for people with diabetes................................................................................................................................ 38 Risk estimation and the prevention of cardiovascular disease 9.4 Antiplatelet agents for people with hypertension ..................................................................................................................... 38 9.5 Antiplatelet agents for people with chronic kidney disease .................................................................................................. 38 10 Lipid lowering....................................................................................................................................................................39 10.1 The role of total and low-density lipoprotein cholesterol in cardiovascular disease...................................................... 39 10.2 Measuring lipid levels............................................................................................................................................................................. 39 10.3 Lowering cholesterol to reduce cardiovascular risk.................................................................................................................... 40 10.4 Statin therapy............................................................................................................................................................................................ 40 10.5 Special considerations........................................................................................................................................................................... 48 10.6 Other lipid-lowering agents................................................................................................................................................................. 51 10.7 Management of combined dyslipidaemia..................................................................................................................................... 55 11 Blood pressure lowering.................................................................................................................................................57 11.1 Blood pressure thresholds for intervention with drug therapy.............................................................................................. 57 11.2 Target values for blood pressure lowering..................................................................................................................................... 62 11.3 Selection of antihypertensive therapy............................................................................................................................................. 64 11.4 Multiple risk interventions.................................................................................................................................................................... 67 12 Psychological issues.........................................................................................................................................................68 12.1 The impact of psychological wellbeing on cardiovascular risk............................................................................................... 68 12.2 Interventions for psychological distress.......................................................................................................................................... 69 13 Provision of information.................................................................................................................................................72 13.1 Sources of further information........................................................................................................................................................... 72 13.2 Checklist for provision of information.............................................................................................................................................. 73 14 Implementing the guideline...........................................................................................................................................74 14.1 Implementation strategy...................................................................................................................................................................... 74 14.2 Resource implications of key recommendations......................................................................................................................... 74 14.3 Auditing current practice...................................................................................................................................................................... 74 14.4 Health technology assessment advice for NHSScotland.......................................................................................................... 75 15 The evidence base............................................................................................................................................................76 15.1 Systematic literature review................................................................................................................................................................. 76 15.2 Recommendations for research......................................................................................................................................................... 77 16 Development of the guideline.......................................................................................................................................78 16.1Introduction............................................................................................................................................................................................... 78 16.2 The guideline development group................................................................................................................................................... 78 16.3 The steering group.................................................................................................................................................................................. 79 16.4 Consultation and peer review............................................................................................................................................................. 80 Abbreviations.................................................................................................................................................................................82 Annexes...........................................................................................................................................................................................85 References......................................................................................................................................................................................99 1 • Introduction 1Introduction 1.1 THE NEED FOR A GUIDELINE Cardiovascular disease (CVD) is an umbrella term that describes a range of conditions caused by blood clots (thrombosis) or build up of fatty deposits inside an artery that cause the artery to harden and narrow (atherosclerosis). The main underlying causes of CVD are coronary heart disease (CHD), stroke, peripheral arterial disease (PAD) and aortic disease. In 2015, 15% of adults aged 16 and over had any CVD condition, which represents an estimated 670,000 people living with cardiovascular disease in Scotland. Both incidence and prevalence of CVD are higher amongst men, the elderly and in deprived areas of Scotland.1 Cardiovascular disease caused more than a quarter of all deaths in Scotland in 2015.2 Of particular relevance to Scotland are the effects of socioeconomic status on the risk of developing CVD. The incidence and mortality rates from acute myocardial infarction in those aged under 65 are higher in deprived areas than in more affluent areas.3-6 Cardiovascular disease has a multifactorial aetiology with a number of potentially modifiable risk factors. The established Framingham risk factors of age, sex, cigarette smoking, blood pressure, total cholesterol and high-density lipoprotein (HDL) cholesterol have proved consistent risk factors in every population studied. In addition, this guideline considers and reports on physical activity and sedentary behaviour. Some ethnic groups may show differences in population baseline risk.7 Scotland’s ethnic population is growing: at the 2011 census around 4% of the country’s 5.3 million people were from minority ethnic backgrounds, double the proportion from the previous census in 2001.8 Recent estimates show that disease incidence rates are falling and, although the reasons for this decline are complex, improvements in the management of risk factors, in particular, a reduction in smoking rates, are significant factors. Between 2005/6 and 2015/6 the age-standardised incidence rate for CVD fell by 13% in men and nearly 16% in women, driven by a significant fall in CHD incidence and a smaller decline in stroke rates.6,9 (ISD Scotland. Personal communication, 13 March 2017). Recognising CVD as a continuum challenges the traditional concepts of primary and secondary prevention, with healthcare professionals adopting a ‘high-risk’ approach to prevention (one which involves the clinical identification of individuals in that portion of the population at highest risk over a defined time period and their intensive treatment through lifestyle or pharmacological means).10 In fact, most cases of CVD occur in the large number of individuals at lower levels of absolute risk.11 High-risk approaches have been facilitated both by the availability of scoring systems to estimate absolute risk (rather than the traditional use of single risk factors) and by the advent of several treatments, principally statins and antihypertensives, which produce marked and apparently independent reductions in CVD risk in people at high risk.12 The guideline has attempted to devise effective strategies for the reduction of CVD that take a combined approach using both ‘high-risk’ and population approaches. 1.1.1 UPDATING THE EVIDENCE This guideline updates SIGN 97: Risk estimation and the prevention of cardiovascular disease to reflect the most recent evidence. Where no new evidence was identified to support an update, text and recommendations are reproduced verbatim from SIGN 97. The original supporting evidence was not re-appraised by the current guideline development group (GDG). |1 Risk estimation and the prevention of cardiovascular disease 1.2 REMIT OF THE GUIDELINE 1.2.1 OVERALL OBJECTIVES This guideline deals with the management of cardiovascular risk, both primary prevention, defined as the potential for intervention prior to the disease presenting through a specified event (any incident linked to critical disruption of blood flow that may cause damage to the heart, brain or peripheral tissues), and secondary prevention, defined as the potential for intervention after an event has occurred. The guideline development group has tried to consider CVD as a continuum from the preclinical to the end-stage disease, potentially offering different opportunities to intervene, both prior to, and after an event, so creating the potential to alter the outcome of the disease process. The guideline development group believes that it is more relevant to consider an individual in terms of whether they have a low or high risk of cardiovascular events rather than in terms of primary or secondary prevention. The guideline provides recommendations on estimation of cardiovascular risk and interventions to reduce this risk in people with and without established CVD. The guideline does not make specific recommendations for the management of people with chronic heart failure, acute coronary syndrome, stable angina or cardiac arrhythmias as these are contained within other SIGN guidelines.13-16 Cardiac rehabilitation is the subject of a further SIGN guideline.17 1.2.2 TARGET USERS OF THE GUIDELINE This guideline will be of interest to healthcare professionals involved in the management of patients with cardiovascular disease including cardiologists, dietitians, general practitioners, lipidologists, pharmacists, physiotherapists, practice nurses, psychologists and public health staff, as well as patients, carers, voluntary organisations and policy makers. 1.2.3 PATIENT VERSION A patient version of this guideline is available from the SIGN website, www.sign.ac.uk 1.2.4 SUMMARY OF UPDATES TO THE GUIDELINE, BY SECTION 1.1 The need for a guideline Updated 1.1.1 Updating the evidence New 1.2.1 Overall objectives Minor update 1.2.2 Target users of the guideline New 1.2.4 Summary of updates to the guideline, by section New 1.3.1 Definitions (risk estimation) Updated 1.3.2 Risk scores Updated 1.4 Statement of intent Minor update 1.4.1 Influence of financial and other interests New 1.4.2 Prescribing of licensed medicines outwith their marketing authorisation New 1.4.3 Health technology assessment advice for NHSScotland Updated 2 Key recommendations New 3.1 Risk factors Updated 3.2 The concept of risk and why it matters Minor update 3.3 Risk scoring systems Completely revised 3.4 What is meant by high risk? Completely revised 4.1 Assessing risk Updated 4.2 Recording risk factor information Updated 4.3 Using risk assessment tools Updated 4.4 How to determine cardiovascular risk Updated 2| 1 • Introduction 5.1.1 Total and saturated fat Updated 5.1.2 Omega-3 supplementation Updated 5.3 Fruit and vegetable intake Minor update 5.4.2 Folate supplementation Completely revised 5.4.3 Stanol esters and plant sterols Updated 5.5 Dietary patterns New 5.6 Giving dietary advice Minor update 5.7 Weight reduction and cardiovascular risk Completely revised 5.8 Metabolic syndrome Updated 6.1 Definitions (physical activity) Updated 6.2.1 Physical inactivity as an independent risk factor Minor update 6.2.2 Levels of physical activity Minor update 6.2.3 Vigorous and high-intensity physical activity New 6.2.4 Risks of sedentary behaviour New 6.2.5 Effects of physical activity on other key risk factors Minor update 7.1.1 Active smoking Minor update 7.2.1 The general population (smoking cessation interventions) Updated 7.2.2 Electronic cigarettes New 7.2.3 Special populations Updated 8.1 Alcohol and cardiovascular risk Updated 8.1.1 Effects of alcohol consumption levels on cardiovascular disease mortality Updated and morbidity 8.1.2 Methods of modifying alcohol consumption Minor update 9.1 Antiplatelet agents for people with established cardiovascular disease Minor update 9.2 Antiplatelet agents for people without cardiovascular disease Completely revised 9.3 Antiplatelet agents for people with diabetes Completely revised 9.4 Antiplatelet agents for people with hypertension Completely revised 9.5 Antiplatelet agents for people with chronic kidney disease New 10.1 The role of total and low-density lipoprotein cholesterol in cardiovascular Minor update disease 10.2 Measuring lipid levels Updated 10.3 Lowering cholesterol to reduce cardiovascular risk Updated 10.4.1 The effects of statins on LDL cholesterol Completely revised 10.4.2 The effects of statins on cardiovascular end points New 10.4.3 Statin therapy for individuals without cardiovascular disease Updated 10.4.4 Statin therapy for individuals with established cardiovascular disease Completely revised 10.4.5 Safety of statin therapy Updated 10.4.6 Reported intolerance to statin therapy New 10.4.7 Benefits and harms of statin therapy New 10.5.1 People with diabetes Updated 10.5.2 Familial hypercholesterolaemia Updated 10.5.4 Older people Updated 10.5.5 Sex New 10.5.6 Chronic kidney disease New 10.6.1 Bile acid sequestrants Minor update 10.6.2 Ezetimibe Updated |3 Risk estimation and the prevention of cardiovascular disease 10.6.3 Fibrates Updated 10.6.4 Nicotinic acid Updated 10.6.5 PCSK9 inhibitors New 10.7 Management of combined dyslipidaemia Updated 11.1 Blood pressure thresholds for intervention with drug therapy Updated 11.1.1 Blood pressure thresholds for individuals with symptomatic cardiovascular Completely revised disease 11.1.2 Blood pressure thresholds for individuals without symptomatic Completely revised cardiovascular disease 11.1.3 Blood pressure thresholds for specific groups at high cardiovascular risk New 11.2 Target values for blood pressure lowering Updated 11.2.1 Type 2 diabetes New 11.2.2 Chronic kidney disease New 11.2.3 Dialysis New 11.2.4 Conclusions (target values for blood pressure lowering) New 11.3 Selection of antihypertensive therapy Minor update 11.3.1 The British Hypertension Society algorithm Updated 12.1 The impact of psychological wellbeing on cardiovascular risk Updated 12.2.1 Psychological interventions Updated 12.2.2 Pharmacological interventions for depression New 13 Provision of information Updated 14 Implementing the guideline Updated 1.3 RISK ESTIMATION For many health professionals the calculation of absolute cardiovascular risk is the starting point for the development of CVD prevention strategies. 1.3.1DEFINTIONS Absolute risk is also known as total risk or global risk. This risk is defined as the percentage chance of an individual having a CVD event over a given period of time, for example a ten-year risk of 20%. The specific factors used to estimate absolute risk in the ASSIGN (Assessing cardiovascular risk using SIGN guidelines to ASSIGN preventive treatment) score are age, sex, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, family history of premature CVD, diagnosis of diabetes, diagnosis of rheumatoid arthritis and deprivation (see section 3.3 for further information on ASSIGN). While these are the most significant risk factors which predict cardiovascular risk, other risk calculators include a wide range of other factors including antihypertensive treatment, atrial fibrillation, chronic kidney disease, ethnicity and body mass index. Relative risk refers to the risk of someone who has risk factors having a CVD event compared with an individual of the same age and sex without risk factors. In a similar way, results from randomised intervention trials may be presented as absolute or relative changes to the outcomes of interest, depending on whether the result from participants within the trial who received the intervention is subtracted from the result of those who do not receive the intervention (absolute effect) or divided by it (relative effect). Although the relative effects of a treatment is the same regardless of baseline risk, patients with a lower baseline risk will have a lower absolute chance of benefiting and a lower residual risk. Patients with a greater baseline risk will have a greater absolute chance of benefiting but also a greater residual risk. While absolute event rates can be useful to communicate the impact of a treatment to patients, trial selection may influence the apparent rates due to differences in baseline risk in the populations, and so the potential benefits or hazards when the trial results are applied in current practice may be different. 4| 1 • Introduction 1.3.2 RISK SCORES Risk scores cannot perfectly predict absolute risk. They are extremely useful in assessing or estimating risk and in prioritising treatment on an equitable basis. In Scotland, absolute CVD risk is usually calculated from electronic decision support tools based on the ASSIGN algorithm (see section 3.3). 1.4 STATEMENT OF INTENT This guideline is not intended to be construed or to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement should only be arrived at through a process of shared decision making with the patient, covering the diagnostic and treatment choices available. It is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be documented in the patient’s medical records at the time the relevant decision is taken. 1.4.1 INFLUENCE OF FINANCIAL AND OTHER INTERESTS It has been recognised that financial interests in, or close working relationships with, pharmaceutical companies may have an influence on the interpretation of evidence from clinical studies. It is not possible to completely eliminate any possible bias from this source, nor even to quantify the degree of bias with any certainty. SIGN requires that all those involved in the work of guideline development should declare all financial interests, whether direct or indirect, annually for as long as they are actively working with the organisation. By being explicit about the influences to which contributors are subjected, SIGN acknowledges the risk of bias and makes it possible for guideline users or reviewers to assess for themselves how likely it is that the conclusions and guideline recommendations are based on a biased interpretation of the evidence. Signed copies of declaration of interests forms are retained by the SIGN Executive and a register of interests is available in the supporting material section for this guideline at www.sign.ac.uk 1.4.2 PRESCRIBING OF LICENSED MEDICINES OUTWITH THEIR MARKETING AUTHORISATION Recommendations within this guideline are based on the best clinical evidence. Some recommendations may be for medicines prescribed outwith the marketing authorisation (MA) also known as product licence. This is known as ‘off-label’ use. Medicines may be prescribed ‘off label’ in the following circumstances: yy for an indication not specified within the marketing authorisation yy for administration via a different route yy for administration of a different dose yy for a different patient population. An unlicensed medicine is a medicine which does not have MA for medicinal use in humans. Generally ‘off-label’ prescribing of medicines becomes necessary if the clinical need cannot be met by licensed medicines within the marketing authorisation. Such use should be supported by appropriate evidence and experience.18 “Prescribing medicines outside the conditions of their marketing authorisation alters (and probably increases) the prescribers’ professional responsibility and potential liability”.18 |5 Risk estimation and the prevention of cardiovascular disease The General Medical Council recommends that when prescribing a medicine ‘off label’, doctors should: yy b e satisfied that such use would better serve the patient’s needs than an authorised alternative (if one exists) yy be satisfied that there is sufficient evidence/experience of using the medicines to show its safety and efficacy, seeking the necessary information from appropriate sources yy record in the patient’s clinical notes the medicine prescribed and, when not following common practice, the reasons for the choice yy take responsibility for prescribing the medicine and for overseeing the patient’s care, including monitoring the effects of the medicine. Non-medical prescribers should ensure that they are familiar with the legislative framework and their own professional prescribing standards. Prior to any prescribing, the licensing status of a medication should be checked in the summary of product characteristics (www.medicines.org.uk). The prescriber must be competent, operate within the professional code of ethics of their statutory bodies and the prescribing practices of their employers.19 1.4.3 HEALTH TECHNOLOGY ASSESSMENT ADVICE FOR NHSSCOTLAND Specialist teams within Healthcare Improvement Scotland issue a range of advice that focuses on the safe and effective use of medicines and technologies in NHSScotland. The Scottish Medicines Consortium (SMC) provides advice to NHS boards and their Area Drug and Therapeutics Committees about the status of all newly-licensed medicines and new indications for established products. NHSScotland should take account of this advice and ensure that medicines accepted for use are made available to meet clinical need where appropriate. In addition, Healthcare Improvement Scotland reviews Multiple Technology Appraisals (MTAs) produced by the National Institute for Health and Care Excellence (NICE) and provides advice about their applicability in NHSScotland. If Healthcare Improvement Scotland advises that MTA guidance is applicable in Scotland, NHSScotland should take account of this and ensure that recommended medicines and treatment are made available to meet clinical need where appropriate. NICE MTAs deemed valid for NHSScotland supersede extant SMC advice as they are generally underpinned by a larger and more recent evidence base. SMC advice and NICE MTA guidance relevant to this guideline are summarised in section 14.4. 6| 2 • Key recommendations 2 Key recommendations The following recommendations were highlighted by the GDG as the key clinical recommendations that should be prioritised for implementation. 2.1 ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered at high risk of cardiovascular events: yy established cardiovascular disease, or yy stage 3 or higher chronic kidney disease or micro- or macroalbuminuria, or yy familial hypercholesterolaemia, or yy who are over the age of 40 and have diabetes, or yy who are under the age of 40 and have diabetes, and – at least 20 years duration of disease, or – target organ damage (eg proteinuria, micro- or macroalbuminuria, proliferative retinopathy or autonomic neuropathy), or – significantly elevated cardiovascular risk factors. 2.2DIET R Patients, and individuals at risk of cardiovascular disease, who are overweight or obese, should be targeted with interventions designed to reduce weight by at least 3 kg, and to maintain this reduction. 2.3 PHYSICAL ACTIVITY R Physical activity of at least moderate intensity (eg breathing faster than normal) is recommended for the whole population (unless contraindicated by an individual’s condition). 2.4SMOKING R All people who smoke should be advised to stop and offered support to help facilitate this in order to minimise cardiovascular and general health risks. 2.5 ANTIPLATELET THERAPY R Aspirin is not recommended for primary prevention of cardiovascular disease. 2.6 LIPID LOWERING R Adults who are assessed as being at high cardiovascular risk, but with no established CVD, should be offered treatment with atorvastatin 20 mg/day following an informed discussion of risks and benefits between the individual and their responsible clinician. In those already taking an alternative regimen due to reported intolerance with atorvastatin, there is no need to change their current regimen. |7 Risk estimation and the prevention of cardiovascular disease 3 Cardiovascular risk 3.1 RISK FACTORS The INTERHEART study assessed the importance of risk factors for coronary artery disease worldwide.20 Nine measured and potentially modifiable risk factors accounted for more than 90% of the proportion of the risk for acute myocardial infarction. Smoking, history of hypertension or diabetes, waist:hip ratio, dietary pattern, physical activity, alcohol consumption, blood apolipoproteins and psychosocial factors were identified as the key risk factors. The effect of these risk factors was consistent in men and women across different geographic regions and by ethnic group. The British Regional Heart Study also found that smoking, blood pressure and cholesterol accounted for 90% of attributable risk of CHD.21 Worldwide, the three most important modifiable and causal cardiovascular risk factors are smoking, hypertension and abnormal lipids. Further risk factors which are modifiable and causal include obesity, diabetes, poor diet, alcohol intake, and physical activity. Psychosocial factors may contribute directly and indirectly to cardiovascular risk. Age, sex, ethnicity and genetics, although not modifiable, also contribute to risk in a multiplicative way. Cardiovascular risk factors do not differ widely across populations (although their relative contributions to risk may).22 Taken together, all risk factors contribute to absolute cardiovascular risk which is directly modifiable both by lifestyle interventions and pharmacological treatment. 3.2 THE CONCEPT OF RISK AND WHY IT MATTERS Most cardiovascular deaths will occur in individuals at moderate risk as they constitute the largest group. High-risk individuals will have the most to gain from risk factor modification and historically are given the highest priority in clinical practice.23 When estimating risk total CVD outcomes, rather than CHD end points, should be used to encompass stroke prevention as well as CHD prevention. Stroke deaths are underestimated using traditional CHD end points.7 Not all current risk-prediction systems accurately predict the different risk profiles that exist in different ethnic groupings and cultures. For example, a risk score derived from white European cohorts may substantially overpredict the risk in a Chinese population.24 CVD risk prediction based on absolute risk is now advocated for treatment decisions for lipid-lowering therapy, antihypertensives and, in people with atrial fibrillation, for warfarin. 3.2.1 PREDICTING RISK Intervention studies have shown that while relative risk reduction may remain broadly constant, absolute risk reduction varies considerably because it is a function of the initial level of baseline risk (see section 1.3.1). Consider the example in Table 1 of a man with a baseline risk of a cardiovascular event of 10% over ten years who takes effective preventive treatment and lifestyle measures. His risk falls by a third, a relative risk reduction of 33.3%, while his absolute risk is reduced to 6.7%, an absolute risk reduction (ARR) of 3.3%. If another man with a higher baseline absolute risk of 30% takes the same effective treatments his risk also falls by about a third to 20%. However, his absolute risk reduction is 10%. Relative risk reductions in CHD events in the statin trials appear similar regardless of baseline risk and baseline cholesterol.25 This would support the concept that the best way to target patients is to calculate absolute risk. Table 1: Example illustrating absolute and relative risk reductions Post-treatment Baseline ten-year Relative risk reduction ten-year absolute risk Absolute risk reduction absolute risk of CVD of CVD 10% 33% 6.7% 3.3% 30% 33% 20% 10% 8| 3 • Cardiovascular risk Overprediction of CVD risk means that people with less to gain potentially become patients and are exposed to the risks of lifelong pharmacological treatment. Underprediction means that people with much to gain may not be offered preventive treatment. The best way to target patients for risk reducing interventions is to estimate absolute risk. 3.3 RISK SCORING SYSTEMS The concept of risk scoring for CVD is now well established worldwide in high- and middle-income countries, based and extended from the original Framingham risk score in the US.26,27 Since 2007, the ASSIGN score has been used in Scotland to identify individuals at highest risk of CVD. ASSIGN was tailored to the Scottish population by inclusion of social deprivation and family history of premature CVD as additional CVD risk modifiers. In so doing, when implemented, ASSIGN was world leading and its approach helped classify more people with a positive family history and who are socially deprived as being at high risk. When used in Scotland it attenuated a large social gradient in future CVD sufferers not identified for preventive treatment by the Framingham cardiovascular score.28 It therefore improved social equity, although overall discrimination of future events was not greatly improved.29 Since then, other risk scores have copied this approach and implemented social factors into their risk score as well as other important risk modifiers which meaningfully improve risk prediction. Most notably, the Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) risk score, based on the QRISK2 algorithm developed for use in England and Wales, now includes a measure of social class as well as family history of premature CVD.30 It has also added blood pressure treatment, rheumatoid arthritis, and presence of atrial fibrillation as risk modifiers, together with ethnicity, diabetes and chronic kidney disease. Importantly, it has introduced additional metrics such as an estimate of years to be gained from preventive treatments based on when lipid lowering, blood pressure treatment or smoking cessation is started, as well as heart age and other useful outputs which may improve patient understanding of their risks and therefore their motivation and adherence to treatment. Whilst ASSIGN was innovative in 2007, there is now scope to improve its performance and presentation in light of more recent developments in risk scoring. 3.4 WHAT IS MEANT BY HIGH RISK? In addition to more comprehensive scoring systems with greater functionality, the greatest change to risk scoring is defining the level of risk of CVD deemed high enough to merit intervention. Currently in Scotland, high risk is defined as asymptomatic individuals without established CVD (or other conditions which confer automatically high cardiovascular risk) who are estimated to be at 20% or greater risk of a cardiovascular event over the next 10 years. In 2014, based on economic modelling, NICE recommended that the risk threshold for statin initiation be reduced to a blanket 10% threshold so that all individuals with more than a 1 in 10 chance of having a heart attack or stroke in the next 10 years are considered at high risk and offered statin therapy.31 Whilst this approach identifies the proportion of the population which is cost effective to treat, it is less clear how the additional workload within primary care to implement this policy is accounted for. Similarly, the societal ramifications of this new threshold effectively placing almost all people in England and Wales above 65 years of age at high risk of CVD were not explored. There is a strong age gradient in CVD events; hence the vast majority of older people are classified as being at high risk. In Scotland, almost 95% of individuals are at 10% or greater risk of a cardiovascular event within ten years by the age of 60–64. Implementing this threshold in Scotland would increase the total number eligible for preventive treatment by around 70% to over 1.3 million. There is increasing recognition that the age at which statin therapy is commenced may dictate a patient’s capacity to benefit in terms of life years gained. Essentially, the later one starts treatment, the lower the capacity to gain extra life years, and vice-versa. This effect is partly explained by competing risks so that in older individuals, the chances of dying from a cause other than CVD increases. For example, in the PROSPER trial, where the average participant was 75 years of age when pravastatin was commenced, an average of 3.2 years of therapy provided long-term protection against CHD events and CHD mortality but did not increase life expectancy, possibly due to competing mortality with deaths from other causes.32 Such an effect should |9 Risk estimation and the prevention of cardiovascular disease be contrasted with the long-term results from the WOSCOPS trial which found that five years of pravastatin treatment in 45 to 64-year old Scottish men maintained improved survival resulting from decreased mortality from cardiovascular causes and an ongoing reduction in cardiovascular hospital admissions over 20 years.33 The focus on short-term risk has been driven by a number of factors. Firstly, this strategy identifies individuals most likely to benefit from drug therapy in the short term, thereby maximising the cost effectiveness of (sometimes expensive) medications. Additionally, most trials of CVD risk-factor intervention are of short duration with limited data regarding the long-term effects of pharmacological therapy. Consequently, it can be argued that short-term risk assessment translates more directly than long-term risk assessment into clinical interactions and  decision making. However, given that age is heavily weighted in most risk calculators, modest elevations in risk factors have little effect on short-term risk among men aged <45 and women aged <65 years.34 The current short-term emphasis of risk estimation aims to help reduce the risk of individuals experiencing a CVD event. However, this approach also focuses attention on individuals who, most likely, already have advanced atherosclerosis. The complications of atherosclerosis occur most commonly in individuals aged >50 , but the pathophysiological processes begin in childhood and mainly result from the effects of modifiable risk factors; cholesterol, blood pressure, and smoking as well as their lifestyle determinants, including poor diet and physical inactivity.35 A pooled survival analysis of several large observational studies of individuals free from CVD showed that even though approximately 40% of individuals with optimal risk factor levels at age 55 eventually had a CVD event by age 95 years, their age at onset of total CVD was an average of 8 to 14 years later than individuals with at least two major risk factors. Maintenance of optimal risk factors through ages 45–65 may not guarantee a life free from total CVD, but it increases the probability that more years will be lived free of CVD.36 Therefore, there is significant scope for widespread benefits at a population level if prevention efforts and risk factor modification could begin before the age of 50 and the widespread development of atherosclerosis. These findings are particularly important for individuals who, by virtue of clinical features associated with increased vascular burden (for example hypertension or hypercholesterolaemia), are likely to be at greater risk of cardiovascular events measured across their lifetime, compared with individuals without such factors, but by virtue of younger age, or absence of other risk factors do not reach the short-term (ten-year) threshold for preventive treatment. In view of concerns about lowering the risk threshold and in order to explore options to normalise the effects of age on short-term risk, the GDG has considered alternatives to a fixed 10% CVD risk threshold. These include a measure of capacity to benefit (through life expectancy metrics) or adopting differential thresholds at different ages, with lower treatment thresholds at younger ages and higher thresholds at higher ages. The latter approach would tend to identify younger individuals at higher trajectories of risk. It would also mean that not all elderly individuals are necessarily recommended for preventive therapy. This approach was introduced in Norway in 2009 and arguments have recently been made in support of age-differentiated risk thresholds, noting that this approach can improve the sensitivity and specificity of statin guidelines.37,38 Additional work is necessary to assess these alternatives. It is clear that any new approach needs evaluation and must be backed up with economic analysis, be fully implemented into an online risk scoring system (updating the ASSIGN risk score, as necessary), and be acceptable and liked by patients and doctors. This work is outwith the scope of this guideline. Consequently, the current ASSIGN CVD risk scoring system remains in place and the 20% treatment threshold unchanged. This guideline will be updated when a new algorithm for risk scoring and new thresholds are available. 10 | 4 • Estimating cardiovascular risk 4 Estimating cardiovascular risk 4.1 ASSESSING RISK Treatment decisions are based on the likelihood that an individual will have a cardiovascular event over a given period of time. Assessment of absolute cardiovascular risk is the starting point for discussions between healthcare professionals and patients who are potentially at significant risk of a cardiovascular event. The prevention of cardiovascular events is the goal of treatment. This guideline uses many of the risk assessment strategies outlined in JBS3.30 4 The following individuals should be offered an assessment of cardiovascular risk at least every five years: yy all adults aged 40 years or above, and yy individuals at any age with a first-degree relative who has premature atherosclerotic CVD or familial dyslipidaemia. The following groups of people should be assumed to be at high risk and do NOT require risk assessment with a scoring system: yy p eople with established cardiovascular disease (including previous myocardial infarction, acute coronary syndrome, revascularisation, stroke, transient ischaemic attack, aortic aneurism, peripheral arterial disease or those with significant plaque on coronary angiography or carotid ultrasound) yy people with stage 3 or higher chronic kidney disease (CKD), or micro- or macroalbuminuria yy people with familial hypercholesterolaemia yy people with diabetes over the age of 40 years yy people with diabetes under the age of 40 years with – a long duration of diabetes (20 years), or – micro- or macroalbuminuria, or – proliferative retinopathy or autonomic neuropathy, or – significant other risk factors​in the view of the healthcare professional. 4.2 RECORDING RISK FACTOR INFORMATION Cardiovascular risk is the product of the effect of several risk factors. Individual risk factors can cluster together in significant patterns and tend to have a multiplicative effect on an individual’s total cardiovascular risk.39 Measuring any single risk factor will usually not adequately estimate total cardiovascular risk. | 11 Risk estimation and the prevention of cardiovascular disease 4.2.1 TAKING A CLINICAL HISTORY The following items of information should be collected routinely when assessing cardiovascular risk.30 Table 2: Items to include in a clinical history for cardiovascular risk assessment Risk factor Rationale for measurement age Cardiovascular risk increases with age. sex Other factors being equal, men are at higher risk of a cardiovascular event. lifetime smoking habit Categorising an individual’s smoking status as current smoker or non- (and number of cigarettes smoker is insufficient for the calculation of accurate CVD risk. A current smoked per day) smoker may have less lifetime exposure to tobacco and less associated cardiovascular damage than an ex-smoker. The CVD risk of an ex-smoker is likely to be intermediate between a current smoker and a lifelong non- smoker. family history of In people with a family history of clinically-proven cardiovascular disease cardiovascular disease (angina, myocardial infarction, transient ischaemic attack, or ischaemic stroke) in a first-degree relative (parent, sibling) before the age of 60 years, the risk of a coronary event is approximately doubled.40 ethnicity Rates of cardiovascular disease vary considerably between ethnic groups which may reflect increased susceptibility and differential exposure to risk factors (see section 4.3). socioeconomic status For given levels of other risk factors, populations which are more deprived have a higher CVD risk. ASSIGN uses the Scottish Index of Multiple Deprivation calculated via linkage to postcode of residence to measure socioeconomic status. Regular physical activity has both preventive and therapeutic effects on many chronic conditions such as CHD and stroke.41 Although not included as a risk factor in the ASSIGN algorithm, discussing levels of activity can help to prioritise intervention in those who are not meeting current targets (see section 6.2). Healthcare professionals should also be aware of potential psychosocial issues during CVD risk assessment as these have the potential to modify management decisions (see section 12). 12 | 4 • Estimating cardiovascular risk 4.2.2 CLINICAL MEASUREMENTS The following should be measured when assessing cardiovascular risk.30 Table 3: Factors that should be measured for cardiovascular risk assessment Risk factor Rationale for measurement blood pressure Systolic blood pressure should be measured according to the NICE/British Hypertension Society (BHS) guideline.42 The mean systolic pressure measured over two separate occasions should be used to calculate risk. In individuals taking antihypertensive medication the most recently recorded pretreatment value should be adopted. weight and body Individuals with a body mass index (BMI) >30 kg/m2 have a 40-fold increased mass index risk of developing diabetes and a two to three-fold increased risk of CHD43,44 and stroke compared with individuals with a normal BMI (≤25 kg/m2).45 Although not included as a risk factor in ASSIGN, these data may be used to inform lifestyle interventions and monitor risk reduction. cholesterol Total cholesterol (TC), HDL cholesterol and triglyceride should be measured in a laboratory from a random (non-fasting) sample of blood. A fasting sample with calculated LDL cholesterol is needed when a diagnosis of familial hypercholesterolaemia (FH) is being considered (see section 10.5.2). The accuracy of measuring HDL cholesterol in the context of high triglyceride levels may be compromised. Intercurrent illness may also affect circulating lipid levels. diabetes Diabetes confers, on average, twice of the risk of cardiovascular events compared with those without the disease. Furthermore, risks escalate with duration of diabetes so that lifetime risks are high, especially in those who develop diabetes at a younger age. Consequently, risk estimation is not recommended for individuals with diabetes and many will be directly eligible for preventive treatment (see section 4.1). For individuals without a diagnosis of diabetes but with risk factors (for example, obesity, hypertension, dyslipidaemia, family history of diabetes or specific ethnicities) a range of validated tools may be used to screen for the presence of diabetes (glycated haemoglobin (HbA1c), fasting plasma glucose measurement or oral glucose tolerance testing).46 Glycated haemoglobin is not suitable for the diagnosis of type 1 diabetes or diabetes in pregnant women.47 rheumatoid arthritis Individuals with rheumatoid arthritis (RA) are at significantly increased risk of cardiovascular events.48,49 People with RA, within the QRESEARCH database, had an elevated CVD risk independent of other risk factors, with adjusted hazard ratios (HR) of 1.50 (95% confidence interval (CI) 1.39 to 1.61) in women and 1.38 (95% CI 1.25 to 1.52) in men, respectively.50 renal function Individuals with CKD are at significantly increased risk of cardiovascular events.51,52 To aid the differential diagnosis of CKD, renal function should be estimated from glomerular filtration rate (eGFR). An eGFR <60 ml/min/1.73 m2 is indicative of stage 3 CKD and such individuals do not require risk estimation but should have aggressive interventions to reduce their risk of cardiovascular events. Albuminuria at any level above the normal threshold of 30 mg/g confers cardiovascular risk and warrants preventive treatment.52 | 13 Risk estimation and the prevention of cardiovascular disease 4.3 USING RISK ASSESSMENT TOOLS The ASSIGN cardiovascular risk assessment tool allows clinicians to estimate ten-year risk of CVD events in asymptomatic individuals with no clinical evidence of cardiovascular disease. The calculation of risk will be via a computer-based desktop tool. Computer programs give a more precise estimate of risk than charts, presenting risk as a continuous variable rather than a threshold, such as ≥20%.53 True CVD risk will be higher in the following groups than the results indicated by risk estimation tools which do not include these in prediction algorithms: yy those with atrial fibrillation yy those from specific minority ethnic groups (eg, Indian, Pakistani, Bangladeshi or other Asian, see Table 4) yy women with premature menopause. In some ethnic minorities, risk tools under- and overestimate CVD risk, because they have not been validated in these populations. For example, in people originating from the south Asian subcontinent it is safest to assume that the CVD risk is higher than predicted from most scoring tools. Adjusted hazard ratios for cardiovascular disease have been calculated in ethnic groups within the cohort study underpinning the QRISK2 tool (see Table 4 and section 3.3).50 The ASSIGN risk tool incorporates family history as a risk factor which may account for some of the excess CVD risk of individuals from some ethnic minorities. Table 4: Adjusted hazard ratios (95% CI) for cardiovascular disease in subgroups of the derivation cohort of QRISK2 Ethnic group Women Men White/not recorded 1 1 Indian 1.43 (1.24 to 1.65) 1.45 (1.29 to 1.63) Pakistani 1.80 (1.5 to 2.17) 1.97 (1.70 to 2.29) Bangladeshi 1.35 (1.06 to 1.72) 1.67 (1.40 to 2.01) Other Asian 1.15 (0.86 to 1.54) 1.37 (1.09 to 1.72) Black Caribbean 1.08 (0.94 to 1.24) 0.62 (0.53 to 0.73) Black African 0.58 (0.42 to 0.82) 0.63 (0.47 to 0.85) Chinese 0.69 (0.44 to 1.10) 0.51 (0.32 to 0.83) 4.4 HOW TO DETERMINE CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered at high risk of cardiovascular events: yy established cardiovascular disease, or yy stage 3 or higher chronic kidney disease or micro- or macroalbuminuria, or yy familial hypercholesterolaemia, or yy who are over the age of 40 and have diabetes, or yy who are under the age of 40 and have diabetes, and – at least 20 years duration of disease, or – target organ damage (eg proteinuria, micro- or macroalbuminuria, proliterative retinopathy or autonomic neuropathy), or – significantly elevated cardiovascular risk factors. RAsymptomatic individuals should be considered at high risk if they are assessed as having a ≥20% risk of a first cardiovascular event within ten years. RCardiovascular risk assessment should be offered at least once every five years in adults over the age of 40 years with no history of cardiovascular disease, familial hypercholesterolaemia, CKD or diabetes and who are not being treated to reduce blood pressure or lipids. 14 | 4 • Estimating cardiovascular risk RIndividuals at high cardiovascular risk should be supported to make lifestyle changes and be offered drug therapy, to reduce their absolute risk. 99 onsider an annual review to discuss lifestyle modification, medicines adherence and address CVD C risk factors. Frequency of review may be adapted to the individual. 99 ther risk factors not included in the CVD risk prediction should be taken into account when assessing O and managing a person’s overall CVD risk. These may include: ethnicity, body mass index, atrial fibrillation, psychological wellbeing and physical inactivity. Some individuals will have extreme values of single risk factors. Although absolute risk takes several risk factors into account, possession of such a ‘lighthouse’ risk may mandate intervention.54 Single risk factors in this range include total cholesterol ≥8 mmol/l (see section 10.5.2) or elevated blood pressure (systolic 2++ pressure ≥160 mm Hg or diastolic pressure ≥100 mm Hg, or lesser degrees of hypertension with associated 4 target organ damage (see section 11).55,56 In these cases, whilst treatment is aimed at the single elevated risk factor, the reduction of global risk is the ultimate goal. Management of other risk factors is also important, especially where the key risk factor proves refractory. | 15 Risk estimation and the prevention of cardiovascular disease 5Diet Environmental factors, including diet, play an important role in the development of CHD. The diet of any individual is related to other lifestyle factors (smoking, exercise, etc). Randomised controlled trials of diet are able to eliminate such bias but are more difficult to conduct than those of drugs or supplements. National reporting has indicated little progress in meeting the Scottish dietary goals over the period 2001 to 2012.57 5.1 ALTERING DIETARY FAT INTAKE 5.1.1 TOTAL AND SATURATED FAT A Cochrane review of 48 trials of at least six months duration examined the effect of reduction of total and saturated fat in the diet on reducing serum cholesterol levels and on total and cardiovascular mortality and morbidity.58 Saturated fat reduction (through total dietary fat reduction and/or replacement of saturated 1++ with unsaturated dietary fat) may be protective of cardiovascular events overall, reducing them by 14% (risk ratio (RR) 0.86, 95% CI 0.77 to 0.96, 24 comparisons, 65,614 participants). However, there were no clear effects of dietary fat changes on total mortality (RR 0.98, 95% CI 0.93 to 1.04, 71,790 participants) or cardiovascular mortality (RR 0.94, 95% CI 0.85 to 1.04, 65,978 participants). The dietary reference value for saturated fat in the UK, which represents the maximum contribution that saturated fat should make to the population average intake for those aged five years and over, is 11%.59 The average healthy man and woman require around 2,500 calories and 2,000 calories respectively to maintain their weight, although estimates for individuals may vary depending on age, metabolism and levels of physical activity. The recommended maximum intake of saturated fat translates to around 30 g/day for men and 20 g/day in women. R Diets low in saturated fats should be recommended to all for the reduction of cardiovascular risk. 99 .. The average man should aim to consume no more than 30 g of saturated fat per day. The average woman should aim to consume no more than 20 g of saturated fat per day. 5.1.2 OMEGA-3 SUPPLEMENTATION There is no clear evidence that increased consumption of omega-3 fats, suggested as the protective element of oily fish consumption, reduces CVD when consumed as supplements. In a meta-analysis of RCTs examining the effects of omega-3 fatty acid for sudden cardiac death (SCD) prevention in patients with cardiovascular + 1 disease, benefits were only observed in patients receiving suboptimal medical management. In patients treated according to guidelines, omega-3 fatty acids did not reduce the risk ratio of SCD (RR 0.96, 95% CI 0.84 to 1.10).60 The impact of statins, aspirin, angiotensin converting enzyme (ACE) inhibitors and antiplatelet agents (reflecting current medical management) removed any benefit from the omega-3 fatty acid supplements. In a meta-analysis of trials in adults with or at high risk of CVD, no clear effect from omega-3 fatty acids was reported on composite cardiovascular outcomes (RR 0.96, 95% CI 0.90 to 1.03), total mortality (RR 0.95, 95% CI 0.86 to 1.04), non-vascular mortality (RR 0.97, 95% CI 0.84 to 1.11), coronary events (RR 0.86, 95% CI, 0.67 to 1.11) or revascularisation (RR 0.95, 95% CI 0.89 to 1.00). There was also no evidence of benefit for 1+ cerebrovascular events (RR 1.03, 95% CI 0.92 to 1.16) or arrhythmia (RR 0.99, 95% CI 0.85 to 1.16). Omega-3 fatty acids did protect against vascular death (RR 0.86, 95% CI 0.75 to 0.99) but not sudden death (RR 1.00, 95% CI 0.75 to 1.33) which reflects the effects from omega-3 oils in those with CVD without current medical management. Adverse events were more common in those taking omega-3 fatty acids than placebo (RR 1.18, 95% CI 1.02 to 1.37), and were mainly gastrointestinal.61 16 | 5 • Diet Current dietary guidelines suggest consumption of two 140 g portions of fish per week, one of which should 4 be an oily fish.62 R Omega-3 fatty acid supplements should not be offered for reduction of CVD risk. 99 s fish consumption may help to reduce intake of (saturated) fat from meat, and may have a role in A reducing fatal CHD with low risk of adverse effects, individuals should be advised to follow Government dietary guidelines to consume two 140 g portions of fish per week, one of which should be an oily fish. 5.2 REDUCING DIETARY SALT A meta-analysis of 28 trials on the effect of moderate salt reduction on blood pressure demonstrated that a modest reduction in salt intake for four or more weeks has a significant effect on blood pressure in both hypertensive and normotensive individuals. The pooled estimates of blood pressure fall were 4.96/2.73 ± 0.40/0.24 mm Hg in hypertensive patients (p<0.05).63 A Cochrane review of salt restriction for the prevention of CHD cited too few cardiovascular events in the trials, of at least six months duration, to make a clear conclusion. It did report a small but significant reduction in systolic blood pressure in participants who had followed a salt-restricted diet and reductions were greater 1+ in subgroups with hypertension.64 Another Cochrane review of advice to reduce salt intake lasting at least six months also reported small but significant benefits to blood pressure. Long-term maintenance of low- sodium diets was difficult for individuals, even with considerable advice, support and encouragement.65 The Food Standards Agency has recommended that adults should consume no more than 6 g of salt per day (approximately equivalent to one teaspoonful).66 4 RPeople with hypertension should be advised to reduce their salt intake as much as possible to lower blood pressure. 99 All individuals should aim to consume less than 6 g of salt per day. 5.3 FRUIT AND VEGETABLE INTAKE Diets with at least 400 g of fruit and vegetables (equivalent to five portions) per day are recommended in Scotland.58 Two systematic reviews of cohort studies examined the benefits of fruit and vegetable consumption for the reduction of CHD risk. There is evidence from one review supporting increased vegetable (RR 0.77) 2++ and fruit (RR 0.86) intake to reduce CHD event rates,67 and a 15% reduction in relative risk of CHD for those 2+ consuming high levels of fruit and vegetables compared with those consuming low levels (equivalent to a fourfold increase in fruit and doubling of vegetables) in another.68 RIncreased fruit and vegetable consumption is recommended for the entire population to reduce cardiovascular risk. 5.4 EFFECT OF SPECIFIC MINOR DIETARY COMPONENTS 5.4.1 ANTIOXIDANT VITAMIN SUPPLEMENTATION Several systematic reviews of RCTs were identified that investigated the association between vitamin supplementation and prevention of CHD. One systematic review of 84 RCTs found that neither supplements of vitamin E alone nor given with other agents yielded a statistically significant beneficial or adverse pooled 1++ relative risk for all-cause mortality, cardiovascular mortality, fatal or non-fatal myocardial infarction or reduction in blood lipids.69 Another meta-analysis of RCTs of vitamin supplementation identified a lack of any statistically significant or clinically important effects of vitamin E on cardiovascular disease.70 A meta-analysis examining the effect of vitamin E dose on all-cause mortality identified that high-dose (≥400 international units per day) vitamin E increased all-cause mortality by 39 per 10,000 individuals treated 1++ (95% CI 3 to 74 per 10,000; p<0.035). Low-dose trials did not significantly reduce all-cause mortality.71 | 17 Risk estimation and the prevention of cardiovascular disease The US Preventive Services Task Force guideline investigated evidence on the role of antioxidant supplementation in reducing the incidence of or progression to CHD. The guideline found little evidence that 4 any single vitamin supplementation (vitamin A, vitamin C, vitamin E, β-carotene), combined antioxidants or multivitamins had a benefit on primary or secondary prevention.72 RAntioxidant vitamin supplementation is not recommended for the prevention or treatment of coronary heart disease. 5.4.2 FOLATE SUPPLEMENTATION A Cochrane review of 12 RCTs of at least one year follow up in 47,429 participants at risk of, or with, established CVD found no effect of homocysteine-lowering interventions (vitamins B6, B9 or B12, alone on in any combination) compared with placebo, on non-fatal or fatal myocardial infarction (MI) (RR 1.02, 95% CI 0.95 1 ++ to 1.10), stroke (RR 0.91, 95% CI 0.82 to 1.00), death by any cause (RR 1.01, 95% CI 0.96 to 1.07) or serious adverse events (cancer) (RR 1.06, 95% CI 0.98 to 1.13).73 A systematic review and meta-analysis of 16 RCTs of folic acid supplementation compared with placebo found no effect of supplementation on major cardiovascular events (RR 0.98, 95% CI 0.93 to 1.04), stroke (RR 0.89, 95% CI 0.78 to 1.01), MI (RR 1.00, 95% CI, 0.93 to 1.07), or deaths from any cause (RR 1.00, 95% CI + 1 0.96 to 1.05). Moreover, folic acid as compared with placebo also had no effect on the following secondary outcomes: risk of revascularisation (RR 1.05, 95% CI 0.95 to 1.16), acute coronary syndrome (RR 1.06, 95% CI 0.97 to 1.15), cancer (RR 1.08, 95% CI 0.98 to 1.21), vascular death (RR 0.94, 95% CI 0.88 to 1.02), or non- vascular death (RR 1.06, 95% CI 0.97 to 1.15).74 RHomocysteine-lowering interventions (folate or B-vitamin supplementation) are not recommended for the prevention or treatment of cardiovascular disease. 5.4.3 STANOL ESTERS AND PLANT STEROLS Stanol esters and plant sterols are present in small amounts in normal diets, and can be supplemented using dietary products, such as certain margarines and yoghurt drinks. Two systematic reviews provide evidence that they can reduce low-density lipoprotein (LDL) cholesterol.75,76 In the larger review which included 41 RCTs, 2 g per day supplements of stanol esters and plant sterols led to a 10% reduction in LDL cholesterol.75 + 1 There was no benefit from further dosage increases. In a cross-over RCT carried out in Colombia, subjects 1- with a BMI <25 kg/m2 demonstrated a larger total cholesterol reduction during treatment with 8 g plant 1++ stanol esters per day compared with placebo than those with BMI ≥25 kg/m2 (18.5 mg/dl, 8.6% v 12.6 mg/dl, 5.8%). LDL reduction showed the opposite trend where falls were smaller in those with lower BMI (11.3 mg/dl, 9.6% in those with BMI <25 kg/m2) and (12.8 mg/dl, 11.0% in those with BMI ≥25 kg/m2).77 There is no evidence on whether these reductions in cholesterol persist into the longer term and whether they translate to reduction in CVD events. There is an absence of long-term data (more than five years) on their safety. 5.4.4NUTS There is limited evidence from two RCTs that consuming certain nuts may improve lipid profiles, reducing serum cholesterol by up to 0.4 mmol/l.78,79 The trials were small with short-term follow up only, and involved consuming large amounts of unsalted nuts, which may be unrealistic for the general population in Scotland: 1 + Twenty per cent of the calorie intake was derived from nuts (averaging about 75 g/day).The effects of nut consumption in the context of a Mediterranean diet is discussed in section 5.5. There is insufficient evidence to support a recommendation. 18 | 5 • Diet 5.4.5 SOYA INTAKE Soya-based foods are an important constituent in many vegetarian diets and have been investigated for possible beneficial effects on lipid profiles. Two small randomised trials, have suggested that substitution of moderate to large amounts of soya-based foods into the diet may have a small impact in lipid profiles.80,81 1- Consuming 50 g of soya protein a day (in the form of burgers) was reported to reduce total cholesterol by 0.4 mmol/l. There is insufficient evidence to support a recommendation. 5.5 DIETARY PATTERNS Mediterranean diets are generally characterised as having moderate fat intake (where the main sources of added fat are olive oil and unsalted nuts), being rich in vegetables and fruits and low in red meat (with poultry and fish replacing beef and lamb). There is no universal definition nevertheless there is a wide range of diets described as Mediterranean or having features of Mediterranean diets. Some interventions induced weight loss, making the impact of dietary changes alone difficult to estimate. A Cochrane review of RCTs which randomised participants to at least three months of advice to follow a Mediterranean-style dietary pattern or provision of dietary factors relevant to a Mediterranean diet compared with no or minimal intervention included 52,044 adult participants from the general population with or without CVD. Overall, modest lowering of total cholesterol (-0.16 mmol/l, 95% CI -0.26 to -0.06) and 1++ LDL cholesterol (-0.07 mmol/l, 95% CI -0.13 to -0.01) were observed with the interventions. Clinical events were reported in only one trial. The Women’s Health Initiative of 48,835 postmenopausal women, while not described as a Mediterranean diet incorporated increased fruit and vegetable and cereal intake. No statistically significant effects from the intervention were seen on fatal and non-fatal end points at eight years.82 A meta-analysis of six RCTs (n=3,650) comparing Mediterranean diet patterns with low-fat diets (≤30% energy from fat) with two years follow up in overweight or obese adults at high risk of CVD reported greater reductions in weight (2.2 kg, 95% CI 3.9 to 0.6) systolic (1.7 mm Hg, 95% CI 3.3 to 0.05) and diastolic blood pressure 1+ (1.5 mm Hg, 95% CI 2.1 to 0.8) and total cholesterol 0.19 mmol/l (95% CI 0.26 to 0.11) with Mediterranean diet patterns, but there was no usual diet comparator and the greater weight loss in the Mediterranean diet patterns means that it is unclear whether the risk factor changes were mediated by weight loss or the Mediterranean diet patterns themselves.83 A more recent RCT (PREDIMED) randomised 7,447 individuals aged 50–80 who were at high risk of CVD to one of two Mediterranean diet pattern (Med) arms, either with additional unsalted nuts (around 30 g per day) (n=2,554) or additional extra virgin olive oil (EVOO) (around 30 g per day consumed) (n=2,543) or to a control low-fat diet (n=2,450). Advice was energy unrestricted and mean baseline BMI ranged from 29.7–30.2 kg/m2. Median follow up was 4.8 years. A primary end-point event (MI, stroke and death from CVD) occurred in 288 1++ participants in total across all arms. Multivariable-adjusted hazard ratios were 0.72 (95% CI 0.54 to 0.96) and 0.70 (95% CI 0.54 to 0.92) for the Med diet with additional nuts and EVOO, respectively, compared with the control group. Total mortality was not different between Med diet groups and control. Subgroup analysis by BMI category suggested that the greatest benefit may occur in overweight and obese individuals (HR 0.51, 95% CI 0.37 to 0.71) compared with those at normal weight (HR 1.04, 95% CI 0.71 to 1.54) or underweight (HR 0.69, 95% CI 0.29 to 1.67). Weight change is not reported.84 A prospective cohort analysis of the PREDIMED study, where the exposure was olive oil, divided participants into energy-adjusted tertiles of their self-reported total olive oil and EVOO consumption prior to intervention. Those in the highest tertile of total olive oil and EVOO consumption had an estimated 35% (HR 0.65, 95% CI 0.47 to 0.89) and 39% (HR 0.61, 95% CI 0.44 to 0.85) reduction in cardiovascular events (ARR 1% and 1.9%, 2++ respectively). Higher total olive oil consumption was associated with a 48% relative reduction in risk of cardiovascular mortality (HR 0.52, 95% CI 0.29 to 0.93, ARR 0.4%). These associations suggest that greater consumption of olive oil was associated with reduced mortality risk, making olive oil a key element of the Mediterranean diet pattern.85 | 19 Risk estimation and the prevention of cardiovascular disease Altering glycaemic index of the diet is another approach to changing dietary pattern. A systematic review and meta-analysis of RCTs comparing low and high glycaemic index diets reported that studies of at least 20 1++ weeks’ duration, but some in excess of one year, showed no significant effects on total or LDL cholesterol.86 Given that individuals with established CVD are at increased absolute cardiovascular risk compared with individuals without CVD but estimated to be at high risk and with similar characteristics, the recommendation for Mediterranean diet can be extrapolated to this group. RAdopting a Mediterranean diet pattern supplemented with 30 g extra virgin olive oil or unsalted nuts per day is recommended for adults at high risk of CVD or with established CVD. The Eatwell Guide defines the UK Government’s advice on healthy eating and is a visual representation of how different foods contribute towards a healthy balanced diet (see Annex 2). Its recommendations support the components of a Mediterranean diet pattern. 99 se the Eatwell Guide to help individuals make informed choices around the selection of dietary U components and their optimal proportions which conform to Mediterranean diet patterns and support restricting saturated fat, sugars and salt intake. 5.6 GIVING DIETARY ADVICE Randomised trials have shown that dietary advice can have effects on self-reported dietary intake as well as objective risk factors. Most evidence on beneficial effects is for patients with cardiovascular disease rather than those estimated to be at higher risk. These effects reduce with time,87 although, in one study a measurable effect persisted for six to nine years.88 5.6.1 WHO SHOULD GIVE DIETARY ADVICE? In one systematic review dietitians were better than doctors at lowering cholesterol through dietary advice 1++ alone, but there were no significant differences between dietitians and nurses or self-help resources.89 5.6.2 HOW SHOULD DIETARY ADVICE BE GIVEN? A variety of methods has been attempted varying from brief advice to comprehensive multifactorial lifestyle interventions. In one RCT, up to two hours of counselling achieved greater effects than 10 minutes of counselling, but the differences were small.90 In another RCT, 14 group sessions (90 minutes each) during one year increased self-reported fruit and vegetable intake and reduced self-reported fat intake, but without 1+ ++ 1 significant changes to lipid profiles.91 One RCT found that telephone coaching led to a 10% reduction in total and LDL cholesterol.92 The intervention involved five telephone calls over 24 weeks and included assessment to establish knowledge, explanation, assertiveness training, goal setting, and reassessment. Length of telephone calls varied, but median times were 20 minutes for the first call and 10 minutes for subsequent calls. 99 I nterventions to improve diet should be based on educational competencies (improved knowledge, relevance, individualisation, feedback, reinforcement and facilitation). 5.7 WEIGHT REDUCTION AND CARDIOVASCULAR RISK Four systematic reviews of lifestyle intervention (diet and/or physical activity) to reduce weight which evaluated effects on blood pressure were identified.93-96 Interventions which reduced weight by 3–11 kg were moderately effective in reducing blood pressure, with reductions in systolic blood pressure (SBP) of around 1 mm Hg per kg weight lost. 2+ 1+ Three systematic reviews evaluated the effects on blood lipids of moderate weight loss through lifestyle 1++ intervention.93-95 Weight loss of at least 3 kg led to reductions in LDL cholesterol of approximately 0.2–0.3 mmol/l. There were insufficient data to determine the effects of lifestyle-mediated weight loss on morbidity or mortality outcomes. 20 | 5 • Diet One systematic review comparing the effects of bariatric surgery with non-surgical interventions in RCT or cohort studies reported a substantially (~50%) lower risk of CVD events and mortality with surgery.97 Another systematic review of RCTs comparing bariatric surgery (>25 kg weight loss) with non-surgical interventions 2++ reported greater diabetes remission with surgery, both in a complete case analysis (relative risk 22.1, 95% 1++ CI 3.2 to 154.3), and in a conservative analysis assuming diabetes remission in all non-surgically-treated individuals with missing data (relative risk 5.3, 95% CI 1.8 to 15.8).98 Thus, the data suggest that substantial (surgically-induced) weight loss may reduce morbidity and mortality. RPatients, and individuals at risk of cardiovascular disease, who are overweight or obese, should be targeted with interventions designed to reduce weight by at least 3 kg, and to maintain this reduction. 99 Patients’ weight should be measured annually. 5.8 METABOLIC SYNDROME The metabolic syndrome is characterised by insulin resistance and visceral obesity and is associated with hypertension, impaired glucose handling, lipid abnormalities and a variety of more subtle metabolic anomalies. Previously, metabolic syndrome criteria were proposed as a way to simultaneously predict diabetes and cardiovascular risk. However, the fact that people with metabolic syndrome are at increased risk of cardiovascular disease events or diabetes does not mean that the construct is useful for risk prediction 3 in itself or compared with other approaches. Evidence now indicates that metabolic syndrome performs relatively poorly for risk prediction compared with established risk predictors for each condition in clinical practice, highlighting that these established risk predictors and not metabolic syndrome should be used for this purpose.99 Importantly, relevant information can be easily collected at the same time for the prediction of both conditions, with measurement of HbA1c in non-fasting individuals thought to be at elevated risk of diabetes, at the same time that lipids are checked. | 21 Risk estimation and the prevention of cardiovascular disease 6 Physical activity Regular activity has both preventive and therapeutic effects on many chronic conditions such as CHD, stroke, 4 cancer, musculoskeletal disorders, obesity, diabetes and mental-health problems.41 6.1DEFINITIONS Physical activity has been defined as any bodily movement that results in energy expenditure.100 Physical activity can be categorised as occupational (physical activity at work), leisure time (non-occupational physical activity), exercise (physical activity that is structured and done for a specific reason) and active living (for example non-recreational walking, housework and gardening). Physical activity is commonly described as having four dimensions: duration (for example minutes, hours), frequency (for example times per week or month), intensity (for example rate of energy expenditure) and type (for example walking, gardening, swimming).101 For most people, the easiest and most acceptable forms of physical activity are those that can be incorporated into everyday life. Examples include walking or cycling.41 Exercise intensity can be defined (or monitored) using a number of indices including percentage of maximal heart rate (HRmax), percentage of maximal oxygen uptake (VO2max), rate of energy expenditure (reported in metabolic equivalents (METS), or multiples of resting metabolic rate), self-reported rating of perceived exertion (RPE) or talk test. Table 5: Classification of absolute and relative exercise intensity Absolute Relative intensity intensity Intensity HRmax (%) VO2max (%) RPE METs Talk Test Very light to <57–63 <37–45 9–11 1.5<3 Conversation light uninhibited Moderate 64–76 46–63 12–13 3<6 Conversation possible Vigorous 77–95 64–90 14–17 6<9 Conversation harder but possible High to ≥96 ≥91 ≥18 ≥9 Conversation difficult maximum to impossible Table adapted with permission from Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al; American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc.2011;43(7):1334-59. The table refers to the general population. Examples of activities undertaken at each intensity, can be found be found in Annex 3. Sedentary behaviour is defined as non-sleeping activities in a sitting or reclining posture with energy expenditure ≤1.5 METS.102 6.2 PHYSICAL ACTIVITY AND CARDIOVASCULAR RISK 6.2.1 PHYSICAL INACTIVITY AS AN INDEPENDENT RISK FACTOR Ten observational studies that examined the association of physical activity with CVD, after controlling for other key risk factors, were identified. All studies (or specific elements of the studies) confirmed an inverse relationship between physical activity and the risk of a coronary event.20,103-111 22 | 6 • Physical activity Effect sizes ranged from non-significant relationships for specific types of activity (for example active commuting; hazard ratio for cardiovascular mortality=1.08, 95% CI 0.95 to 1.23)104 to highly significant associations (for example men who ran for an hour or more per week had a 42% risk reduction, RR 0.58, 95% CI 0.44 to 0.77, ARR 0.3%) compared with men who did not run (p<0.001).111 One well-conducted case-control 2++ study reported a multivariate odds ratio (OR) of 0.51 (95% CI 0.29 to 0.90) when comparing low levels of occupational physical activity against higher levels.103 Similar results were reported for leisure time activity. This suggests that physical activity can reduce the risk of a coronary event, when all other major risk factors are controlled for, by as much as a half. There is also evidence that reduced cardiorespiratory fitness (ie the ability of the body to use oxygen to do physical work), which is improved by increasing physical activity, is a risk factor for CVD.112,113 6.2.2 LEVELS OF PHYSICAL ACTIVITY The types of activity, durations, frequencies and intensities included in the ten studies varied greatly. This lack of consistency makes it difficult to draw conclusions in relation to the exact type, quantity and quality of activity required for a benefit. The evidence indicates that activities of moderate intensity are protective. For example, INTERHEART, one of the largest case-control studies of its kind, reported a reduced incidence of myocardial infarction from activities that included walking, cycling or gardening (OR 0.86, 95% CI 0.76 to 0.97).20 In another study that 2++ compared distance walked per day, those who walked less than 0.25 miles per day had double the risk of CHD mortality or morbidity of those who walked more than 1.5 miles per day (RR 2.3, 95% CI 1.3 to 4.1) which represented an increase in the absolute risk of incidence of CHD of 2.6% across two to four years of follow up.105 The evidence also suggests a dose-response relationship for both intensity and duration. For example, a study of postmenopausal women showed that women in increasing quintiles of energy expenditure measured in METS had adjusted relative risks of total CVD of 1.00, 0.89, 0.81, 0.78 and 0.72, respectively (p for trend 2+ <0.001).109 The reduction in absolute risk of CVD between the lowest and highest quintiles of physical activity was 0.5%. Similar trends exist for duration of exercise.106 The type of activity appears to be relatively unimportant. For example, one good-quality study reported 2++ comparable effects for both occupational and leisure time activity.103 Activity may not need to be continuous to be of benefit. One study reported that after accounting for total energy expended on physical activity and potential confounders, duration of activity did not have an 2+ independent effect on CHD risk (p trend=0.25); that is, longer sessions of exercise did not have a different effect on risk compared with shorter sessions, as long as the total energy expended was similar.108 6.2.3 VIGOROUS AND HIGH-INTENSITY PHYSICAL ACTIVITY One systematic review and four RCTs were identified comparing the effects of vigorous- and high-intensity physical activity with moderate-intensity physical activity on cardiovascular disease risk factors and cardiorespiratory fitness (VO2max)114-118 These consistently reported greater improvements in VO2max with vigorous- and high-intensity exercise. There was mixed evidence on whether vigorous- or high-intensity physical activity resulted in greater improvements on CVD risk factors, with one study showing greater blood 1+ pressure reductions with high-intensity compared with moderate-intensity physical activity in patients with hypertension.117 Another reported clinically marginal but statistically significant greater benefits in reducing HbA1c, triglycerides and total cholesterol, but not in other risk factors or CHD risk scores for vigorous- compared with moderate-intensity physical activity in patients with type 2 diabetes.114 Other studies reported no differences between physical activity intensity groups for blood pressure and lipid changes in patients with heart failure, or after revascularisation.115,116,118 In a systematic review of exercise-based rehabilitation in patients with heart failure, withdrawal of exercising patients from studies decreased with increasing exercise intensity. The relative risk for the composite end 1+ point of death or hospitalisation was 0.86 (95% CI 0.79 to 0.94, p=0.001) in patients undertaking a vigorous- intensity physical-activity intervention compared with control groups.115 | 23 Risk estimation and the prevention of cardiovascular disease The potential risks of adverse events associated with vigorous- and high-intensity exercise have been evaluated in a number of studies, all of which reported that risks were extremely low. In an RCT of 303 patients with type 2 diabetes, no significant difference in adverse events between moderate- and vigorous-intensity physical-activity interventions over 12 months was reported.114 In a systematic review of patients with heart failure no deaths were directly attributable to exercise in 123,479 patient hours of training (including 7,223 1+ hours of high-intensity and 84,655 hours of vigorous-intensity physical activity).115 In patients undergoing cardiac rehabilitation, rates of cardiac events were low for both moderate- and high- intensity exercise (1 per 129,456 training hours for moderate-intensity exercise and 1 per 23,182 hours for high-intensity exercise).119 In a meta-analysis of observational studies of vigorous physical activity in the general population the absolute risk increase associated with an hour of additional physical activity per week was 2 to 3 per 10,000 person years for MI and 1 per 10,000 person years for SCD.120 This risk was reduced in those undertaking habitual ++ 2 physical activity (by 47% for each additional physical activity session per week for MI and 30% for each additional session per week for SCD). Thus, the benefits of physical activity (see sections 6.2.1 and 6.2.2) far outweigh the risks of an adverse event and vigorous-intensity physical activity can be regarded as safe. 6.2.4 RISKS OF SEDENTARY BEHAVIOUR A systematic review of prospective observational studies suggested that high levels of total sedentary behaviour are associated with higher risk of CVD and mortality.121 The relative risk of being in the highest compared with lowest population groups of sedentary behaviour was 2.47 (95% CI 1.44 to 4.24) for CVD, 1.90 (95% CI 1.36 to 2.66) for CVD mortality and 1.49 (95% CI 1.14 to 2.03) for all-cause mortality. Many, but not all, of the studies included in this meta-analysis adjusted for physical activity or energy expenditure, 2++ + 2 suggesting that high levels of sedentary behaviour may be associated with additional CVD risk at any level of physical activity. However, a recent meta-analysis suggests that undertaking very high levels of physical activity (more than one hour per day of moderate to vigorous physical activity) eliminates the association between excess sitting and CVD risk.122 Evidence for the risks associated with occupational sitting is less consistent, with about half of studies suggesting greater risk of CVD and two thirds of studies suggesting greater risk of all-cause mortality 2+ associated with high levels of sitting.123 Due to the observational nature of these data causality between sedentary behaviour and CVD or mortality cannot be definitively ascribed. Nevertheless, there are data which associate adverse changes + 2 to cardiometabolic risk factors with short-term imposition of sedentary behaviour, suggesting a potential mechanistic link between sedentary behaviour and CVD risk.124 Although definitive evidence from long-term RCTs of benefits of reducing sedentary behaviour is lacking, given that the harms associated with reducing sedentary behaviour are negligible, it would be prudent to provide general advice to minimise periods of prolonged sitting in line with current UK physical activity guidance.41 RPhysical activity of at least moderate intensity (eg breathing faster than normal) is recommended for the whole population (unless contraindicated by an individual’s condition). RPhysical activity may include occupational and/or leisure-time activity and should incorporate accumulated bouts of moderate-intensity activities such as brisk walking. RThose who are moderately active and are able to increase their activity should be encouraged to do so. Activity can be increased through a combination of changes to intensity, duration or frequency. 24 | 6 • Physical activity RThose who are already moderately active without contraindication can safely be encouraged to undertake vigorous-intensity exercise to achieve additional benefits. RIndividuals should be advised to minimise the amount of time spent being sedentary (sitting) over extended periods. 99 ll patients, irrespective of health, fitness or activity level, should be encouraged to increase activity A levels gradually. The evidence reviewed and corresponding recommendations are in general agreement with nationally recognised recommendations that state all adults should:41 yy a im to be active daily. Over a week, activity should add up to at least 150 minutes (2.5 hours) of moderate- intensity activity in bouts of 10 minutes or more, or 75 minutes of vigorous-intensity activity. 4 yy undertake physical activity to improve muscle strength (such as weight training, carrying heavy load, heavy gardening, push ups or sit ups) on at least two days a week. Older adults (aged 65 years and older) at risk of falls should incorporate physical activity to improve balance and co-ordination on at least two days a week. All children and young people should engage in moderate- to vigorous-intensity physical activity for at least 60 minutes and up to several hours every day. National guidance is available on the most effective way to promote physical activity.125,126 6.2.5 EFFECTS OF PHYSICAL ACTIVITY ON OTHER KEY RISK FACTORS Several meta-analyses provide evidence for a significant effect on CHD risk factors from exercise. One meta-analysis combined the results of 28 RCTs of mainly healthy white adults.127 Despite a large degree of variability, endurance exercise training had a favourable influence overall on the blood lipid profile relative to future risk of CHD. The most commonly observed lipid change in all weight categories in relation to endurance training was a significant (p<0.05) increase in HDL cholesterol. Reductions in LDL cholesterol 1+ (-5.0%, p<0.05), triglycerides (-3.7%, p<0.05), and total cholesterol (-1%, not significant) were observed less frequently (independent of dietary interventions). There was a marked inconsistency in response of blood lipids. Twenty-four of 51 studies showed an increase in HDL cholesterol but the range over all studies was from -5.8% to +25%. It was not possible to establish a dose-response relationship between duration, intensity or frequency of exercise and blood lipid response. A further meta-analysis of 54 trials showed that previously sedentary adults could decrease systolic blood pressure by 3.8 mm Hg (95% CI 2.7 to 5.0 mm Hg, p<0.001) with regular aerobic exercise.128 Exercise lowered blood pressure in people who were normotensive or hypertensive; overweight or of normal weight; and 1+ black, white, or Asian. The blood pressure reductions tended to be less marked in trials with longer follow- up periods, most likely because adherence to the intervention programme decreased over time. All forms of exercise studied appeared to be effective in reducing blood pressure. There was no relation between the frequency or intensity of the exercise and the clinical result. | 25 Risk estimation and the prevention of cardiovascular disease 7Smoking 7.1 TOBACCO EXPOSURE AND CARDIOVASCULAR RISK This section summarises the evidence describing the relationship between tobacco exposure and cardiovascular health and focuses on cessation interventions for the vulnerable population subgroup of people with depression. No relevant evidence was identified for interventions in ethnic subgroups. 7.1.1 ACTIVE SMOKING Tobacco smoking is strongly and dose-dependently associated with all cardiovascular events, including CHD, stroke, PAD and cardiovascular death.129,130 Smoking cessation reduces these risks substantially, although the decrease is dependent on the duration of cessation.131,132 Men who smoke are three times more likely to die aged 45–64 and twice as likely to die aged 65–84 than non-smokers.129 Studies done in women during 2++ the 1950s and 1960s reported relative risks for total mortality ranging from 1.3 to 1.4. Smokers in the Nurses’ 4 Health Study were at nearly 1.9 times the risk compared with people who have never smoked.133 In the Million Women’s Study, those smoking at baseline had a mortality rate ratio of 2.76 (95% CI 2.71 to 2.81) compared with never smokers after 12 years. There was an average lifespan difference between the two groups of 11 years.134 The additional risk of cardiovascular disease conferred by smoking is mediated by the number of cigarettes smoked. A large case-control study noted the strong relationship between risk of MI and number of cigarettes 2++ smoked, with individuals who smoked over 40 cigarettes per day having almost ten times the relative risk of MI as non-smokers (OR 9.16, 99% CI 6.18 to 13.58).20 The proportion of adults (aged 16 and over) who smoke in Scotland has been falling consistently in recent years. In 2003, 28% of adults in Scotland smoked compared with 21% in 2015. Over the same period, the proportion of all adults who have never smoked, or have never smoked regularly, increased from 50% to 55%. Among all smokers aged 16 and over, there was also a significant fall over time in the mean number of cigarettes smoked per day from a mean of 16.7 per day in 1995 to 12.6 in 2015.1 The prevalence of regular (at least weekly) smoking among 13 year olds has decreased since 1994 from 11% to 2% among boys and from 10% to 2% among girls. Among 15 year old children, the prevalence of regular smoking has decreased from 30% in 1996 to 7% in 2015 in both boys and girls. Smoking prevalence is currently at its lowest rates since records began in 1982.135 There is evidence that young people can become addicted to tobacco very quickly136 and many want to stop smoking.137 99 Priority should be given to identifying and supporting young people to help them stop smoking. The prevalence of smoking is highest amongst those on low incomes. Amongst some groups smoking rates as high as 75% have been reported.138 Regular smokers are less likely than non-smokers to live in the least deprived areas.135,139 99 riority should be given to developing programmes and targeting smokers on low incomes to stop P smoking, recognising the particular difficulties experienced by this group of smokers. A prospective cohort study of over 120,000 males suggested that smoking cigars increases risk of early death from CHD.140 The association between cigar smoking and death from CHD was stronger among younger men and current rather than former smokers, as is observed with cigarette smoking. No increased risk was 2++ observed among current cigar smokers aged 75 or older, or for former cigar smokers of any age. For men younger than 75 who were current cigar smokers at baseline, the adjusted rate ratio for CHD mortality was 1.30 (95% CI 1.05 to 1.62). 26 | 7 • Smoking A case-control study, involving 587 individuals who smoked cigarettes with differing known tar yields and 2,685 controls, indicated that smoking higher-yield cigarettes is associated with an increased risk of MI. The study revealed a dose-response relationship between total tar consumption per day and MI.141 The odds 2+ ratios for individuals smoking medium- and high- compared with low-tar-yield cigarettes were 1.86 (95% CI 1.21 to 2.87) and 2.21 (95% CI 1.47 to 3.34), respectively. RAll people who smoke should be advised to stop and offered support to help facilitate this in order to minimise cardiovascular and general health risks. 7.1.2 PASSIVE SMOKE EXPOSURE Several systematic reviews and observational studies provide evidence that exposure to environmental tobacco smoke (ETS) is associated with CVD events. In 2015, 12% of children in Scotland lived in accommodation in which someone smoked inside (down from 19% in 2012 and 16% in 2013 and 2014). However, a lower proportion (6%) of children were reported to be exposed to second-hand smoke in their home (down from 12% in 2012).1 One systematic review calculated that environmental exposure to tobacco smoke causes an increase in relative risk of CHD of around 25%. It is of similar magnitude to the effects of exposure to ETS on lung cancer, but the number of excess deaths from heart disease compared with lung cancer will be far greater in non- smokers due to the higher prevalence of CHD. Individuals who have never smoked have an estimated 30% increased relative risk of CHD if they live with a smoker (p<0.001). The excess risk from smoking one cigarette per day is 39%, similar to the risk in a non- smoker living with a smoker. Reversal of the effect would reduce the risk of CHD by about as much as taking 2++ 2+ aspirin or by what many people could achieve through dietary change.130 Other systematic reviews highlight the increased risk of CHD events through exposure to ETS in the workplace142 and at home.143 Two observational studies indicated that non-smokers exposed to cigarette smoke had an increased risk of 2++ acute coronary syndrome of 51% (OR 1.51, 95% CI 1.21 to 2.99) compared with non-smokers not exposed 2+ to smoke.144,145 Another case-control study examined the relationship between ETS and MI, in the workplace and at home.146 The odds ratio for MI was 1.58 (95% CI 0.97 to 2.56) for an average daily passive exposure to the smoke from 20 cigarettes per day or more at home. Combined exposure at home and work showed an increasing odds ratio for MI, up to 1.55 (95% CI 1.02 to 2.34) in the highest category of weighted duration, that is, more than 2++ 90 hour-years of exposure (1 hour-year=365 hours, or one hour per day for one year). In addition, more recent exposure appeared to convey a higher risk. This study confirms an increased risk of MI from exposure to ETS and suggests that intensity of spousal exposure, combined exposure from home and work, and time since last exposure are important. R Exposure to passive smoking increases cardiovascular risk and should be minimised. 7.2 SMOKING CESSATION INTERVENTIONS 7.2.1 THE GENERAL POPULATION There are many guidelines and policy documents covering mainstream NHS smoking cessation services 4 and wider primary prevention.147-150 In 2015, 64% of smokers and recent ex-smokers who had ever attempted to quit had used some form of nicotine replacement therapy (NRT) or e-cigarettes, for this purpose in the last three months, with the figure higher for women (69%) than men (64%). The particular items most likely to have been used as part of the quit attempt were nicotine patches (36%) and e-cigarettes (33%). Nicotine gum and nasal sprays/nicotine inhalers were used by 18% and 9% respectively, with other products, such as lozenge/microtab, varenicline and bupropion, being less common.139 | 27 Risk estimation and the prevention of cardiovascular disease The main pharmacological interventions that are offered include nicotine replacement therapy (single or combination), varenicline, or bupropion. These can be offered on their own or as part of a programme of group support provided through a smoking cessation service or individual support that is usually provided by a pharmacist. The most common route of referral for people that are ready to attempt stopping smoking is directly to a smoking cessation service in a pharmacy, where these are available. The choice of products in any smoking cessation regimen is determined by patient preference and smoking habits (for example number smoked per day or time of first cigarette). The mainstay of treatment for combination nicotine replacement therapy is usually a patch which releases nicotine over a 16- or 24-hour period, combined with an immediate-release form of nicotine (spray, mist, lozenge etc) to help cope with cravings and withdrawal symptoms that are experienced while using the patch. Varenicline is an alternative form of treatment usually offered as a pill that acts as a selective nicotine receptor partial agonist. Varenicline binds nicotine receptors and its partial agonist activity is sufficient to alleviate the symptoms of craving and withdrawal; simultaneously varenicline prevents nicotine from binding to receptors and this reduces the reward and reinforcing effects of smoking (antagonist activity). For these reasons varenicline is not used in combination with nicotine replacement therapy and the safety and efficacy of varenicline combined with other nicotine replacement therapy has not been studied. Bupropion is another tablet treatment option which was originally developed as an antidepressant but is now licensed in the UK only for smoking cessation. It works as a nicotine antagonist and its effects on smoking cessation are independent to its antidepressant properties. One systematic review and two RCTs comparing smoking cessation interventions were identified. A systematic review of 20 studies concluded that quitting smoking is associated with a 36% reduction in crude relative risk of mortality for patients with CHD who quit compared with those who continued smoking 2++ (RR 0.64, 95% CI 0.58 to 0.71).151 Two RCTs addressed lifestyle advice/training and reported a reduction in smoking in those who went through an educational programme.87,152 Both studies only included male patients and lacked sufficient power to allow a firm conclusion to be drawn. In the Oslo Diet and Antismoking Trial, advice to change diet and smoking habits reduced the relative risk of CHD mortality in men with high triacylglycerol concentrations after 23 years follow up. Men with normal 1+ triacylglycerol concentrations did not appear to achieve similar long-term benefit from lifestyle intervention.152 The Vestfold Heartcare Study Group trial investigated whether a comprehensive programme of lifestyle modification could favourably influence dietary and exercise habits in addition to smoking cessation.87 After following a low-fat diet, regular exercise, smoking cessation and psychological support and education 1+ sessions, patients in the lifestyle intervention group reduced the intake of saturated fat, sugar and cholesterol (p<0.001) increased their exercise level (p<0.001) and stopped smoking (p<0.05) compared with the usual care group. Results indicated a relative reduction of 22% in five-year risk of CHD in males (95% CI 9 to 35), however, the study lacked statistical power and should be interpreted with caution. Two Cochrane meta-analyses, which include over 20 RCTs, indicate a large treatment effect from varenicline compared with placebo, bupropion, and single NRT in relation to biochemically-confirmed quit rates up to six months post-treatment, but an equivalent effect to combination NRT.153,154 Varenicline gives a pooled relative risk for sustained abstinence at six months or longer compared with placebo of 2.27 (95% CI 2.02 to 2.55, 14 trials, 6,166 people). Varenicline also increases the odds of quitting compared with placebo (OR 2.88, 1 ++ 95% CI 2.40 to 3.97). A lower dose of varenicline reduces adverse effects and still gives a relative risk of 2.09 (95% CI 1.56 to 2.78, four trials, 1,272 people) compared with placebo for sustained abstinence at six months or longer. Varenicline offers a 12–15% chance of a successful quit compared with 4–5% with placebo, meaning that approximately 10–12 people needed to be treated with varenicline for each additional successful quit attempt at six months or longer. The SMC reported that a cost-utility analysis from the manufacturer indicated that varenicline results in lower lifetime NHS costs for a cohort of smokers as well as generating more Quality Adjusted Life Years (QALYs), compared with other ways of quitting smoking.155 28 | 7 • Smoking A large meta-analysis, including over 10,000 participants in 39 RCTs has indicated that minor side effects with varenicline are common, affecting around 20% of people.156 These include nausea, sleep disturbance and insomnia although most people tolerate these and continue with their treatment and the side effects reduce 1++ over time. There is no reliable evidence that varenicline is associated with an increased risk of significant adverse neuropsychiatric events. The NHS Health Scotland guideline on smoking cessation recommends that varenicline, single NRT, combination NRT (interventions involving more than one type of nicotine replacement delivery), and 4 bupropion may all be used as treatments depending on patient preferences and other factors.147 These can be offered alongside behavioural support (individual or group support service) or on their own. One systematic review which compared different forms of NRT concluded that all forms of NRT can help people to stop smoking, almost doubling long-term success rates. The risk ratio for abstinence with any form 1++ of NRT compared with control was 1.60 (95% CI 1.53 to 1.68).157 A systematic review of the effect of antidepressants on smoking cessation showed that buproprion and nortryptiline approximately doubled the odds of a motivated individual stopping smoking.158 Based on 19 trials of bupropion monotherapy with over 4,000 participants, the pooled OR for smoking cessation was 2.06 1++ (95% CI 1.77 to 2.40). Serious adverse effects using bupropion at the doses indicated for smoking cessation are rare (less than one per 1,000 treated).159 Nortryptiline is not licensed for use in smoking cessation and is contraindicated in patients with recent 4 myocardial infarction or arrhythmias (particularly heart block).160 RVarenicline or combination nicotine replacement therapy should be offered alone or as part of a smoking cessation programme to augment professional advice and increase long-term abstinence rates. RBupropion and single nicotine replacement therapy may also be considered as smoking cessation treatments. 7.2.2 ELECTRONIC CIGARETTES In 2015, 7% of adults aged 16 and over currently used electronic cigarettes (e-cigarettes) in Scotland, with a further 11% having previously used them (17% having ever used). These figures were similar for both men and women. E-cigarette use is strongly associated with smoking behaviour, with both current and past use of e-cigarettes much higher among current cigarette smokers than among ex-regular or never regular smokers. In total, 16% of smokers reported currently using e-cigarettes and an additional 36% said they had done so in the past, the equivalent figures for ex-regular smokers were 9% and 7%, respectively.139 A Cochrane meta-analysis which included two RCTs and 11 observational studies showed a relative risk of a successful quit attempt of 2.29 for nicotine-containing e-cigarettes over placebo e-cigarettes (95% CI 1.05 to 4.96). The relative risk for reducing tobacco consumption by at least half with nicotine-containing e-cigarettes over placebo e-cigarettes was 1.31 (95% CI 1.02 to 1.68).161 No statistically significant differences 1++ were found between nicotine-containing e-cigarettes and nicotine patch on either of the above measures. No significant adverse events were attributed to e-cigarettes and there was no difference in the likelihood of minor side effects with nicotine-containing e-cigarettes compared with placebo e-cigarettes. These findings are supported by a further RCT.162 However, some uncertainty persists about the benefits of nicotine-containing e-cigarettes as a smoking cessation intervention on account of significant methodological weaknesses in the studies included in the Cochrane review and the relatively small sample size of the RCT. While the constituents of nicotine- containing e-cigarettes are not known to be harmful to health when ingested as food or drink, there is no reliable health surveillance data available on the long-term impact of inhaling these substances. Nicotine- containing e-cigarettes are not licensed as smoking cessation treatments, while alternative licensed products are available. Furthermore, the use of e-cigarettes is being superseded by electronic nicotine delivery systems (ENDS) which may be more efficient at delivering nicotine to the body although their harms and benefits as a smoking cessation intervention have not been extensively researched. | 29 Risk estimation and the prevention of cardiovascular disease 7.2.3 SPECIAL POPULATIONS Patients with depression One meta-analysis163 and three RCTs164-166 were identified which considered smoking cessation in individuals with clinical depression. The meta-analysis considered whether a history of major depression is associated with failure to quit smoking. No differences in either short-term (three months or less) or long-term (six months or more) abstinence rates 2++ were observed between smokers who were positive versus negative for history of depression. The authors conclude that a lifetime history of major depression does not appear to be an independent risk factor for cessation failure in smoking cessation treatment. The three RCTs considered different smoking cessation strategies for patients with depression. One trial investigated the effect of nortriptyline hydrochloride and cognitive behavioural therapy (CBT) on smoking treatment outcomes in smokers with a history of major depressive disorders.165 Nortriptyline produced 1+ higher abstinence rates than placebo, independent of depression history and alleviated a negative affect occurring after smoking cessation. Cognitive behavioural therapy was more effective for participants with a history of depression. A smaller trial investigated the effect of sertraline as a cessation aid to patients with clinical depression. The trial showed that sertraline did not add to the efficacy of intensive individual counselling. However, given + 1 that the end-of-treatment abstinence rate for the placebo group was much higher than expected, it is unclear whether a ceiling effect of the high level of psychological intervention received by all participants prevented an adequate test of the drug.164 One small trial examined the efficacy of a mood management intervention for smoking cessation in abstinent alcoholics with a history of major depression.166 Patients were randomised to either behavioural counselling (BC) alone or counselling with a CBT component. Significantly more smokers in the CBT group had quit smoking by the end of the intervention period (69.2%; 9 of 13) than in BC (31.3%; 5 of 16) (p=0.04). 1 _ The abstinence rates remained unchanged at one month follow up. At three month follow up, differences in smoking abstinence rates were not significant between CBT (46.2%; 6 of 13) and BC (25.0%; 4 of 16) conditions. At 12 month follow up, significantly more participants in CBT were abstinent from smoking (46.2%; 6 of 13) than in BC (12.5%; 2 of 16) (p=0.04). Antidepressants have an effect on smoking cessation rates in this group (but are not licensed specifically for this indication). It is not clear whether this effect is mechanistic or related directly to the treatment of depression. There are no significant trials of other pharmacological interventions (eg NRT, buproprion) in this group of patients. RSmokers with coronary heart disease and comorbid clinical depression should be offered treatment to reduce depressive symptoms and to increase the likelihood of stopping smoking. Patients from ethnic minorities There have been few statistically reliable nationwide surveys of the prevalence of smoking or effectiveness of cessation interventions among ethnic minorities in Scotland. Scottish Health Survey data have been combined for ethnic minority groups over a period of four years (2008–2011) to provide information on the health behaviours in this sector of the community.167 Respondents from Pakistani and ‘Asian, other’ ethnic groups (people who did not self identify as belonging to Asian Indian, Chinese or Pakistani groups) were significantly less likely to smoke than the national average (prevalence of 13% and 9% respectively compared with 25% among the White British respondents. This is consistent with other UK-wide research indicating that smoking rates in ethnic minority groups tend to be the same or lower than in the general population.168 30 | 7 • Smoking While smoking rates for men and women in the UK on the whole are converging, amongst minority ethnic groups there are still marked gender differences in smoking behaviour. Rates are low, in particular, among south Asian women, however research conducted by Action on Smoking and Health (ASH) Scotland has indicated that smoking is escalating among south Asian girls in Scotland, particularly in young Pakistani women.169 ASH Scotland has conducted a mapping exercise to identify smoking cessation projects, services, resources and training courses available to individuals from ethnic subgroups. Although some material was identified which had been specifically targeted to ethnic subgroups (mostly leaflets), generally, mainstream tobacco services were not attracting representative proportions of individuals from ethnic subgroups.170 | 31 Risk estimation and the prevention of cardiovascular disease 8Alcohol 8.1 ALCOHOL AND CARDIOVASCULAR RISK Excess alcohol consumption is a well-established risk factor for cardiovascular disease, as well as being a causal factor in more than 200 disease and injury conditions. Worldwide, 3.3 million deaths per year result from harmful use of alcohol, representing 5.9% of all deaths.171 The effects of alcohol on other long-term conditions, for example, mental health, liver disease and cancer are not considered in this guideline but should be taken into account when providing advice in a clinical setting. There is considerable confusion over the definition of a standard unit of alcohol. One unit of alcohol in the UK means a beverage containing 8 g or 10 ml of ethanol. The amount of alcohol in units is calculated as: volume of drink (litres) x percentage by volume alcohol.1 There is a commonly held belief that half a pint of beer, or one glass of wine equate to a unit, but exact strength and volume are critical, as the examples in Table 6 illustrate (see Annex 4). Drinks poured at home are often larger than standard pub measures. Table 6: Volumes of drinks equivalent to one unit of alcohol Drink Percentage alcohol Volume equivalent to one unit Beer/lager 3.5% 0.5 pint Beer/lager 5.0% 0.35 pint Wine 10% 100 ml (one 750 ml bottle = 7.5 units Wine 13% 77 ml (one 750 ml bottle = 9.75 units) Fortified wine/sherry 17.5% 57.1 ml Spirits 40% 25 ml 99 Examples of what constitutes a ‘drink’ or unit of alcohol should be given to the patient. Most adults in Scotland consume alcohol with men reporting an average of 17.2 units of alcohol per week and women reporting an average of 8.7 units per week. Thirty six per cent of men and 17% of women report drinking at harmful or hazardous levels (defined as more than 14 units of alcohol consumption per week in men and women).1 8.1.1 EFFECTS OF ALCOHOL CONSUMPTION LEVELS ON CARDIOVASCULAR DISEASE MORTALITY AND MORBIDITY Systematic reviews of cohort and case-control studies show a 'J'-shaped relationship between alcohol 2- consumption and cardiovascular risk of mortality and morbidity.172-177 However, there are social considerations, 2++ individual factors and likely unmeasured covariates that act as confounding variables in these studies. 2+ A systematic review and meta-analysis of prospective cohort studies showed a lower risk of all-cause mortality for light to moderate drinkers compared with non-drinkers. There was a ‘J'-shaped association with the lowest risk associated with consumption of 2.5–14.9 g/day (approximately one to one and a half drinks per day) - 2 (RR 0.83, 95% CI 0.80 to 0.86) compared with non-drinkers and an elevated risk for consuming >60 g/day (approximately five or more drinks per day) (RR 1.30, 95% CI 1.22 to 1.38). Risk of cardiovascular mortality was lowered in a dose-dependent relationship ranging from 29% in studies reporting <2.5 g/day alcohol consumption to 15% in studies reporting 30–60 g/day alcohol consumption.172 Another systematic review showed that compared with no alcohol intake, low alcohol intake (<15 g/day) was associated with a lower risk of total stroke (RR 0.85. 95% CI 0.75 to 0.95), ischaemic stroke (RR 0.81, 95% CI 0.74 to 0.90) and stroke mortality (RR 0.67, 95% CI 0.53 to 0.85), but no significant association with haemorrhagic 2++ stroke (RR 0.96, 95% CI 0.74 to 1.24). Heavy alcohol intake (>30 g/day) was associated with an increased risk of total stroke (RR 1.20, 95% CI 1.01 to 1.43) but it had no significant associations with haemorrhagic stroke, ischaemic stroke or stroke mortality.173 32 | 8 • Alcohol Epidemiological studies have reported that alcohol consumption is associated with blood pressure with evidence of a 'J'-shaped curve suggesting cardioprotection at low levels of consumption in women, but not 1- in men.178 A meta-analysis of 15 RCTs showed that alcohol reduction was associated with a significant and dose-dependent reduction in mean systolic and diastolic blood pressures.179 It has been suggested that the apparent cardioprotective effect of alcohol may be accounted for by methodological flaws in the evidence. There may be a bias towards the publication of studies which identify a benefit, suggesting that intakes lower than the maximum reported may be optimal.146 Abstainers may have 2++ higher rates of pre-existing ill health (ie reverse causality), which would result in relatively poorer outcomes in comparative studies with alcohol drinkers.180 Mendelian randomisation is used as a tool to try and overcome some of the limitations in existing observational studies, as allocation of genetic variants is random with regard to potential confounders. A recent Mendelian randomisation analysis of 56 epidemiological studies which included a total of 261,991 participants considered carriers of the rs1229984 variant in the alcohol dehydrogenase 1B gene (ADH1B), which encodes an enzyme involved in the primary pathway of alcohol metabolism.181 This gene variant has been associated with reduced consumption of alcohol due to unpleasant side effects. The analysis reported that carriers of this variant consumed 17.2% fewer units of alcohol per week (95% CI 3 -18.9% to -15.6%), had a lower prevalence of binge drinking and higher abstention than non-carriers. Carriers also had significantly lower systolic blood pressure (0.88 mm Hg, 95% CI -1.19 to 0.56), odds of hypertension (OR 0.94, 95% CI 0.91 to 0.98), odds of CHD (OR 0.90, 95% 0.84 to 0.96), non-HDL cholesterol (-0.03 mmol/l, 95% CI -0.05 to -0.01), and also lower waist circumference and BMI. Carriers had lower odds of ischaemic stroke (OR 0.83, 95% CI 0.72 to 0.95) but no association with combined subtypes of stroke (OR 0.98, 95% CI 0.90 to 1.07) was found. These effects remained the same across all categories of alcohol consumption. When analysis was restricted to non-drinkers there was no association between carriage of the polymorphism and CHD (OR 0.98, 95% CI 0.88 to 1.10). This is consistent with the assumption that the associations ascribed to the ADH1B variant are mainly due to alcohol consumption. Evidence is consistent in showing that heavy drinking is associated with the highest risk of CVD and that light to moderate consumption carries a lower risk. However evidence from studies which reduce the limitations of traditional observational data has challenged the view that light to moderate alcohol consumption confers reduced risk of cardiovascular disease compared with abstention. Individuals with a genetic predisposition to consume less alcohol had a reduced risk of CHD and ischaemic stroke, and lower levels of established and emerging risk factors for cardiovascular disease. These findings suggest that reductions of alcohol consumption, even for light to moderate drinkers, may be beneficial for cardiovascular health. RPatients with or without evidence of cardiovascular disease should be advised to reduce alcohol consumption and that even light to moderate alcohol consumption may increase cardiovascular risk. 99 When giving advice to patients with coronary heart disease, national health promotion advice should be followed.182 yy M en and women are advised not to drink regularly more than 14 units per week to keep health risks from drinking alcohol to a low level. yy If you do drink as much as 14 units per week, it is best to spread this evenly over three days or more. If you have one or two heavy drinking sessions, you increase your risks of death from long- term illnesses and from accidents and injuries. yy T he risk of developing a range of illnesses (including, for example, cancers of the mouth, throat and breast) increases with any amount you drink on a regular basis. yy If you wish to cut down the amount you’re drinking, a good way to help achieve this is to have several drink-free days each week. | 33 Risk estimation and the prevention of cardiovascular disease 8.1.2 METHODS OF MODIFYING ALCOHOL CONSUMPTION Three systematic reviews consider methods of reducing alcohol intake in those whose drinking is considered to be harmful or risky.183-185 All conclude that brief interventions are the most effective method with increased ++ 1 benefit from multicontact interventions. One review concluded that for benefit an intervention had to include 1+ two of the three key elements: feedback, advice and goal setting.160 Many of the individual studies included 2++ in the reviews were not UK-based and some reviews included interventions which may not be deliverable in primary care in the UK (for example electric aversion therapy). Brief interventions may include some of the following: information, feedback and advice on prevalence of drinking, adverse effects of alcohol, drinking cues, drinking diaries, drinking agreement/contract, retrospective self report of drinking alcohol or current alcohol qualities and types of alcohol consumed, injuries, healthcare utilisation, recommended levels of alcohol consumption, education on risks involved in consumption of alcohol, strategies for changing drinking habits, feedback of personal health data.186,187 There is a range of suggested timescales for brief interventions from five minutes to 20 minutes, from a single occasion up to five sessions, and vary from face to face to by telephone. A single RCT of participants with type 2 diabetes and/or hypertension confirmed the benefit of multicontact, brief counselling to reduce alcohol consumption in high-risk individuals (11% absolute reduction in numbers 1++ of heavy drinkers in the intervention group).187 One review specifically looked at the effectiveness of untargeted screening prior to delivering a brief intervention to modify alcohol consumption.186 It found that of 1,000 patients 90 screened positive, 25 of + 1 whom qualified for a brief intervention. At one year, two or three of these would have reduced their drinking to within the recommended alcohol intake levels. RBrief multicontact interventions should be used to encourage patients to reduce their levels of drinking if their current intake is hazardous to their health. 99 Universal screening as a case-finding exercise in primary care is not recommended. 34 | 9 • Antiplatelet therapy 9 Antiplatelet therapy 9.1 ANTIPLATELET AGENTS FOR PEOPLE WITH ESTABLISHED CARDIOVASCULAR DISEASE The favourable benefit to risk profile of aspirin for patients with established cardiovascular disease is well recognised. In meta-analyses, the Antithrombotic Trialist’s (ATT) Collaboration showed clear evidence of a reduction in all-cause mortality, vascular mortality, non-fatal reinfarction of the myocardium, and non-fatal 1++ stroke in people with acute coronary syndrome, stroke, transient ischaemic attacks (TIAs), or other vascular disease.188,189 The trials used aspirin doses of 50–325 mg/day. The meta-analysis provided no evidence of any greater benefit from high-dose aspirin, while adverse effects from aspirin are minimised at lower dosages. A meta-analysis compared the benefit and gastrointestinal risk of low dose (<325 mg aspirin) use for the secondary prevention of thromboembolic events. It showed that aspirin reduced all-cause mortality by 18%, the number of strokes by 20%, myocardial infarctions by 30%, and other vascular events by 30%. Patients 1++ who took aspirin were 2.5 times more likely than those in the placebo group to have gastrointestinal tract bleeding. The number needed to treat (NNT) for aspirin to prevent one death from any cause of mortality was 67, while 100 needed to be treated to detect one non-fatal gastrointestinal tract bleed.190 The evidence supports daily doses of aspirin in the range of 75–325 mg for the long-term prevention of serious vascular events in high-risk people, and it is usual practice to prescribe 75 mg daily. Although there is no clinical trial evidence of treatment beyond a few years, there is likely to be ongoing benefit, so it is usual to continue aspirin therapy for life. RIndividuals with established atherosclerotic disease should be offered treatment with 75  mg aspirin daily. The P2Y12-receptor antagonist clopidogrel was equivalent to aspirin in prevention of further events in patients with CHD or ischaemic stroke.191 In a subgroup analysis, clopidogrel appeared to be more effective than 1+ aspirin among patients with peripheral vascular disease, although the study was not powered to detect a significant effect in any subgroup. Clopidogrel should be used as monotherapy if aspirin causes side effects.191 99 lopidogrel should be considered in patients with symptomatic cardiovascular disease who have C aspirin hypersensitivity or intolerance or in whom aspirin causes unacceptable side effects. A P2Y12-receptor antagonist is recommended in combination with aspirin in patients with proven troponin- positive acute coronary syndrome for six months following the acute event. Longer durations may be used where the risks of atherothrombotic events outweigh the risk of bleeding. Shorter durations may be used 4 where the risks of bleeding outweigh the risk of atherothrombotic events (see SIGN guideline number 148 on acute coronary syndrome).15 Meta-analysis of two large RCTs with 20,000 patients in each showed that starting daily aspirin (160–300 mg) promptly in patients with suspected acute ischaemic stroke reduced the immediate risk of further stroke or death in hospital and the overall risk of death or dependency.192 Odds of recurrent ischaemic stroke were 1++ reduced by 30% in the group taking aspirin (OR 0.70, p<0.000001; ARR 0.7%). Death without further stroke was reduced by 8% (OR 0.92, p=0.05; ARR 0.4%). In total there was a net decrease of 11% in the overall risk of further stroke or death in hospital (OR 0.89, p=0.001; ARR 0.9%). One RCT assigned patients to aspirin (30–325 mg daily, median 75 mg) with (n=1,363) or without (n=1,376) dipyridamole (200 mg twice daily) within six months of a transient ischaemic attack or minor stroke of presumed arterial origin.193 Combination therapy with aspirin and dipyridamole reduced the composite 1++ outcome of death from all vascular causes, non-fatal stroke, non-fatal MI or major bleeding complication by 20% (HR 0.80, 95% CI 0.66 to 0.98; ARR 1.0% per year, 95% CI 0.1 to 1.8). | 35 Risk estimation and the prevention of cardiovascular disease A large RCT followed up individuals aged over 55 who had experienced an ischaemic stroke within less than 90 days before randomisation and allocated them to receive aspirin (25 mg) plus extended-release dipyridamole (200 mg) twice daily (n=10,181) or clopidogrel (75 mg) daily (n=10,151). The mean duration of follow-up was 2.5 years (range, 1.5 to 4.4). There was no significant difference between groups for primary (first recurrence of stroke) or secondary (composite of stroke, myocardial infarction, or death from vascular causes) outcomes. Recurrent stroke occurred in 916 patients (9.0%) receiving aspirin plus dipyridamole and in 898 patients (8.8%) receiving clopidogrel (HR 1.01, 95% CI 0.92 to 1.11). The secondary outcome occurred 1++ in 1,333 patients (13.1%) in each group (HR for aspirin/dipyridamole 0.99, 95% CI, 0.92 to 1.07). No statistically significant differences were recorded in safety outcomes between groups, although adverse events leading to permanent discontinuation of the study medication were more common in the group receiving aspirin plus dipyridamole (1,650 patients, 16.4%) compared with the group receiving clopidogrel (1,069 patients, 10.6%). The rate of new or worsening congestive heart failure was significantly lower in the group receiving aspirin plus dipyridamole (144 patients, 1.4%) than in the group receiving clopidogrel (182 patients, 1.8%) (HR 0.78, 95% CI, 0.62 to 0.96).194 RIndividuals with a history of stroke or transient ischaemic attack and who are in sinus rhythm should be considered for treatment with clopidogrel 75 mg daily or combination of low dose aspirin (75–300 mg daily) and dipyridamole (200 mg twice daily) to prevent stroke recurrence and other vascular events. 9.2 ANTIPLATELET AGENTS FOR PEOPLE WITHOUT CARDIOVASCULAR DISEASE A health technology appraisal of nine systematic reviews, which mostly include the same nine major trials, and a meta-analysis of three further RCTs of aspirin for the primary prevention of CVD noted that aspirin doses used varied from 75–500 mg/day, and from 100–325 mg on alternate days, and the rate of cardiovascular events in the control arms differed by a factor of ten between trials.195 The overview reported results from 1 ++ several meta-analyses across multiple outcomes. All included studies were formally appraised and rated as high quality. Given that most of the included reviews incorporated the same trials, a selection of important results is noted below. All-cause mortality in those receiving aspirin was marginally reduced by 6% compared with placebo, a result which is only of borderline statistical significance (RR 0.94, 95% CI 0.88 to 1.00). Pooling data from several meta-analyses yielded an absolute risk estimate of 33–46 deaths avoided over ten years per 10,000 patients treated. Individual patient data in the ATT Collaboration, which was also included in this analysis, is consistent with this, with 30 deaths avoided per 10,000 patients treated for 10 years (or a 10-year likelihood of survival increased from 94.7% to 95% with aspirin), although this analysis included only 6 of the 9 RCTs analysed in the other reviews.196 Major cardiovascular events (MCE), defined as the composite of non-fatal MI, non-fatal stroke or cardiovascular death, were non-significantly reduced by 14% (OR 0.86%, 95% CI -26 to 1%).197 Assuming a control group risk of 3.25% (random-effects pooled estimate) and OR of 0.86, the NNT to avoid an event was calculated at 226 and would result in 64 fewer events among 10,000 people over 10 years. Other study-level meta-analyses of the same group of RCTs show an odds ratio of 0.90 (95% CI 0.85 to 0.96) for the same composite end point which was statistically significant, yielding an NNT of 253 and 57 fewer events per 10,000 individuals over 10 years.198 Using a pooled estimate of risk for the control group of 5.84%, 84 such events may be avoided per 10,000 patients treated for 10 years. Individual patient data analysis from the ATT Collaboration showed the pooled yearly event rate ratio to be 0.88 (95% CI 0.82 to 0.94) for the composite end point, and an absolute difference of 70 events avoided for 10,000 persons followed up for 10 years. The same analysis showed a relative risk of 0.82 (95% CI 0.75 to 0.90) for the combined end point of non-fatal MI or CHD death, and the corresponding absolute benefit of 55 events avoided for 10,000 persons over 10 years.196 Stroke mortality was increased with aspirin treatment (RR 1.23, 95% CI 0.84 to 1.74) although this was not statistically significant. In the ATT Collaboration analysis, ischaemic strokes were reduced by aspirin (RR 0.86, 95% CI 0.74 to 1.00, p=0.05) while haemorrhagic strokes were increased by 32% (RR 1.32, 95% CI 1.00 to 1.75, p=0.05). Due to both comparisons including confidence limits of 1.0, a null effect cannot be ruled out.196 36 | 9 • Antiplatelet therapy Assessment of the risk of bleeding events is not straightforward due to the differences in definitions of bleeding used in the primary prevention trials, some using major bleeding and others using non-trivial bleeding. In addition there were significant differences in the bleeding risks in the control arms of the studies, as well as variable (and non-dose-related) responses to aspirin. The meta-analyses are consistent in their findings of a statistically significant increase in bleeding. The relative risk for major bleeding with aspirin was 1.62 (95% CI 1.31 to 2.00). The number of extra major bleeds was estimated to be 46–49 per 10,000 individuals followed for 10 years.198,199 The analysis of the individual patient data by the ATT showed an RR of 1.54 (95% CI 1.30 to 1.82) with aspirin, and an absolute excess of major bleeds of 35 per 10,000 people over 10 years.196 Table 7 describes risk ratios for patient-level variables associated with major gastrointestinal or other extracranial bleeds Table 7: Rate ratios associated with risk factors for bleeding in people with no known vascular disease in primary prevention trials Variable Major or other extracranial bleed (95% CI) Age (per decade) 2.15 (1.93 to 2.39) Male sex 1.99 (1.45 to 2.73) Diabetes mellitus 1.55 (1.13 to 2.14) Current smoker 1.56 (1.25 to 1.94) Mean blood pressure (per 20 mm Hg) 1.32 (1.09 to 1.58) Cholesterol (per 1 mmol/l) 0.99 (0.90 to 1.08) Body mass index (per 5 kg/m²) 1.24 (1.13 to 1.35) Adapted from Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technology Assessment (Winchester, England) 2013;17 (43):1-253. The number of excess gastrointestinal bleeds over 10 years varied from 68–117 per 10,000 people treated depending on the method of calculation of the risk in the control group.199 Haemorrhagic strokes were increased with a RR of 1.32 (95% CI 1.00 to 1.75), estimating an excess of these events of eight per 10,000 1++ people treated over 10 years.196 A summary of benefits and harms was calculated by aggregating the rate of averted or of incurred events from study-level data and is shown in Table 8.195 Table 8: Events averted or incurred with aspirin use for 10,000 persons with no known vascular disease followed up for 10 years Benefits Harms 36–46 deaths averted 30–49 major bleeds 60–84 MCE averted 68–117 gastrointestinal bleeds 8–25 haemorrhagic strokes R Aspirin is not recommended for primary prevention of cardiovascular disease. | 37 Risk estimation and the prevention of cardiovascular disease 9.3 ANTIPLATELET AGENTS FOR PEOPLE WITH DIABETES A health technology appraisal identified seven meta-analyses which provided data on the benefits and harms of aspirin when taken by individuals with diabetes who are without cardiovascular disease.195 Aspirin use was associated with no significant reduction in total mortality, cardiac deaths or ischaemic stroke in any of the included meta-analyses. Pooled point estimates for reduction in MCE were all around 10%, however all 1++ of the upper confidence limits included the possibility of no improvement, and, in some cases, implied the possibility of greater risk from aspirin. Bleeding risks were variously defined in different meta-analyses, but in each case, the pooled point estimates for these outcomes were strongly in favour of the comparator (RR approximately 2 to 3), but were associated with considerable uncertainty so that effect sizes were statistically insignificant and the 95% lower confidence interval encompassed protection by aspirin. Improvement in precision and confidence of treatment in people with diabetes is anticipated with the results of large ongoing RCTs. Until these trials publish, it is vital to consider both the absolute benefits and risks of aspirin on an individual basis, as for non-diabetic patients. RAspirin is not routinely recommended in people with diabetes who do not have a diagnosis of cardiovascular disease. 9.4 ANTIPLATELET AGENTS FOR PEOPLE WITH HYPERTENSION In contrast to the benefits of antiplatelet therapy with aspirin in those with established cardiovascular disease, there is a paucity of data on the primary prevention of cardiovascular events in individuals with hypertension. A Cochrane review of antiplatelet agents and anticoagulants for patients with hypertension identified four trials, with only a single RCT reporting on total mortality and showing no effect compared with placebo. It 1++ also reported a non-significant reduction in cardiovascular events (pooled OR 0.92, 95% CI 0.81 to 1.05; two trials) and stroke (pooled OR 0.94, 95% CI 0.76 to 1.17; two trials), but a statistically significant excess of both major (calculated OR 1.85, 95% CI 1.38 to 2.48, absolute risk increase 0.65%; one trial) and minor non-fatal bleeding (calculated OR 1.80, 95% CI 1.39 to 2.35, absolute risk increase 0.73%; one trial).200 RAspirin is not recommended for primary prevention of cardiovascular disease in patients with hypertension. 9.5 ANTIPLATELET AGENTS FOR PEOPLE WITH CHRONIC KIDNEY DISEASE A systematic review included data on a number of studies of antiplatelet therapy for CKD, but these were almost all conducted in patients with established vascular disease.201 The only analysis of primary prevention with aspirin in patients with CKD which was specifically identified in this review was derived from a subgroup 1++ of the Hypertension Optimal Treatment (HOT) study. The findings were similar to the overall trial in showing a reduction in MI (when silent MI was excluded) but no significant benefit to overall mortality and with a doubling of risk of major haemorrhage compared with placebo. There is insufficient evidence to form a recommendation on the use of aspirin for primary prevention of cardiovascular disease in individuals with CKD. 38 | 10 • Lipid lowering 10 Lipid lowering 10.1 THE ROLE OF TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN CARDIOVASCULAR DISEASE The link between cardiovascular risk and variation in blood lipid concentration was shown in a study of over 356,000 men aged 35–57 years who were followed up for six years. The study demonstrated a continuous, graded, strong relationship between serum cholesterol and six-year age-adjusted CHD mortality.202 This 2++ relationship persisted in smokers and non-smokers, people with and without hypertension and was evident irrespective of the presence or absence of vascular disease.203-205 Other epidemiological evidence has shown that populations with higher cholesterol levels experience more atherosclerosis and CHD than populations with lower levels206 and the higher the level of cholesterol, the 2++ greater the risk of a coronary event.202 Low-density lipoprotein cholesterol usually makes up 60–70% of total serum cholesterol and the strong relationship between total cholesterol level and CHD suggests that LDL cholesterol is a powerful risk factor.207 The role of LDL cholesterol in atherosclerosis is confirmed by studies carried out in individuals with genetic disorders that result in extreme elevations of cholesterol levels, such as FH.208 These individuals tend to develop premature CHD with evidence of advanced atherosclerosis even in the absence of any other risk factor for coronary disease. Genetic variants which affect LDL cholesterol provide further evidence of the causal relationship between LDL cholesterol and cardiovascular disease.209 There is also strong evidence to support the role that not only LDL cholesterol but other triglyceride-rich apolipoprotein B-carrying particles also play a causal role in cardiovascular disease and non-HDL cholesterol (which includes all apo-B-carrying lipoproteins) is a powerful predictor of cardiovascular events (see section 10.2).210 10.2 MEASURING LIPID LEVELS Most biochemistry laboratories directly measure total cholesterol, HDL cholesterol and triglycerides but not LDL cholesterol. Low-density lipoprotein cholesterol can be calculated indirectly by measuring total cholesterol, HDL cholesterol and triglycerides (TG) from a fasting venous blood sample and applying the Friedewald equation: LDL=TC–HDL–(TG/2.2) (all in mmol/l) where TG/2.2 approximates to very low-density lipoprotein cholesterol levels.188 This method is not suitable for individuals with TG levels >4.5 mmol/l. Non- HDL cholesterol is calculated as TC–HDL. Given the practical problems of routinely collecting 12-hour fasting samples, non-fasting blood samples are generally collected for estimation of TC and HDL cholesterol and this approach is suitable for cardiovascular risk estimation in the vast majority of individuals. Prediction of cardiovascular events is more accurate when total cholesterol and HDL cholesterol are included (for example, by the TC:HDL ratio, as in the JBS3 and QRISK2 risk calculators, or non-HDL cholesterol, as in ASSIGN) rather than using calculated LDL cholesterol alone.211 Accurate estimation of LDL cholesterol requires a full lipid profile to be carried out on a fasting venous blood sample as HDL cholesterol and TG levels vary between fasting and non-fasting states. HDL cholesterol is lower by 5% to 10% in the non-fasting state than in the fasting state and TG levels are 20–30% higher. It should, however, be recognised that in specific situations, such as pretreatment investigation of those with total cholesterol >7.5 mmol/l in whom a diagnosis of FH is considered or for LDL cholesterol-based cascade testing in relatives of an individual with FH, fasted blood sampling remains clinically useful. The accuracy of measuring HDL cholesterol in the context of high triglyceride levels may be compromised. Intercurrent illness may also affect circulating lipid levels. 99 lipid profile taken to assess cardiovascular risk should include total cholesterol, HDL cholesterol and A triglycerides and should not be taken at the time of intercurrent illness. | 39 Risk estimation and the prevention of cardiovascular disease 10.3 LOWERING CHOLESTEROL TO REDUCE CARDIOVASCULAR RISK There is strong evidence from both genetic studies and RCTs of various medicines to support the role of lowering LDL cholesterol to reduce cardiovascular risk. Genetic studies provide evidence that lifelong lower LDL cholesterol results in reductions in cardiovascular events.25,209 Statin therapy (see section 10.4) has been shown to reduce major atherosclerotic cardiovascular events and the need for arterial revascularisation by about 20–25% per 1 mmol/l reduction in LDL cholesterol in meta-analyses of numerous RCTs, while other approaches to LDL cholesterol lowering such as bile acid sequestrants and ezetimibe have also demonstrated benefit in trials (see sections 10.6.1 and 10.6.2).212,213 An extensive systematic review and meta-analysis quantifying the effect of cholesterol lowering on the risk of vascular events in patients with and without CVD emphasised the importance of cholesterol reduction, 1++ in itself, rather than treatment modality.214 Evidence for lipid-lowering drugs other than statins is presented in section 10.6. 10.4 STATIN THERAPY 10.4.1 THE EFFECTS OF STATINS ON LDL CHOLESTEROL Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are central to lipid-lowering therapy for the prevention of first and recurrent vascular events. Statins inhibit cholesterol synthesis in the liver, increasing hepatocyte LDL receptor expression and thereby increasing hepatic uptake of LDL cholesterol from the circulation. The primary action of statins is to lower LDL cholesterol with only small effects on HDL cholesterol or triglyceride levels. A meta-analysis of 164 short-term RCTs of lipid lowering by different statins showed the absolute LDL- cholesterol reduction achieved with different doses of different statins (see Table 9).214 The reductions in LDL cholesterol are dose dependent and log linear, so that with each doubling of the dose of statin, LDL levels fall by approximately 6%. Table 9: Absolute reductions (mmol/l) (95% confidence intervals) and percentage reductions in serum LDL cholesterol concentration according to statin and daily dose Daily dose (mg) Statin 5 10 20 40 80 atorvastatin 1.51 1.79 2.07 2.36 2.64 (1.28 to 1.74) (1.62 to 1.97) (1.90 to 2.25) (2.12 to 2.59) (2.31 to 2.96) 31% 37% 43% 49% 55% fluvastatin 0.46 0.74 1.02 1.30 1.58 (0.18 to 0.75) (0.55 to 0.93) (0.90 to 1.13) (1.19 to 1.41) (1.40 to 1.76) 10% 15% 21% 27% 33% pravastatin 0.73 0.95 1.17 1.38 1.60 (0.54 to 0.92) (0.83 to 1.07) (1.10 to 1.23) (1.31 to 1.46) (1.46 to 1.74) 15% 20% 24% 29% 33% rosuvastatin 1.84 2.08 2.32 2.56 2.80 (1.74 to 1.94) (1.98 to 2.18) (2.20 to 2.44) (2.42 to 2.70) (2.63 to 2.97) 38% 43% 48% 53% 58% simvastatin 1.08 1.31 1.54 1.78 2.01 (0.93 to 1.22) (1.22 to 1.40) (1.46 to 1.63) (1.66 to 1.90) (1.83 to 2.19) 23% 27% 32% 37% 42% Percentage reductions are independent of pretreatment LDL-cholesterol concentration and are based on an average baseline LDL level of 4.8 mmol/l. Table reprinted from Law MR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326 (7404):1423 with permission from BMJ Publishing Group Ltd. 40 | 10 • Lipid lowering 10.4.2 THE EFFECTS OF STATINS ON CARDIOVASCULAR END POINTS Meta-analyses of individual patient data from randomised, placebo-controlled, double-blinded trials of statins which have included those with and without established vascular disease show a consistent relative reduction in clinical end points across the spectrum of baseline cardiovascular risk.25 Treatment with various statin regimens yielded a mean difference in LDL cholesterol between the treatment and control groups of 1++ 1.07 mmol/l at one year from average baseline LDL cholesterol of 3.7 mmol/l. This was associated with an annual reduction in first major vascular events (non-fatal myocardial infarction, coronary death, stroke or coronary revascularisation) from 3.6% to 2.8%, and an overall weighted average of 21% fewer vascular events per 1 mmol/l reduction in LDL cholesterol over a median of five years with reductions of 27% in non-fatal MI and 20% in coronary deaths Various subgroups have been studied in further detail and the results remain consistent. This meta-analysis25 included subgroup analyses of major CVD events according to sex, age (<65, 65–75, >75 years), systolic (<140, 140-160, >160 mm Hg) and diastolic (<80, 80–90, >90 mm Hg) blood pressure, smoking status, eGFR (<60, 60–90, >90 mL/min/1.73 m2) and, importantly, baseline LDL cholesterol (<2.0, 2.0–2.5, 2.5–3.0, 3.0–3.5, >3.5 mmol/l). Relative benefit per mmol/l reduction in LDL cholesterol was similar across all subgroups. Proportional reductions in cardiovascular events for any given reduction in LDL cholesterol are as large for those at lower risk as populations at higher risk and there is clear evidence for cardiovascular benefit even 1++ at event rates of <5% over five years.215 Individuals at higher levels of absolute risk consequently gain more absolute risk reduction from statin intervention than those at lower levels. 10.4.3 STATIN THERAPY FOR INDIVIDUALS WITHOUT CARDIOVASCULAR DISEASE Individual RCTs have established that primary prevention with statins reduces major clinical end points. A meta-analysis of 18 trials, including almost 57,000 individuals, demonstrated the magnitude of the clinical 1++ effectiveness of this therapy, mostly in those identified as being at relatively high risk of coronary events due to existing risk factors.216 In individual patient data meta-analysis of 70,025 statin trial participants, first major vascular events were reduced by 25% per 1 mmol/l lower LDL cholesterol, similar to that achieved in those with pre-existing CHD 1++ (21% reduction per 1 mmol/l lower LDL cholesterol).25 Given this effect, for an individual the absolute reduction in CVD risk will be dependent on both their baseline cardiovascular risk and their level of LDL cholesterol with those at higher levels accruing greater absolute risk reduction compared with those at lower levels for the same statin regimen. Table 10 demonstrates expected LDL cholesterol and CVD risk reductions (after the first year of treatment) associated with different statins at a range of doses across two sample levels of baseline LDL cholesterol. | 41 Risk estimation and the prevention of cardiovascular disease Table 10: Absolute LDL-cholesterol reduction (mmol/l) and approximate CVD risk reduction (%) associated with statin therapy at different doses (mg) and baseline LDL cholesterol levels (mmol/l) Statin/ dose 5 10 20 40 80 Baseline LDL-c 2 4 2 4 2 4 2 4 2 4 atorvastatin LDL-c reduction 0.6 1.2 0.7 1.5 0.9 1.7 1.0 2.0 1.1 2.2 CVD reduction 16% 29% 18% 35% 23% 39% 25% 44% 27% 47% fluvastatin LDL-c reduction 0.2 0.4 0.3 0.6 0.4 0.8 0.5 1.1 0.7 1.3 CVD reduction 6% 11% 8% 16% 11% 22% 13% 27% 18% 31% pravastatin LDL-c reduction 0.3 0.6 0.4 0.8 0.5 1.0 0.6 1.2 0.7 1.3 CVD reduction 8% 16% 11% 22% 13% 25% 16% 29% 18% 31% rosuvastatin LDL-c reduction 0.8 1.5 0.9 1.7 1.0 1.9 1.1 2.1 1.2 2.3 CVD reduction 22% 35% 23% 39% 25% 42% 27% 45% 29% 48% simvastatin LDL-c reduction 0.5 0.9 0.5 1.1 0.6 1.3 0.7 1.5 0.8 1.7 CVD reduction 13% 23% 13% 27% 16% 31% 18% 35% 22% 39% LDL cholesterol and risk reductions apply from year two of treatment. Risk reduction calculated as 1-0.75 LDL-cholesterol reduction in mmol/l based on the Cholesterol Treatment Trialists’ (CTT) Collaboration meta-analyses. Absolute LDL cholesterol reduction based on percentage reductions in Table 9 and baseline LDL cholesterol of either 2 or 4 mmol/l One meta-analysis presented data on first major cardiovascular events according to strata of CVD risk (specifically five-year CVD event risks of <5, 5–10, 10–20, 20–30 and >30%).215 Cardiovascular benefit was also demonstrated in those in the lower absolute risk groups. In those with five-year risk <5%, first major CVD events were reduced by 38%, coronary events by 43% and revascularisation by 48% per 1 mmol/l lower LDL 1++ cholesterol. Similarly, in those with 5–10% five-year risk, major CVD events were reduced by 31%, coronary events by 39% and revascularisation by 37% per 1 mmol/l lower LDL cholesterol. These two lowest risk groups were combined for analysing stroke events and this provided a similar 24% reduction. It should be noted that the lowest risk group (<5% CVD events over five years) was dominated by the JUPITER trial. As JUPITER was stopped early, it is possible that the CVD benefit in this group is overestimated. A further meta-analysis used a different definition for low-risk individuals in their study-level analysis of 29 trials with 80,711 participants, namely those with <20% 10-year risk of CVD death or non-fatal MI.217 Mean 10-year risk of CVD death or non-fatal MI was 6%. Total mortality, non-fatal MI and non-fatal stroke were all reduced by statin therapy with no clear evidence of heterogeneity between higher potency and lower potency statin ++ 1 regimens. Because of the lower event rates in the low-risk group (and hence the lower absolute risk reductions achieved, the number needed to treat to avoid one death was 239, and 153 to avoid a non-fatal MI (compared with NNT 86 and 62, respectively, in meta-analyses of higher-risk groups) over a median of two years. This meta- analysis also compared outcomes of low-potency statins (lovastatin, fluvastatin, pravastatin and simvastatin) with high-potency statins (rosuvastatin and atorvastatin), but did not demonstrate any statistically significant difference in all-cause mortality, fatal or non-fatal MI or stroke between low- and high-potency statins. Simvastatin and atorvastatin undergo metabolic inactivation by cytochrome P450 (see section 10.4.4) and levels are therefore more likely to be affected by other agents which are metabolised by this pathway, either increasing the risks of toxicity or decreasing their efficacy. Other statins have less potential for drug interactions. Generic statin interventions are likely to be cost effective at annual levels of vascular disease risk down to 1%.25 1++ 42 | 10 • Lipid lowering The NICE guideline on lipid modification reported that high-intensity statin treatment reduced cardiovascular outcomes to a greater degree than low-intensity statin treatment compared with placebo (cardiovascular mortality – RR 0.73, 95% CI 0.61 to 0.88 v 0.84, 95% CI 0.78 to 0.91, respectively; non-fatal MI – RR 0.46, 95% CI 0.37 to 0.59 v 0.78, 95% CI 0.72 to 0.84, respectively). High-intensity statin treatment using atorvastatin 4 20 mg is cost effective compared with medium-intensity statin treatment for people who do not have CVD and who have a 10-year QRISK2 cardiovascular risk score above 6.8%. Overall there was no consistent trend for the rates of adverse events and intensity of statin and no increase in myalgia with statin intensity. The NICE guideline development group concluded that high-intensity statins are the most clinically effective option for primary prevention of CVD and are cost effective compared with all other options.31 RAdults who are assessed as being at high cardiovascular risk, but with no established CVD, should be offered treatment with atorvastatin 20 mg/day following an informed discussion of risks and benefits between the individual and their responsible clinician. In those already taking an alternative regimen due to reported intolerance with atorvastatin, there is no need to change their current regimen. 99 In individuals without established cardiovascular disease, lifestyle measures to reduce cholesterol levels should be encouraged, irrespective of the need for pharmacological treatment. 99 S econdary causes of dyslipidaemia should be considered and excluded before commencing lipid- lowering drug therapy. 10.4.4 STATIN THERAPY FOR INDIVIDUALS WITH ESTABLISHED CARDIOVASCULAR DISEASE Individuals with established CVD are at higher risk of future cardiovascular events than those without previous vascular disease. A meta-analysis of data from 170,000 participants in 26 randomised trials of statin therapy showed an annual rate of major vascular events of 1.8% in untreated individuals without previous CVD compared 1++ with 5.6% in individuals with established CHD. While CVD event rates are now lower due to secular declines this demonstrates that individuals with CVD are likely to be at significantly higher risk than most individuals without CVD who are estimated to be eligible for preventive treatment by means of formal risk calculation.25 Although the relative reduction in risk of CVD events with statin therapy is approximately constant across all baseline levels of total or LDL cholesterol and cardiovascular risk (per mmol/l reduction in LDL cholesterol), the absolute risk reduction is affected by global cardiovascular risk, with individuals who are at the highest global risk achieving the greatest absolute risk reduction from statins (see Table 1). Individuals who are at high cardiovascular risk, such as those with established symptomatic CVD or those with FH, will gain more benefit from more aggressive lipid lowering than individuals at lower absolute levels of risk. Multiple major randomised trials have confirmed that statins reduce cardiovascular events in those with established CVD. Relative reductions are similar to those observed in primary-prevention trials. In 87,903 participants with established CHD, major vascular events were reduced by 21% while in 25,920 participants with non-coronary vascular disease, major vascular events were reduced by 19% per 1 mmol/l lower LDL cholesterol in individual participant data analyses.25 Based on the relationship between absolute cardiovascular risk and the benefit obtained from LDL-cholesterol reduction, five trials were included in meta-analyses of individual patient data to assess the risks and benefits 1++ of more intensive cholesterol-lowering therapy versus standard dosing of statins.25 All trials were undertaken in patients with coronary disease, three in populations with stable coronary artery disease and two in populations with acute coronary syndrome (ACS), and included 39,612 patients. The mean baseline LDL was 2.5 mmol/l, and the observed annual event rate for major cardiovascular events in the less-intensively treated group varied from 3.8 to 13.1%. Median follow up was 5.1 years. There was a reduction in the absolute annual rate of vascular events from 5.3% with lower-dose statin to 4.5% in the more aggressively treated group, a relative reduction of 15%. The mean difference in LDL-cholesterol levels between the groups at one year was 0.51mmol/l (or 28% risk reduction per mmol/l lower LDL cholesterol, a figure consistent with the event reductions achieved per mmol/l reduction in placebo- and standard care-controlled trials). There were also significant relative reductions of 19% in revascularisation procedures and 16% in ischaemic stroke. | 43 Risk estimation and the prevention of cardiovascular disease Another meta-analysis examined ten trials of intensive- compared with moderate-dose statin treatment.218 All were secondary-prevention studies, three of which were conducted in patients with ACS. Total mortality and cardiovascular mortality were not significantly reduced overall while, in the ACS trials, mortality was 1+ reduced by 25% and cardiovascular deaths by 26%. There was a non-significant 15% reduction in the combined end point of cardiovascular deaths/non-fatal MI in the ACS trials, while the same end point had a highly significant reduction of 10% in the overall analysis of the ten studies. Strokes were reduced by 14% with more-intensive therapy. There are no convincing short-term benefits from initiating statins within 14 days of an ACS event, although the benefits of more-intensive therapy in the longer term are clear. To examine short-term benefit, a Cochrane ++ 1 review reported data, at one and four months, from 18 placebo/standard-care-controlled trials (n=14,303) which commenced statins within 14 days of ACS. There was no reduction in all-cause death, MI or stroke though there was an isolated 24% reduction in unstable angina at four months.219 Trials in these meta-analyses used fixed doses of statins (at low dose versus high dose) and cannot directly justify whether statins should be prescribed at the doses used in trials or titrated to achieve LDL targets. However, the size of the proportional reduction in major vascular events is directly related to the absolute LDL-cholesterol reduction achieved (see Tables 9 and 10) and suggests that the goal of statin therapy for secondary prevention should be to reduce LDL cholesterol as much as possible without increasing myopathy risk, rather than treating to prespecified targets. The statins tested in major trials produced broadly similar beneficial outcomes indicating a class, rather than statin-specific effect, with different levels of potency among the different drugs. Statin treatment results in substantial relative reduction in total and LDL cholesterol in all individuals at high risk of any type of major vascular event, irrespective of their pretreatment total or LDL-cholesterol values. The NICE guideline on lipid modification found that high-intensity statin treatment using atorvastatin 20 mg, 40 mg or 80 mg is cost effective compared with medium-and low-intensity statin treatment and to no treatment for people who already have CVD.31 While NICE’s analysis indicated that atorvastatin 20 mg was the most cost-effective option, this was driven by the assumption of equal efficacy among all high-intensity statins with respect to clinical outcomes, although there is evidence of modest differences in terms of reducing LDL cholesterol levels for different doses (see Table 9). However, further threshold analysis showed that atorvastatin 80 mg would be cost effective compared with atorvastatin 20 mg if it was 2% relatively 4 more effective in decreasing CVD events and there was no loss in utility due to greater adverse events. Given the evidence of increased LDL-lowering efficacy associated with atorvastatin 80 mg compared with atorvastatin 20 mg and calculated CVD risk reductions (see Table 10) the GDG concluded that the difference in CVD risk reduction between the two regimens was likely to exceed 2% and therefore it may be considered cost effective at a threshold of £20,000 per QALY. As simvastatin 80 mg is more expensive than any dose of atorvastatin and there is no evidence for superiority to atorvastatin,214 and given the evidence of increased risk of myopathy on simvastatin 80 mg,220 NICE concluded that individuals newly initiated on statin therapy for secondary prevention of CVD should be offered atorvastatin 80 mg. RAll patients with established atherosclerotic cardiovascular disease should be offered intensive statin therapy with atorvastatin 80 mg/day following an informed discussion of risks and benefits between the individual and responsible clinician. 99 onsider a lower dose of atorvastatin in patients at increased risk of adverse effects or drug-drug C interactions. F or individuals commenced on statin therapy it would be appropriate to repeat lipid measurements and if there has been a reduction in non-HDL cholesterol of less than 1 mmol/l or 40% to check adherence to medication and lifestyle changes. 44 | 10 • Lipid lowering 10.4.5SAFETY OF STATIN THERAPY A comprehensive review of all statin trials to date, undertaken by a Task Force of the US National Lipid Association, provides strong support for the safety of statins,221 which is confirmed by a second meta- analysis.222 Overall, there was no increased risk of cancer or non-cardiovascular mortality. Raised levels of liver enzymes (aspartate and alanine aminotransferase) to more than three times their upper normal limit occurred in fewer than 1% of participants treated across the dose range of the marketed statins, with the exception 1++ of atorvastatin administered at maximal (80 mg) dose and combination statin and ezetimibe therapy (see 1+ 4 sections 10.5.2 and 10.6.2). A large-scale meta-analysis of 170,255 patients from 76 placebo/standard-care- controlled trials showed 12% and 30% increases in the reporting of elevated aspartate aminotransferase and alanine aminotransferase respectively.223 In a meta-analysis of lipid-lowering trials, an absolute increase of 1% was reported for raised transaminases in high- versus moderate-dose statin trials which was largely driven by high-dose atorvastatin. This effect is completely reversible upon withdrawal of treatment. Myopathy, with raised levels of creatine kinase to more than ten times the upper normal limit, and rhabdomyolysis (a similar or greater elevation in creatine kinase which leads to renal failure) are very rare. In a meta-analysis of major statin trials with 170,000 participants there were four additional cases of rhabdomyolysis per 10,000 participants in the five trials of more versus less intensive statin therapy (based 1++ on 14 cases in 19,829 participants on intensive therapy and six cases in 19,783 participants on less-intensive therapy). All of these cases involved patients taking simvastatin 80 mg daily. In the 21 trials of standard statin therapy versus control there was only one additional case of rhabdomyolysis per 10,000 participants on statins.25 Statins interact with a number of other medications. The risk of myopathy increases when statins are used in combination with gemfibrozil or nicotinic acid (niacin) and these combinations should be avoided.160 Some statins (particularly atorvastatin and simvastatin) are metabolised by cytochrome P450 3A4 and concomitant use of other potent inhibitors of this enzyme (for example ‘azole’ anti-fungal agents and human immunosuppressive virus protease inhibitors) may increase plasma levels of these statins and increase the 4 risk of adverse effects, such as myopathy and rhabdomyolysis. The risk of myopathy is also increased when high doses of simvastatin are combined with less potent cytochrome P450 inhibitors, including amiodarone, verapamil, and diltiazem. The consumption of even modest quantities of grapefruit juice can significantly increase exposure to simvastatin, increasing the risk of myopathy. Patients taking atorvastatin should also avoid drinking large quantities of grapefruit juice. These concerns do not apply to fluvastatin, which is metabolised by a different cytochrome P450 enzyme, or to pravastatin and rosuvastatin, which are not substantially metabolised by cytochrome P450.224 Statins should be avoided in: yy p atients with active liver disease or persistently abnormal liver function tests (with the important exception of mild non-alcoholic fatty liver disease where statin therapy will often be required and should not be avoided) yy women who are pregnant or likely to be pregnant and in those who are breastfeeding (see section 10.5.3).160 Data regarding the risk of haemorrhagic stroke in people on statins are inconclusive. A meta-analysis of 39,612 individuals in five trials reported only 126 first such events.25 However, by combining results from this meta-analysis with other trials the authors suggested that statins could increase the risk of haemorrhagic stroke, relatively, by 21%. They acknowledge that, although statistically significant, the absolute size of this 1++ potential hazard would be about 50 times smaller (perhaps a few extra haemorrhagic strokes annually per 10,000 treated) than the definite absolute benefits (a few hundred occlusive events avoided annually per 10,000 treated) for patients who are at high risk of vascular events. Importantly, ischaemic strokes are far more common than haemorrhagic strokes in Western populations. Concerns have been raised about statin treatment increasing the risk of developing diabetes. One meta- analysis reported a new diagnosis of diabetes in 3.8% of statin-treated patients compared with 3.5% on 1+ placebo, a significantly increased risk of 9% (17 of 76 trials).223 A further meta-analysis reported a larger relative 1++ increase in risk of 18% in two studies.216 There is insufficient evidence about any effect of statin therapy on the development of microvascular complications related to diabetes. | 45 Risk estimation and the prevention of cardiovascular disease Statins have no effect on non-cardiovascular mortality (RR 0.97, 95% CI 0.92 to 1.03) or on risk of developing cancer (RR 0.99, 99% CI 0.91 to 1.09).25 A review of data from most of the major randomised trials of statin therapy concluded that lowering LDL cholesterol by 2 mmol/l with statin therapy in 10,000 individuals for 1++ five years would cause about five cases of myopathy, 50–100 cases of new-onset diabetes and possibly 4 5–10 haemorrhagic strokes. However, at the same time statin therapy would prevent 1,000 individuals from suffering a major cardiovascular event in a secondary-prevention population (10% absolute benefit), or 500 individuals in a primary-prevention population at high cardiovascular risk (5% absolute benefit).225 99 S imvastatin 80 mg should not be offered for primary or secondary prevention of CVD due to the risk of myopathy. Any patients currently on this regimen may continue on it if they have been stable for at least one year. 99 Statins should not be prescribed with gemfibrozil. 99 atients who are using medications that influence cytochrome P450 metabolism should avoid P concomitant use of atorvastatin or simvastatin. In such cases, pravastatin or rosuvastatin are acceptable alternative lipid-lowering therapies. 99 Statins should not be offered to: yy patients with active liver disease or persistently abnormal liver function tests, or yy women who are pregnant, likely to be pregnant or breastfeeding. 10.4.6 REPORTED INTOLERANCE TO STATIN THERAPY The evidence from a small number of studies suggests that that the vast majority (70–90%) of patients who report prior statin intolerance (to one or more statins with discontinuation or myopathy or other apparent statin-related side effect) are able to take some form of statin when rechallenged. In a retrospective analysis of patient records in one observational study, statins were discontinued at least temporarily for 57,292 out of 107,835 patients. Statin-related events were documented for 18,778 (17.4%) patients and 11,124 of these patients discontinued statins at least temporarily. Over the subsequent 12 months 6,579 (59.1%) patients were rechallenged with a statin. Most patients who were rechallenged 2+ (92.2%) were still taking a statin 12 months after the statin-related event. Among the 2,721 patients who were rechallenged with the same statin to which they had a statin-related event, 1,295 (47.6%) were on the same statin 12 months later, including 996 (36.6%) on the same or higher dose.226 Another observational, retrospective study of 1,605 patients with self-reported statin intolerance reported that 72.5% of participants who reported intolerance to at least two statins were able to take long-term statin treatment. More patients who were able to comply with long-term statin therapy used rosuvastatin (43%) + 2 than any other drug. Intermittent dosing of statin was used by 149 (9.3%) patients and these had significantly smaller LDL-cholesterol reduction compared with the daily dosing group (n=1014, 63.2%) (21.3±4.0% v 27.7±1.4%, p<0.001).227 Minor muscle discomfort is common in people treated with statins, though its incidence varies and the incidence of true statin-related myalgia is disputed.228,229 A small RCT recruited 43 patients with documented statin-associated myalgia leading to discontinuation of at least one statin (other than pravastatin) with resolution after discontinuation. Participants were allocated to treatment with either pravastatin or red yeast rice, a lipid-lowering dietary supplement. Of the 22 patients 1++ randomised to pravastatin 40 mg/day, only two withdrew from medication owing to myalgia, while one out of 21 discontinued treatment in the group receiving red yeast rice.230 46 | 10 • Lipid lowering The safety and efficacy of statin therapy was explored in a review which considered the role of different types of evidence and discussed common errors in its interpretation. This review included a meta-analysis of data from 13 major statin trials regarding symptomatic muscle complaints (pain and weakness). The authors 4 concluded that statin therapy may cause such adverse effects in only 50–100 patients per 10,000 treated for 5 years (0.5–1.0% absolute harm) indicating that under double-blind conditions, there is little evidence of any notable excess in muscle symptoms on statin therapy.225 RPatients who report statin intolerance may be rechallenged, if willing, initially with the same dose of the same statin unless they have significant creatine kinase elevation. RIf reported statin intolerance persists, patients should be offered an alternative statin. 99 Patients started on a statin should be advised to report unexplained muscle pains or other adverse effects promptly, especially if associated with fever or malaise. 10.4.7 BENEFITS AND HARMS OF STATIN THERAPY Statin therapy reduces the risk of major vascular events by around 25% each year of treatment (after the first year) per 1 mmol/l reduction in LDL cholesterol (see Table 10). Given the potential for some high-potency statins (see Table 9) to reduce LDL cholesterol by 2 mmol/l or more, such treatment could reduce the risk of heart attacks and strokes by around a half among eligible patients. Only five new cases of myopathy would be expected per 10,000 patients treated for five years with a high-potency statin, and these resolve when treatment is stopped. Converting the absolute benefits and risks of statin treatment to numbers needed to treat (NNT) or harm (NNH) shows that many more individuals eligible for preventive therapy with statins need to be treated to result in a single major harm than to prevent a major event (see Table 11). Treating 2,000 people with statins for five years would prevent 200 major vascular events in people with existing CVD and 100 events in high-risk people without CVD while causing one new case of myopathy, one to two haemorrhagic strokes and 10–20 new cases of diabetes.225 Table 11: Numbers needed to treat and harm for outcomes associated with five years of daily high-intensity statin therapy Primary prevention Secondary prevention NNH NNT NNH NNT Major vascular events 20 10 New diabetes 100–200 100–200 Haemorrhagic stroke 1,000–2,000 1,000–2,000 Myopathy 2,000 2,000 Based on data from Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388(10059):2532-61. | 47 Risk estimation and the prevention of cardiovascular disease 10.5 SPECIAL CONSIDERATIONS 10.5.1 PEOPLE WITH DIABETES Individuals with diabetes are at higher risk of CVD than those without diabetes. The European guidelines on cardiovascular disease prevention in clinical practice reports that the relative risk of CVD events in Scottish patients with type 1 diabetes is two to three times the risk in individuals without diabetes. It also reports a meta-analysis of 102 studies including almost 700,000 people with any form of diabetes. This showed that diabetes confers about a twofold excess risk for a wide range of vascular diseases, independently from other conventional risk factors.231 Statin therapy in people with diabetes appears to be associated with a statistically significant reduction in ++ 1 the risk of various clinical end points including all-cause mortality and fatal and non-fatal MI.232 Data from 18,686 patients with diabetes across 14 trials of lipid lowering showed the same 21% reduction in first major vascular events per mmol/l reduction in LDL cholesterol as is seen in non-diabetic participants.233 Coronary events, stroke, and revascularisation procedures were also reduced to the same extent as in non- diabetic patients with reductions of 22%, 21% and 25% respectively. Among diabetic patients there were 42 fewer major vascular events per 1,000 patients on statin per mmol/l LDL-cholesterol reduction. Absolute 1 + benefit was, as expected, larger in those with vascular disease at baseline (57 fewer vascular events per 1,000 compared with 36 per 1,000 in those without vascular disease) although the proportional effects of statin therapy were similar irrespective of whether there was a prior history of vascular disease. The authors commented that if generic statin treatment producing a reduction in LDL cholesterol of 1 mmol/l is cost effective in individuals with a risk of a major vascular event as low as 1% per year, almost all diabetic patients would be eligible for treatment. 10.5.2 FAMILIAL HYPERCHOLESTEROLAEMIA Patients with FH based on clinical or genetic evidence should be considered for aggressive statin therapy, irrespective of their calculated cardiovascular risk. Their total cholesterol and LDL cholesterol will usually exceed 8 mmol/l and 4.9 mmol/l respectively and may be substantially higher than this. In general, this 1++ treatment should only be considered in children of 12 years or older although it may be applied to younger 4 patients at high risk because of severe hypercholesterolaemia, under specialist supervision.234,235 Ezetimibe may be added to maximally-tolerated statin therapy where adequate cholesterol lowering has not been achieved with the statin alone, or given as monotherapy in those in whom statin therapy is contraindicated.236,237 The NICE guideline on identification and management of familial hypercholesterolaemia reported evidence which showed that statins reduce both TC and LDL cholesterol in adults with FH, and adverse events on statins are rare in the general population (see section 10.4.5).237 Based on the evidence of safety, tolerability and efficacy, statins are recommended as initial therapy in adults with FH. Economic modelling indicated 4 that higher-intensity statins (simvastatin 80 mg and appropriate doses of atorvastatin and rosuvastatin) were cost effective when compared with lower-intensity treatment with simvastatin 40 mg. Given that costs for statins have reduced since the publication of the NICE guideline and a number of previously branded agents are now available in generic forms, these results are likely to be conservative. Results of the IMPROVE-IT trial (see section 10.6.2) indicated that combination therapy with ezetimibe plus a statin is more clinically effective than a statin alone as shown by lower LDL cholesterol and reduced cardiovascular events.212 While this trial was conducted in patients with a recent ACS, not FH, and while the baseline LDL-cholesterol level in trial participants was considerably lower than is seen in FH (resulting 1++ in a smaller absolute reduction (0.4 mmol/l) in LDL cholesterol), results were consistent with large meta- analyses of statin therapy. Extrapolated to a 1 mmol/l reduction in LDL cholesterol, IMPROVE-IT yielded a similar hazard ratio for cardiovascular events (HR 0.80, 95% CI 0.68 to 0.94) to the meta-analysis (HR 0.78, 95% CI 0.76 to 0.80).25 A NICE technology appraisal notes that combination therapy with ezetimibe and a statin is an option for 4 the treatment of FH.236 48 | 10 • Lipid lowering The PCSK9 inhibitors alirocumab and evolocumab reduce lipid levels in patients with heterozygous FH both alone and in conjunction with statins and/or ezetimibe (see section 10.6.5).238 The SMC has accepted these agents for restricted use in NHSScotland for patients with heterozygous FH and LDL cholesterol ≥5.0 mmol/l 1++ for primary prevention of cardiovascular events and heterozygous FH patients with LDL cholesterol ≥3.5 mmol/l for secondary prevention of cardiovascular events (see section 14.4). 99 I ndividuals with a possible diagnosis of familial hypercholesterolaemia should be referred to a specialist clinic for investigation and initial management. RIndividuals with familial hypercholesterolaemia should be offered statin therapy regardless of their calculated cardiovascular risk and may be considered for combination therapy with ezetimibe where LDL cholesterol-lowering is inadequate on maximally-tolerated statin therapy, or for monotherapy where statins are contraindicated. RIndividuals with heterozygous familial hypercholesterolaemia and elevated LDL cholesterol despite statin monotherapy or statin/ezetimibe combination therapy should be considered for a PCSK9 inhibitor. 10.5.3PREGNANCY Statins should be avoided in women who are pregnant or are likely to be pregnant and in those who are breastfeeding (see section 10.4.5).160 Adequate contraception is required during treatment and for one month afterwards as congenital anomalies have been reported and the decreased synthesis of cholesterol may affect fetal development.160 10.5.4 OLDER PEOPLE No trials of initiating statin therapy have specifically recruited the very elderly, that is, those over the age of 85, and many trials define the elderly as those over the age of 65. One meta-analysis of eight trials including 24,674 patients aged ≥65 (average age 73) without established cardiovascular disease concluded that statins reduce the incidence of MI (RR 0.61, 95% CI 0.43 to 0.85) and stroke (RR 0.76, 95% CI 0.63 to 0.93) but do not significantly prolong survival.239 Similarly, an individual patient 1+ data analysis of major statin trials has confirmed reductions in first major cardiovascular events of 22% in those aged 66–75 and 16% in those aged >75 per 1 mmol/l reduction in LDL cholesterol.240 There is little reliable evidence regarding the clinical effects of the cessation of statin therapy in the elderly. One RCT investigating the safety and benefit of stopping statins in people aged on average 74.1 years, with advanced, life-limiting illness, found that stopping statins is safe and may be associated with benefits including improved quality of life.241 The proportion of participants in the discontinuation versus continuation groups 1+ who died within 60 days was not significantly different (23.8% v 20.3%, 90% CI 3.5% to 10.5%) and did not meet the non-inferiority end point. Total quality of life (QoL) was better for the group discontinuing statin therapy (mean McGill QoL score 7.11 v 6.85, p=0.04). Few participants experienced cardiovascular events (13 in the discontinuation group v 11 in the continuation group). In the elderly, the decision to start statin therapy should be based on ten-year cardiovascular risk estimation, 1++ life expectancy, and QoL. Age alone is not a contraindication to drug therapy.32 10.5.5 SEX The relative paucity of female participants in the statin trials, and resulting non-significant effect on cardiovascular events in some trials led to previous concerns that statins may not be beneficial for primary prevention in women, or less beneficial than in men.242 A comprehensive meta-analysis of 174,000 participants 1++ from 27 major statin trials addressed this issue.215 The trials either compared statin therapy to placebo or 1+ standard care, or compared intensive statin therapy to moderate-dose therapy. Across the trials, 27% of participants were women (mean age 65 years) and the analysis was conducted with individual participant data. Lipid-modifying effects were similar in men and women. There was, on average, an approximate 1.1 | 49 Risk estimation and the prevention of cardiovascular disease mmol/l LDL-cholesterol reduction with a statin compared with placebo or standard care, and an approximate 0.5 mmol/l LDL-cholesterol reduction with intensive statin compared with moderate-dose statin in both sexes. Risk reductions for first major cardiovascular events were similar in women (RR 0.84, 99% CI 0.78 to 1++ 0.91) and men (RR 0.78, 99% CI 0.75 to 0.81) per 1 mmol/l lower LDL cholesterol (p value for heterogeneity 1+ 0.33). Similar results were also achieved for major coronary events and stroke, while there was no change in cancer rates and non-cardiovascular mortality in either sex on statins. Therefore, the available evidence shows no difference in the relative effectiveness of statin therapy in men and women. 99 T he decision to start statin therapy should be based on estimated cardiovascular risk only and not the patient’s sex. 10.5.6 CHRONIC KIDNEY DISEASE Individuals with CKD are at elevated cardiovascular risk compared with those with a normal glomerular filtration rate.52,243 A meta-analysis of 38 studies of statins in a total of 37,274 patients with CKD (including those with impaired renal function, those with structural kidney disease with normal renal function, and those with persisting proteinuria) and without CVD was undertaken.244 Patients on dialysis and transplant recipients were not included. Treatment with a statin was compared with placebo or no treatment. Most of the data ++ 1 are derived from post hoc analyses of larger studies with median duration of one year. The main outcomes 4 are summarised in Table 12 and demonstrated reductions in total mortality and major cardiovascular events. There was also clear cardiovascular benefit when analysis was restricted to studies in individuals with no cardiovascular disease at baseline. The meta-analysis reported no increase in creatine kinase (CK) elevation or rhabdomyolysis, no increase in transaminases, no increase in cancer incidence, nor a significant increase in withdrawals due to adverse events, although not all the studies reported adverse events systematically. Table 12: Risk reductions of vascular outcomes associated with statin therapy in individuals with CKD (not adjusted for LDL cholesterol) Control Statin Absolute risk Risk ratios event rate event rate reduction p-value (95% CI) (%) (%) (%) 0.79 Total mortality 2.5 2.0 0.5 <0.001 (0.69 to 0.91) 0.72 Major CV events 2.0 1.4 0.6 <0.00001 (0.66 to 0.79) 0.77 CV mortality 1.5 1.2 0.3 <0.001 (0.69 to 0.87) 0.63 Stroke 1.7 0.97 0.73 NS (0.35 to 1.12) MI 0.55 3.09 1.67 1.42 <0.0001 (fatal and non-fatal) (0.42 to 0.72) A meta-analysis of individual participant data (n=183,419) from 28 trials examined the effect of statin therapy according to renal function. There was evidence of cardiovascular benefit from statin therapy in participants with CKD not on dialysis, though relative reductions in events reduced as eGFR declined. For a 1 mmol/l reduction in LDL cholesterol, major CVD events were reduced by 22% in participants with eGFR 1 ++ ≥60 ml/min/1.73 m2, by 19% in those with eGFR 45–59 ml/min/1.73 m2, and by 15% in those with eGFR below 45 ml/min/1.73 m2. There was no evidence of cardiovascular benefit in patients on dialysis (rate ratio 0.94, 95% CI 0.79 to 1.11).245 50 | 10 • Lipid lowering Another meta-analysis of 18 trials (five trials in a CKD population, 13 including a CKD subgroup) examined the effects of statin monotherapy and combination therapy with ezetimibe.246 Lipid-lowering therapy decreased the risk of cardiac mortality (RR 0.82, 95% CI 0.74 to 0.91), cardiovascular events including revascularisation 1+ (RR 0.78, 95% CI 0.71 to 0.86), and MI (RR 0.74, 95% CI 0.67 to 0.81) but did not improve kidney outcomes. Borderline benefit was observed for all-cause mortality (RR 0.91, 95% CI 0.83 to 0.99) but there was evidence of marked heterogeneity. Individuals with CKD stage 3 and above, or any degree of albuminuria above the normal threshold of 30 mg/g are at significantly increased cardiovascular risk compared with individuals without these factors and should be offered medications to reduce cardiovascular risk (see section 4.2.2). RPatients with CKD stage 3 and above, or with micro- or macroalbuminuria, who are not on dialysis should be offered statin therapy. 10.6OTHER LIPID-LOWERING AGENTS Meta-analysis of trials of cholesterol lowering by means other than statins have demonstrated cardiovascular benefit. For example, a meta-analysis of nine RCTs of pharmacological therapy conducted before the advent of statins showed approximately 20% reductions in coronary events in both primary-prevention and secondary-prevention populations.247 10.6.1BILE ACID SEQUESTRANTS The effect of statins can be accentuated by combining them with agents which interfere with bile acid absorption, for example cholestyramine and colestipol. These drugs lower serum, total and LDL cholesterol and cause mild, and usually transient, elevation of triglyceride levels.248,249 Clinical trial evidence from the 1980s demonstrates the benefit of these drugs as monotherapy in primary CHD prevention, but their side-effect profile (gastrointestinal irritation, constipation) frequently makes them unacceptable to most patients and adherence to therapy may be problematic.213 Nevertheless, they may be considered for the treatment of marked hypercholesterolaemia in individuals at high risk (for example, FH) 1+ where statins are contraindicated; or they may be added to maximally-tolerated statin therapy to enhance cholesterol reduction in such individuals. Whereas doubling the dose of a statin produces only a six percent further reduction in LDL cholesterol, adding a moderate dose of a bile acid sequestrant to a statin can further lower LDL cholesterol by 12–16%.250,251 10.6.2EZETIMIBE Ezetimibe is a cholesterol absorption inhibitor which acts by inhibiting Niemann-Pick C1-Like 1 protein (NPC1L1). It has few significant side effects.252 As monotherapy, its cholesterol lowering capability is modest (a reduction of 15–20% in total cholesterol when prescribed as a single dose of 10 mg).253,254 Its coprescription with moderate-dose statin therapy results in a cholesterol reduction equivalent to maximum-dose statin monotherapy. The IMPROVE-IT trial investigated the effect of adding 10 mg daily ezetimibe to 40 mg daily simvastatin in 18,144 patients following recent ACS with a baseline LDL cholesterol 1.3–2.6 mmol/l on lipid-lowering therapy, or 1.3–3.2 mmol/l without therapy.212 During the trial, LDL cholesterol was 0.4 mmol/l lower on ezetimbe plus 1++ simvastatin than simvastatin monotherapy. Over a median of six years, the primary end point (composite of cardiovascular death, non-fatal MI, unstable angina requiring rehospitalisation, coronary revascularisation, or non-fatal stroke) was reduced by 6.4% with an HR of 0.94 (95% Cl 0.89 to 0.99, p=0.016). No notable side effects occurred. Although this trial was conducted in patients with recent ACS and with relatively low baseline LDL cholesterol, the clinical benefit associated with LDL-cholesterol lowering can be extrapolated to other populations with or without CVD and with higher LDL-cholesterol levels. The cost of ezetimibe in 2017 is £26.31 per four-week pack, approximately twenty times more expensive than atorvastatin 20 mg and with a more modest effect on LDL cholesterol. | 51 Risk estimation and the prevention of cardiovascular disease The SHARP trial studied 9,270 patients with CKD (serum creatinine >150 micromol/l in men or >130 micromol/l in women) and no previous MI or coronary revascularisation, 33% of whom were on dialysis.255 Patients were randomised to either the combination of simvastatin 20 mg/day and ezetimibe 10 mg/day, or to placebo. 1++ During the trial, LDL cholesterol was 0.85 mmol/l lower in the intervention arm which led to a 17% reduction (RR 0.83, 95% CI 0.74 to 0.94) in major cardiovascular events over 4.9 years. Notably, there was no ezetimibe monotherapy arm. Use of ezetimibe in patients with FH is covered in section 10.5.2. REzetimibe and bile acid sequestrant therapy should only be considered for primary prevention in patients at elevated CVD risk in whom statin therapy is contraindicated, and in patients with familial hypercholesterolaemia. REzetimibe and bile acid sequestrant therapy should be considered for secondary prevention in combination with maximum tolerated statin therapy if LDL cholesterol is considered to be inadequately controlled. 10.6.3FIBRATES Fibrates are primarily used for lowering triglycerides. Their LDL-cholesterol lowering effects are generally in the range of 10% or less in persons with primary hypercholesterolemia. Trials of fibrate therapy were mostly undertaken in the era prior to routine statin treatment. Fibrates typically raise HDL cholesterol by 5–15% and reduce triglyceride by 25–50%,256-258 with greater 1++ reductions occurring in individuals with severe hypertriglyceridaemia.259 1+ A comprehensive meta-analysis of major-outcome fibrate trials included data for 45,058 participants in 18 trials, although it is important to highlight that only one of these trials was conducted in those on background statin therapy.260 Notably, this meta-analysis includes trials of fibrates which are no longer used in the UK (clofibrate) or seldom used (gemfibrozil, which is contraindicated in combination with a statin). Changes in lipid concentrations were heterogeneous with average reductions in total cholesterol, LDL cholesterol and triglycerides of 0.44 mmol/l, 0.36 mmol/l and 0.48 mmol/l, respectively. Across these trials, fibrate therapy led to modest cardiovascular benefit with a borderline reduction in first major CVD events (RR 0.90, 95% 1 ++ CI 0.82 to 1.00), p=0.048) driven by a 13% reduction in coronary events but without any effect on stroke (RR 0.97), cardiovascular mortality (RR 1.03) or all-cause mortality (RR 1.00). Post hoc analysis has suggested that the cardiovascular effect of fibrates may be more beneficial in those with low HDL cholesterol and/or elevated triglycerides. Serious drug-related adverse events were not increased by fibrates. Few events were recorded and a 14% reduction in the progression of albuminuria was noted in the few trials with available data. Increases in serum creatinine were common on fibrate therapy but these are known to be reversible. The null stroke findings were confirmed in a separate meta-analysis which specifically investigated this endpoint in 10 trials of fibrates compared with placebo.261 Fibrates are known to reversibly increase serum creatinine. In a meta-analysis of eight fibrate trials with 16,869 CKD patients, fibrates reduced TC by 0.32 mmol/l and albuminuria progression by 14% compared with placebo.262 While fibrate therapy increased serum creatinine by about 30 micromol/l on average, there 1+ was no change in progression to end stage renal disease (RR 0.85, 95% CI 0.49 to 1.49) and in the subgroup with eGFR 30–59.9 ml/min/1.73 m2, fibrate therapy reduced cardiovascular events by 30% and cardiovascular death by 40%, but did not reduce all-cause mortality. 52 | 10 • Lipid lowering The NICE guideline on lipid modification conducted meta-analyses of RCTs which compared the effect of fibrates with placebo and the effects of fibrates added to statins with statins alone on a range of cardiovascular outcomes. Across all comparisons, there were no statistically significant differences in all- cause or cardiovascular mortality, sudden cardiac death, stroke or rate of hospitalisation. Moderate-quality 4 evidence suggested that fibrates are potentially more clinically effective when compared with placebo at reducing non-fatal MI at six years (five studies, n=25,015). The only study that compared fibrates plus statin versus statin found no evidence of benefit from the addition of fibrates for any of the outcomes including non-fatal MI. These results applied to populations with and without CVD, and in people with diabetes in mixed primary and secondary prevention populations.31 RFibrates are not routinely recommended for primary or secondary prevention of cardiovascular disease. 99 Individuals with: yy CVD or who are at high cardiovascular risk, and yy marked hypertriglyceridaemia, and yy low HDL cholesterol level should be considered for treatment with a fibrate. 10.6.4 NICOTINIC ACID Nicotinic acid, or niacin, is a powerful HDL-cholesterol-raising agent.263 Two forms of niacin are available, crystalline immediate release which is taken three times daily and modified (extended) release taken once daily. Elevations of 15–35% in HDL cholesterol are reported following dosing with 1–3 g of the drug in its 1+ crystalline form, and are usually accompanied by a drop of 20–30% in LDL cholesterol and of 35–50% in 4 triglyceride.264 An RCT that compared the efficacy and safety of treatment with 1.5 g/day of immediate-release (IR) with modified-release (MR) niacin found similar effects on lipids for both preparations.265 In the Coronary Drug Project niacin was administered in a daily dose of 3 g over 6.5 years to men who had already had an MI. Treatment reduced the frequency of subsequent events by 14% (p<0.005), although there 1+ was no effect on overall mortality.266 After another eight years follow up and despite no attempt being made to maintain those conditions, total mortality showed significant reduction in the niacin-treated cohort.267 By contrast, two more recent placebo-controlled trials have failed to show cardiovascular benefit from niacin when added to background statin therapy (and ezetimibe if needed for optimal control of LDL cholesterol). The AIM-HIGH trial studied 3,414 patients with established CVD, low HDL cholesterol and elevated triglycerides.268 The trial was discontinued after three years due to lack of benefit from niacin. The HPS2-THRIVE trial studied 25,673 adults with cardiovascular disease but eligibility for the trial was not based on lipid thresholds.269 During the trial, niacin recipients had 0.25 mmol/l lower LDL cholesterol and 0.16 mmol/l higher HDL cholesterol. After 3.9 years, there was also no evidence of cardiovascular benefit on combination of niacin with laropiprant (an antagonist of the prostaglandin D2 receptor DP1 that has been shown to improve adherence to niacin therapy by reducing flushing) (RR 0.96, 95% CI 0.90 to 1.03). Both HPS2-THRIVE and AIM-HIGH also showed harms, such as increased risks of gastrointestinal, bleeding and infection adverse events. New-onset diabetes was increased and diabetes-related complications were also increased in those on niacin therapy. Niacin therapy also causes skin flushing which limits adherence to it. R Nicotinic acid is not recommended for cardiovascular risk reduction in any group. 10.6.5 PCSK9 INHIBITORS Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of cholesterol homeostasis. PCSK9 binds to LDL receptors and facilitates their degradation leading to increased serum LDL-cholesterol. Inhibition of PCSK9 with monoclonal antibodies decreases degradation of the LDL receptors and leads to substantial reductions in cholesterol levels. Two PCSK9 inhibitors, alirocumab and evolocumab, have been most extensively researched to date. | 53 Risk estimation and the prevention of cardiovascular disease A meta-analysis of 25 short-term studies reported that monthly evolocumab (420 mg) significantly reduced LDL cholesterol by -54.6% compared with placebo (95% CI -58.7 to 50.5%), although significant heterogeneity was noted, I2=80.4%, and by -36.3% (95% CI 38.8 to -33.9%) compared with ezetimibe. There was an increase in HDL cholesterol of 7.6% (95% CI 5.7 to 9.5%) compared with placebo and 6.4% (95% CI 4.3 to 8.4%) compared with ezetimibe. Fortnightly administration of 140 mg evolocumab 1++ led to even greater LDL reductions than 420 mg monthly treatment compared with placebo (-60.4%, 95% CI-68.8% to -52.0%). Fortnightly alirocumab (50 to 150 mg) lowered LDL cholesterol by -52.6% (95% CI -58.2 to 47.0%) compared with placebo, by -29.9% (95% CI -32.9 to -26.9%) compared with ezetimibe, and increased HDL cholesterol by 8.0% (95% CI 4.2 to 11.7%) compared with placebo. There was a synergistic effect in those already receiving statin therapy.238 Advice on PCSK9 inhibitors from NICE270,271 and SMC272,273 is based on 10 RCTs of alirocumab and four RCTs of evolocumab all of which are included within this meta-analysis.238 A meta-analysis of 24 RCTs reported that PCSK9 inhibitors reduced all-cause mortality in patients with a wide range of hypercholesterolaemia, (OR 0.45, 95% CI 0.23 to 0.86, p=0.015) but not cardiovascular mortality ++ 1 (OR 0.50, 95% CI 0.23 to 1.10; p=0.084). The rate of myocardial infarction was significantly reduced with use of PCSK9 antibodies (OR 0.49, 95% CI 0.26 to 0.93; p=0.030).274 A further meta-analysis of 17 RCTs reported that PCSK9 inhibitors reduced the incidence of all-cause mortality (OR 0.43, 95% CI 0.22 to 0.82, p=0.01) but were associated with an increased incidence of neurocognitive adverse events (OR 2.34, 95% CI 1.11 to 4.93) compared with placebo, although these were restricted to 1 ++ two studies.275 The first large RCT of PCSK9 inhibition which was powered to assess long-term cardiovascular outcomes using evolocumab (FOURIER) showed that evolocumab significantly reduced the risk of the composite primary end point (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation) compared with placebo (1,344 patients (9.8%) v 1,563 patients (11.3%); HR 0.85, 1++ 95% CI 0.79 to 0.92, p<0.001). Evolocumab also reduced the risk of the key composite secondary end point (cardiovascular death, myocardial infarction, or stroke) (816 patients (5.9%) v 1,013 patients (7.4%); HR 0.80, 95% CI, 0.73 to 0.88, p<0.001). At 2.2 years of treatment there was no impact on cardiovascular mortality (HR 1.05, 95% CI 0.88 to 1.25, p=0.62) or total mortality (HR 1.04, 95% CI 0.91 to 1.19, p= 0.54).276 No difference in adverse events or serious adverse events between either evolocumab or alirocumab and placebo was reported in a meta-analysis of 25 trials. Serious adverse events occurred in 1.9% patients on evolocumab, and 1.2% patients on placebo (HR 0.96, 95% CI 0.60 to 1.55). Adverse events leading to discontinuation occurred in 1.6% patients on evolocumab and 1.1% patients on placebo at 12 weeks (HR 0.78, 1 ++ 95% CI 0.46 to 1.32). Serious adverse events occurred in 8.6% patients on alirocumab, and 9.3% patients on placebo (HR 0.94, 95% CI 0.79 to 1.12). Adverse events leading to discontinuation occurred in 4.8% patients on alirocumab and 4.6% patients on placebo at 12 weeks (HR 1.07, 95% CI 0.78 to 1.47).238 In the FOURIER trial, there was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site 1++ reactions, which were more common with evolocumab (2.1% v 1.6%).276 RPCSK9 inhibitors should be considered in patients at high risk of vascular events with cholesterol levels remaining above target levels despite other tolerated lipid-lowering therapy. 54 | 10 • Lipid lowering The SMC has accepted alirocumab and evolocumab for restricted use in NHSScotland. Both medicines are indicated in adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia as an adjunct to diet: yy in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low-density LDL cholesterol goals with the maximum tolerated dose of a statin or, yy alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated. Both medicines are restricted for specialist use only in patients at high cardiovascular risk as follows: yy p atients with heterozygous familial hypercholesterolaemia and LDL cholesterol ≥5.0 mmol/l, for primary prevention of cardiovascular events or, yy patients with heterozygous familial hypercholesterolaemia and LDL cholesterol ≥3.5 mmol/l, for secondary prevention of cardiovascular events or, yy patients at high risk due to previous cardiovascular events and LDL cholesterol ≥4.0 mmol/l or, yy patients with recurrent/polyvascular disease and LDL cholesterol ≥3.5 mmol/l. Evolocumab should be administered at a dose of 140 mg every two weeks. 10.7 MANAGEMENT OF COMBINED DYSLIPIDAEMIA Combined dyslipidaemia, characterised by abnormalities in all of the major lipoprotein species, is associated with increased risk of vascular disease which goes beyond that produced by raised LDL cholesterol alone. Plasma triglyceride is elevated, HDL cholesterol is low and LDL particles are smaller, denser and more atherogenic than 2+ normal.277,278 This profile can be seen in particular disease states and is particularly characteristic of obesity 4 and diabetes mellitus (diabetic dyslipidaemia). Evidence from genetic studies suggests that triglycerides or triglyceride-mediated pathways may be causally related to the risk of cardiovascular disease.279,280 A number of clinical trials have shown that LDL-cholesterol lowering with statins reduces the risk of vascular events (myocardial infarction, stroke and coronary revascularisation) in participants with diabetes with raised 1++ 1+ LDL cholesterol (see section 10.5.1).281,282 The greater the LDL-cholesterol reduction, the greater the benefit.283 The largest vascular end-point trial undertaken with fibrates (FIELD, conducted in participants with diabetes with total-cholesterol/HDL-cholesterol ratio of 4.0 or more and/or plasma triglyceride of 1.0–5.0 mmol/l) provided limited evidence for their benefit in a similar diabetic cohort.284 Although treatment with fenofibrate did not significantly reduce the risk of a coronary event, it produced a 24% relative reduction (p=0.01) in 1+ risk of non-fatal MI. There was a non-significant rise in coronary deaths, but overall cardiovascular disease events (fatal and non-fatal myocardial infarction, stroke and coronary and carotid revascularisation) fell by 11% (p=0.35). Fenofibrate treatment resulted in less albuminuria progression (p=0.002) and fewer cases of retinopathy requiring laser treatment (p=0.0003). Pancreatitis and pulmonary embolism risk rose in the actively-treated group (p=0.031 and 0.022, respectively). Combined statin/fibrate therapy improves the entire dyslipidaemic profile over that seen with statin therapy alone. Trials have reported a significant increase in HDL-cholesterol levels and significant reductions in triglyceride and LDL-cholesterol levels in patients on combined statin/fibrate therapy compared with patients 1+ on statins or fibrate monotherapy.285,286 The effect of combined statin/fibrate therapy compared with statin monotherapy was investigated in the ACCORD-Lipid trial.287 In this study 5,518 patients with type 2 diabetes and established CVD or excess risk and with dyslipidaemia (LDL cholesterol 1.55–4.65 mmol/l, HDL cholesterol below about 1.3 mmol/l and triglycerides below 8.5 mmol/l if not receiving lipid therapy or otherwise below 4.5 mmol/l) were randomised 1++ to fenofibrate or placebo in addition to ongoing open-label statin therapy. No cardiovascular benefit was noted over 4.7 years. There was, however, a borderline interaction suggesting possible benefit in the subgroup with low HDL cholesterol (<0.9 mmol/l) and elevated triglycerides (>2.3 mmol/l), similar to what has been found in post hoc analyses of other fibrate trials.260 | 55 Risk estimation and the prevention of cardiovascular disease It appears that the potential for impaired metabolism of statins with gemfibrozil 288 is greater than with other fibrates, such as fenofibrate.289 This is supported by evidence from healthy volunteers that the combination of fenofibrate with statins is associated with minimal differences in the concentrations of either fenofibrate or statin and also by the safety demonstrated by statin plus fenofibrate combination therapy in ACCORD- 1 ++ 3 Lipid.287,290 In contrast, the concurrent use of certain statins with gemfibrozil has shown a two- to three fold 4 increase in statin levels.291 Analyses of the US Food and Drug Administration Adverse Event Reporting System have suggested that the use of fenofibrate with statins results in fewer reports of rhabdomyolysis per million prescriptions than with gemfibrozil and statins.292 RStatins are the drugs of choice in the management of patients with diabetes with mixed dyslipidaemia and elevated low density lipoprotein cholesterol. 99 Combination therapy with a statin and a fibrate may be considered for combined dyslipidaemia. 99 Statins should not be coadministered with gemfibrozil. 99 L ifestyle advice involving healthy eating habits and physical activity is particularly important in individuals with combined dyslipidaemia. 56 | 11 • Blood pressure lowering 11 Blood pressure lowering Elevated blood pressure (BP) increases the risk of CHD, heart failure, stroke and renal failure.293 Systematic reviews of trials of antihypertensive drugs versus placebo have shown that blood pressure lowering is 1++ associated with reductions in CHD, stroke, heart failure, and cardiovascular and total mortality.294 A dietary pattern low in total fat, saturated fatty acids, and dietary cholesterol, and rich in fruits, vegetables, and low-fat dairy products can produce blood pressure reductions exceeding 11/5 mm Hg in people at 1+ higher cardiovascular risk.295 Weight loss and the restriction of dietary sodium may enhance these effects (see section 5).296,297 An important additional consideration is the use of 24-hour ambulatory blood pressure monitoring (ABPM) for diagnosis of hypertension as recommended in other national guidelines.42 This issue is not addressed in detail as diagnosis of hypertension is not included in this guideline, and major intervention trials of blood pressure-lowering treatment have not used ABPM. 11.1 BLOOD PRESSURE THRESHOLDS FOR INTERVENTION WITH DRUG THERAPY The relationship between ‘usual’ blood pressure and cardiovascular risk is approximately linear between the values of 115/70 and 170/100 mm Hg. Within this range, lower usual blood pressure is associated with lower cardiovascular risk.298 People at greater cardiovascular risk derive the most absolute benefit from treatment. 2++ Once a first cardiovascular event has occurred, blood pressure is a poor predictor of recurrent events. In patients without known cardiovascular disease, age is the most important determinant of risk. Setting an arbitrary blood pressure threshold for the use of blood pressure-lowering therapy may therefore not be the most effective way to reduce risk, although this concept has yet to be tested prospectively. Lowering blood pressure has been shown to reduce the risk of both cardiovascular and total mortality, without adverse effect on quality of life. Trials of antihypertensive drugs show a similar relative reduction in coronary heart disease risk of 15–25% and reduction in ischaemic stroke risk of 30–45%.299-305 One Health 1++ Technology Assessment showed that the risk from pre-existing vascular disease strongly outweighs any 4 other risk factor calculation, and concluded that all such patients should be offered, and will benefit from, blood pressure lowering.306 A large meta-analysis which included 147 RCTs of antihypertensive drug therapy involving 464,000 patients reported that lowering systolic blood pressure by 10 mm Hg or diastolic blood pressure by 5 mm Hg reduced the risk of stroke by an estimated 41% (95% CI 33 to 48) and ischaemic heart disease by 22% (95% CI 17 to 27).305 The percentage reduction in major cardiovascular events was similar in patients with and without 1+ prior cardiovascular disease, irrespective of pretreatment blood pressure values (as low as 110 mm Hg systolic and 70 mm Hg diastolic). The proportional reduction in stroke risk may be greater at higher levels of pretreatment blood pressure. The studies included in this meta-analysis were in participants with no history of cardiovascular disease, where the baseline blood pressure was usually high, and patients with established CVD, where baseline blood pressure was not an inclusion criterion. The Blood Pressure Treatment Trialists’ Collaboration published a meta-analysis of 32 RCTs involving 201,566 participants with and without established CVD. In general, the results suggested that it was unlikely that the effectiveness of BP-lowering treatment depends substantively on the starting blood pressure level. 1++ Furthermore, the data support the use of blood pressure-lowering medication in high-risk patients and support the proposition that patients should be selected for treatment on the basis of the absolute level of cardiovascular risk, rather than simply on blood pressure alone.307 | 57 Risk estimation and the prevention of cardiovascular disease The NICE/British Hypertension Society guideline indicates that the following lifestyle activities are associated with a potential reduction in blood pressure:42 yy weight reduction yy reduced salt intake 4 yy limitation of alcohol consumption yy increased physical activity yy increased fruit and vegetable consumption yy reduced total fat and saturated fat intake. 99 ll individuals with a persistent clinic blood pressure ≥140/90 mm Hg or a family history of hypertension A should receive lifestyle advice to help reduce their blood pressure and CVD risk. Lifestyle advice should continue even when drug therapy is initiated. 11.1.1 BLOOD PRESSURE THRESHOLDS FOR INDIVIDUALS WITH SYMPTOMATIC CARDIOVASCULAR DISEASE In the past, the decision to introduce BP-lowering medication was influenced not only by baseline level of BP but also by the presence or absence of pre-existing target organ damage. Increasingly the decision is based on an overall assessment of CVD risk. Many patients in Scotland with elevated BP, though asymptomatic, have subclinical CVD. Furthermore, many of the RCTs and meta-analyses of antihypertensive therapy include patients with and without CVD, with very few reporting on mutually exclusive populations. Nevertheless, for ease of reference the general distinction of individuals with and without symptomatic CVD is retained in this guideline, as the former group still bears a proportionately higher risk. The Joint British Societies’ guideline on the prevention of cardiovascular disease defines target organ damage as any of the following:30 yy heart failure yy established coronary heart disease yy stroke or transient ischaemic attack yy peripheral arterial disease yy abnormal renal function (elevated serum creatinine or proteinuria/microalbuminuria) yy hypertensive or diabetic retinopathy yy left ventricular hypertrophy on electrocardiogram or echocardiogram. Systematic reviews have demonstrated beyond doubt the benefit of lowering blood pressure. The higher the cardiovascular risk, the greater the absolute risk reduction. The effects of blood pressure lowering at different baseline BP were examined in a meta-analysis of 104,359 individuals from 32 RCTs.308 Stage 1 hypertension was defined at SBP 140–159 or diastolic blood pressure (DBP) 90–99 mm Hg; stage 2 hypertension SBP 160–179 or DBP 100–109; and stage 3 hypertension SBP at least 180 mm Hg or DBP at least 110 mm Hg. Significant benefits were observed from BP lowering at all hypertension grades and this applied to all outcome measures except heart failure in grade 1 hypertension and all-cause mortality in grade 3 hypertension. The largest relative risk reductions were for stroke (27–42% 1 + across different baseline hypertension grades) and heart failure (20–55%), with smaller reductions in CHD (12–17%), cardiovascular mortality (13–22%), and all-cause mortality (7–18%). Risk ratios did not show any significant trend to change with increasing baseline BP levels. Even in patients with stage 1 hypertension, with a low to moderate cardiovascular risk (<5% risk of cardiovascular death over 10 years), and a mean baseline BP of 146/91 mm Hg, the NNT over five years to prevent one cardiovascular event was 29. 58 | 11 • Blood pressure lowering In a meta-analysis of individual patient data in 201,566 patients across 32 RCTs when blood pressure was analysed as a continuous variable, no consistent interaction was found between the baseline blood pressure level and the effectiveness of blood pressure-lowering treatment.307 Blood pressures reported in this study ranged from <140 mm Hg to >180 mm Hg systolic and from <80 mm Hg to >100 mm Hg diastolic. The 1++ authors suggest that these data imply a greater role for blood pressure lowering in high-risk patients with blood pressure levels that are not conventionally hypertensive. This meta-analysis included studies of blood pressure lowering irrespective of the cardiovascular status of the populations involved, therefore includes data from patients without CVD in addition to those with established disease. Given the evidence that blood pressure lowering reduces the risk of CVD irrespective of pretreatment blood pressure, it could be argued that blood pressure-lowering treatment could be offered to any person at high risk of cardiovascular disease, not just those with hypertension. The safety and effectiveness of such an approach has not been tested, however, and the balance between benefits and harms, especially in people with low baseline blood pressure, as well as the cost effectiveness of such a strategy remain unclear. RIndividuals with clinical evidence of cardiovascular disease and sustained clinic systolic blood pressure >140 mm Hg systolic and/or diastolic blood pressure >90 mm Hg should be offered blood pressure-lowering drug therapy. Patients who have had a stroke or TIA The PROGRESS trial randomised patients who had had a stroke to blood pressure-lowering therapy or placebo irrespective of initial blood pressure.301 This trial convincingly demonstrated the benefits of BP lowering in reducing both ischaemic and haemorrhagic stroke. The relative reduction in risk of recurrent stroke was 1++ similar in hypertensive and non-hypertensive individuals (32% v 27%), the mean baseline BP in the latter group being 136/79 mm Hg. Significant reductions in risk of recurrent stroke were reported in patients receiving combination therapy with perindopril plus indapamide in whom BP was lowered by an average of 12/5 mm Hg, but not in those on perindopril alone in whom BP was lowered by an average of 5/3 mm Hg. RIndividuals who have had a haemorrhagic or ischaemic stroke, or TIA should be offered blood pressure-lowering medication, even when their baseline blood pressure is at a level that would be considered conventionally normotensive, to reduce the risk of recurrence. 11.1.2 BLOOD PRESSURE THRESHOLDS FOR INDIVIDUALS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE A number of meta-analyses were identified which report on the effects of BP lowering in patients without CVD. These studies involve a total of over 250,000 participants, giving substantial power to support the conclusions. In general, BP lowering reduces the risk of stroke, heart failure, coronary events, cardiovascular and all-cause mortality. In subsets of patients with specific clinical factors, slightly different conclusions may be drawn about the strength of these effects, which may reflect the smaller numbers and limited power in such subgroup analyses. One meta-analysis of 11 trials, each of which had a minimum of 1,000 patient-years of planned follow up, included a total of 51,917 participants. Seventy five per cent of the participants had no prior history of CVD. Participants were stratified into four groups according to estimated baseline absolute cardiovascular risk. The mean estimated baseline level of five-year cardiovascular risk for each group was 6%, 12.1%, 17.7% and 1++ 26.8% respectively. Although the relative risk reduction was similar in each group (around 15%), in absolute terms, treating 1,000 patients in each risk group with BP-lowering treatment for five years would prevent 14, 20, 24 and 38 cardiovascular events respectively. These results support the use of predicted cardiovascular risk equations to inform BP-lowering treatment decisions.309 A series of publications provide an overview, meta-analyses and meta-regression analyses of 68 trials of BP lowering incorporating 245,885 individuals.310 In 47 trials BP lowering was the primary aim while in the remainder at least 40% of the randomised patients were hypertensive. Trials exclusively in patients with 1+ acute MI, acute stroke, heart failure or dialysis were excluded. Risk reductions were expressed in relation to a standardised 10/5 mm Hg reduction in BP (which is close to the achieved effects shown in intentional | 59 Risk estimation and the prevention of cardiovascular disease placebo-controlled BP-lowering trials). All cardiovascular outcomes were reduced by BP lowering, with mean absolute reductions of 17 (95% CI 14 to 20) strokes, 28 (95% CI 19 to 35) major cardiovascular events and 8 (95% CI 4 to 12) deaths for every 1,000 patients treated for five years. Absolute risk reduction significantly 1+ increased with increasing baseline cardiovascular risk (p for trend <0.001 except for CHD). A 10/5 mm Hg BP reduction reduced the incidence of major cardiovascular events by 7 (95% CI 3 to 10), 30 (95% CI 9 to 50), 56 (95% CI 35 to 76) and 87 (95% CI 62 to 112) events every 1,000 patient treated for five years across groups defined according to risk. A meta-analysis of 68 trials of BP lowering showed that while absolute risk reductions associated with BP lowering were greatest in those at highest baseline cardiovascular risk compared with those at low to moderate risk (87 instead of seven major cardiovascular events prevented by treating 1,000 patients for five years), the risk level that is found after BP lowering (residual risk) remains much higher (almost 10 times 1+ higher for cardiovascular death) when treatment is initiated at the highest rather than at the lowest stratum of cardiovascular risk. In other words, reserving treatment of hypertension to patients at high cardiovascular risk may not allow the accumulative risk to be reversed as patients get older and may increase the risk of treatment failure.311 No studies were identified that directly address this issue, however it suggests further support to the development of risk estimation tools which stratify risk intervention thresholds by age, rather than provide a single threshold which applies to all (see section 3.4). Evidence of target organ damage such as retinopathy, proteinuria or left ventricular hypertrophy, supports a decision to implement drug therapy in patients with stage 1 hypertension.30 4 RIndividuals at high cardiovascular risk, but without established CVD, and sustained clinic systolic blood pressure >140 mm Hg systolic and/or diastolic blood pressure >90 mm Hg should be offered blood pressure-lowering treatment. Some patients at high cardiovascular risk, but without established CVD, with baseline BP <140/90 mm Hg should be considered for BP-lowering treatment, for example those with diabetes or CKD (see section 11.1.3). The following good practice point is based on recommendations from the JBS3 and NICE/BHS guidelines.30,42 4 99 Individuals with hypertension whose ten-year risk of a first CVD event is below the threshold for consideration of pharmacological therapy should continue with lifestyle strategies and have their blood pressure and total CVD risk reassessed every one to five years, depending on clinical circumstances. Persistent blood pressure elevation ≥160 mm Hg systolic and/or ≥100 mm Hg diastolic, equivalent to stage 2 hypertension, causes sufficient CVD risk on the basis of blood pressure levels alone to require drug therapy 2 ++ 4 to reduce blood pressure (see section 4.4).30,56 RIndividuals with clinic blood pressure greater than 160 mm Hg systolic or 100 mm Hg diastolic should be offered antihypertensive treatment and specific lifestyle advice to lower their blood pressure and risk of cardiovascular disease. 11.1.3 BLOOD PRESSURE THRESHOLDS FOR SPECIFIC GROUPS AT HIGH CARDIOVASCULAR RISK Some patients are at high CVD risk, almost approaching that of individuals with established CVD, and are included in this section, especially as many of the studies relating to such individuals included people with and without symptomatic CVD. People with type 2 diabetes A meta-analysis of blood pressure lowering in people with type 2 diabetes included 100,354 patients in 40 RCTs.312 Blood pressure lowering was associated with improved survival and reduced risk of major cardiovascular events in addition to significant benefits in respect of progression of retinopathy and - 1 development of albuminuria. A 10 mm Hg reduction in SBP was associated with reduced relative risk of all-cause mortality (0.87, 95% CI 0.78 to 0.96), cardiovascular events (0.89, 95% CI 0.83 to 0.95), coronary events (0.88, 95% CI 0.80 to 0.98), stroke (0.73, 95% CI 0.64 to 0.83), albuminuria (0.83, 95% CI 0.79 to 0.87) 60 | 11 • Blood pressure lowering and retinopathy (0.87, 95% CI 0.76 to 0.99). The corresponding ARRs, in events per 1,000 patient-years of follow up, were 3.16 (95% CI 0.90 to 5.22) for all-cause mortality, 3.90 (95% CI 1.57 to 6.06) for CVD events, 1.81 (95% CI 0.35 to 3.11) for CHD events, 4.06 (95% CI 2.53 to 5.40) for stroke events, 9.33 for albuminuria 1- (95% CI 7.13 to 11.37) and 2.23 (95% CI 0.15 to 4.04) for retinopathy events. When trials were stratified by baseline SBP, those trials where the baseline was <140 mm Hg showed clear benefit for prevention of stroke and reducing progression of retinopathy and albuminuria, whereas the other end points were not affected. The quality of this evidence is compromised by the literature searches only including one database. RIndividuals with diabetes should be offered blood pressure-lowering treatment if the baseline clinic systolic pressure is >140 mm Hg, to prevent mortality, macrovascular events, and progression of nephropathy and retinopathy. RIndividuals with diabetes should be considered for blood pressure-lowering treatment, even if the systolic clinic blood pressure is <140 mm Hg, to reduce the risk of stroke, progression of retinopathy and albuminuria. At this level of blood pressure, treatment should be targeted at patients thought to be at greatest risk of those complications. People with chronic kidney disease In a meta-analysis from the Blood Pressure Treatment Trialists’ Collaboration data from 152,290 individuals with and without chronic kidney disease participating in 26 RCTs were analysed.313 Compared with placebo, 1++ BP-lowering regimens reduced the risk of major cardiovascular events by 17% per 5 mm Hg reduction in SBP, irrespective of whether they had CKD or not. Specifically, blood pressure lowering in itself, rather than the effects of a particular drug class, seemed to lower the cardiovascular risk. Unfortunately in this analysis no information is provided on baseline blood pressures. Meta-analyses of cohort studies including over 1.4 million individuals reported that after adjustment for traditional cardiovascular risk factors and albuminuria, the risk gradient for cardiovascular mortality was approximately flat when eGFR rates were higher than 75 ml/min/1.73 m² but linearly increased with decreasing eGFR rates below this threshold. Cardiovascular mortality was about twice as high in patients with stage 3 chronic kidney disease (eGFR 30–59 ml/min/1.73 m²) and three times higher at stage 4 (15–29 ml/min/1.73 2++ m²) than that in individuals with normal kidney function. In contrast to the non-linear risk relationship for eGFR, no threshold effect was reported for the association of albuminuria with cardiovascular risk, even after adjustment for traditional cardiovascular risk factors and eGFR. The adjusted risk of cardiovascular mortality is more than doubled at the upper end of the microalbuminuria range (30–299 mg/g), compared with the risk in individuals with normal albuminuria.314,315 This lack of threshold effect indicates that albuminuria even at the upper end of the normal range (threshold 30 mg/g) confers cardiovascular risk. RAll people with stage 3 or higher chronic kidney disease, or micro- or macroalbuminuria should be offered blood pressure-lowering treatment. People on dialysis In patients on dialysis, BP lowering was associated with a lower risk of cardiovascular events (RR 0.71, 95% CI 0.55 to 0.92), all-cause mortality (RR 0.80, 95% CI 0.66 to 0.96), and cardiovascular mortality (RR 0.71, 95% CI 0.50 to 0.99).316 The effects were not clearly associated with the presence or absence of hypertension, although the analysis was not adequately powered to state this with confidence. Similarly, it was underpowered to 1++ distinguish the effects of blood pressure lowering from the effects of individual drug classes. Because of the wide range of baseline blood pressures included in these trials, the wide range of blood pressures reductions achieved, and the innate variability of blood pressure in patients undergoing dialysis, it is not possible to comment on a specific threshold BP for treatment, although the data strongly support the use of BP-lowering treatment in patients on dialysis to prevent cardiovascular events and improve survival. R All patients on dialysis should be offered blood pressure-lowering treatment. | 61 Risk estimation and the prevention of cardiovascular disease Older people Data in the elderly are less robust, but one major RCT examined blood pressure lowering in patients aged over 80.317 At baseline patients had a sustained SBP of ≥160 mm Hg, with a mean baseline BP of 173.0/90.8 mm Hg. First-line treatment in the active-therapy group was indapamide, supplemented by perindopril. In 1+ the active-treatment group there was a 30% reduction in fatal and non-fatal stroke, 21% reduction in all- cause mortality, 23% fewer deaths from cardiovascular disease, and a 64% lower risk of heart failure. Adverse events were less frequent in the active-treatment group. 11.2 TARGET VALUES FOR BLOOD PRESSURE LOWERING The relationship between blood pressure and cardiovascular risk is continuous and targets have been lowered over recent years as evidence of benefit and safety has accumulated. Numerous overviews and meta- analyses have documented beyond reasonable doubt the benefits of blood pressure lowering in patients with hypertension with respect to virtually all major outcome measures. In very general terms, they have also shown that the lower the achieved blood pressure the greater the benefits. A meta-analysis of studies published between 1966 and 2013 included 245,885 patients.310 Although the quality of the individual trials was mixed and heterogeneity was not fully explored, the analysis provides a precise estimate of treatment effects. Overall, lowering BP prevented 28 (95% CI 19 to 35) major cardiovascular events per 1,000 patients treated for five years, including 17 (95% CI 14 to 20) strokes and eight (95% CI 4 to 12) deaths. Benefits were proportional to the reduction of both SBP and DBP, although progressively greater 1 + BP reductions resulted in progressively lower increments of risk reduction. In a subset analysis of achieved blood pressures (104,359 individuals) the relative and absolute risk reductions were greater at an achieved SBP of 140 mm Hg compared with 150 mm Hg. At SBP less than 130 mm Hg, only stroke and all-cause mortality were significantly reduced. Outcomes were significantly reduced at DBP of 80 mm Hg compared with 90 mm Hg, but only stroke was reduced at an achieved DBP below 80 mm Hg.308 Evidence for an optimal level of diastolic blood pressure, drawn from a large meta-analysis of antihypertension intervention trials, indicates that the further the diastolic blood pressure can be reduced, the greater the reduction in cardiovascular risk without any convincing evidence of a J-curve relationship.318 The HOT trial 1 ++ reported that the optimal target blood pressure in patients with a diastolic BP of 100–115 mm Hg was 139/83 mm Hg.299 One meta-analysis reported on more, compared with less strict blood pressure targets, identifying 19 trials of 44,989 patients of any age including those with hypertension, high risk of CVD or renal disease or both.319 During a mean 3.8 years of follow up 2,496 major cardiovascular events were recorded. Patients in the more intensive blood pressure-lowering treatment group had mean blood pressure levels of 133/76 mm Hg, compared with 140/81 mm Hg in the less intensive treatment group. Intensive blood pressure-lowering treatment achieved relative reductions in the risk of major cardiovascular events (14%, 95% CI 4 to 22), myocardial infarction (13%, 95% CI 0 to 24), stroke (22%, 95% CI 10 to 32), albuminuria (10%, 95% CI 3 to 16), and retinopathy progression (19%, 95% CI 0 to 34). More intensive treatment had no clear effects on heart 1 + failure (15%, 95% CI -11 to 34), cardiovascular death (9%, 95% CI -11 to 26), total mortality (9%, 95% CI -3 to 19) or end stage kidney disease (10%, 95% CI -6 to 23).The absolute benefits were greatest in trials in which all enrolled patients had vascular disease, renal disease or diabetes. Serious adverse events associated with blood pressure lowering were only reported in six trials, and had an event rate of 1.2% per year with intensive treatment compared with 0.9% with less intensive treatment. Severe hypotension was more frequent with the more intensive treatment regimens (RR 2.68, 95% CI 1.21 to 5.89, p=0.015) although the absolute excess was small (0.3% v 0.1% per person-year for the duration of follow up). The authors conclude that this analysis provides clear evidence of the benefits of more intensive blood pressure lowering, particularly in high-risk patient groups. The Systolic Blood Pressure Intervention (SPRINT) trial 320 recruited hypertensive patients at high cardiovascular risk, but excluded those with diabetes or prior stroke. Standard treatment aimed for a systolic BP of less than 140 mm Hg, while the intensive treatment group aimed for a systolic BP of less than 120 mm Hg. Critically, these pressures were measured by semiautomated devices, in the absence of a medical attendant, after several 62 | 11 • Blood pressure lowering minutes rest. The study was stopped after only 3.3 years of follow up because of a significantly lower rate of the composite primary outcome (1.65% per year v 2.19%) in the intensive group, although at the expense of an increase in the number of adverse effects from treatment. A number of features of this trial make interpretation of the results problematic, particularly in the context of usual practice within NHSScotland. As a result the GDG has chosen not to give undue emphasis to this individual study, whilst acknowledging that it broadly supports the strategy of considering tighter blood pressure targets in high-risk patients. The cost effectiveness of different targets for the reduction in BP was analysed using clinical data from the HOT trial.321 The trial randomised patients to three DBP target groups, with the hypothesis that the lower the target, the better the outcome but the higher the drug costs. No statistical difference in the number of events avoided for the three target groups was shown. Significant reductions in event rates were found in a subset analysis of people with diabetes, which limited the cost-effectiveness analysis to this group. The study concluded that in patients with diabetes, compared with maintenance doses of calcium channel blockers, intensive treatment to a lower blood pressure target (≤80 mm Hg), was cost effective. 11.2.1 TYPE 2 DIABETES A meta-analysis of blood pressure reduction targets in 37,736 participants with type 2 diabetes or impaired fasting glucose from 13 RCTs investigated intensive blood pressure reduction.322 Lowering blood pressure to a more intensive target of <135 mm Hg systolic compared with a less intensive target (<140 mm Hg) was associated with a 10% reduction in risk of all-cause mortality (OR 0.90, 95% CI 0.83 to 0.98, ARR 0.53%) a 17% reduction in the risk of stroke (OR 0.83, 95% CI 0.73 to 0.95, ARR 0.41%), and a 20% relative increase in the 1++ risk of serious adverse events (OR 1.20, 95% CI 1.08 to 1.32). Although there was a direct linear relationship between SBP and stroke, with lower better, the same was not true for other outcomes. Even more intensive BP control (≤130 mm Hg) was associated with a further reduction in stroke but did not affect cardiac and microvascular outcomes and there was a 40% increase in serious adverse events. A Cochrane review of five RCTs with a mean follow up of 4.5 years involved 7,314 patients with type 2 diabetes.323 The largest of these trials (ACCORD 2) compared outcomes in respect of achieved systolic blood pressure in patients with cardiovascular disease or with increased cardiovascular risk. The incidence of cardiovascular disease (primary event rate) was very close to 2% in both groups. Whilst achieving a blood pressure of 119.3/64.4 mm Hg compared with 133.5/70.5 mm Hg, the only significant benefit in the ‘tighter 1++ control’ group was a reduction in the incidence of stroke (RR 0.58, 95% CI 0.39 to 0.88, ARR 1.1%). The tighter target was achieved only with a significant increase in the risk of serious adverse events (RR 2.58, 95% CI 1.70 to 3.91). In four other trials that examined outcomes by DBP targets no significant differences were found. These trials included some patients who were not hypertensive by conventional definition, and excluded patients with known cardiovascular disease. 11.2.2 CHRONIC KIDNEY DISEASE Little evidence was identified which investigated the impact of different blood pressure treatment targets on cardiovascular outcomes in patients with CKD. A large meta-analysis involving over 150,000 patients with and without CKD reported no clear benefit for more intensive compared with less intensive blood pressure- 1++ lowering regimens in people with CKD, although there was only limited power for these analyses and little capacity to detect whether the effects of treatment varied according to kidney function.313 11.2.3DIALYSIS No evidence was identified which supported the definition of an optimal blood pressure target for patients on dialysis. Physiological and dialysis-related mechanisms influencing blood pressure in patients on dialysis are complex with the effect on cardiovascular risk unclear. A consensus conference of the Kidney Disease: Improving Global Outcomes (KDIGO) group discussed the existence of a ‘U-shaped’ association between predialysis blood pressure and mortality based on a cohort study showing that the risk of death is lowest in dialysis patients with a pre-dialysis SBP between 100 and 125 4 mm Hg, whereas SBP >150 mm Hg was associated with increased mortality. KDIGO notes that the modifying effect of cardiomyopathy in hypertensive patients resulting in attainment of blood pressure targets relevant | 63 Risk estimation and the prevention of cardiovascular disease to non-dialysis patients make it difficult, without further cardiac investigation, to distinguish patients with a satisfactory target blood pressure from those with severe cardiac disease. Use of echocardiography is 4 essential to understand this problem.324 11.2.4CONCLUSIONS The optimal target blood pressures to be achieved with therapy have not yet been unequivocally established from the available evidence. A long-term trend towards lower target pressures has been reversed in recent years, at least for some patient subgroups, for example patients with diabetes, those with CHD, and the elderly. This has been reflected in reports and position statements from the European Society of Cardiology/European Society of Hypertension,325 from the US Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8)326 and from the American Heart Association/ American College of Cardiology/American Society of Hypertension.327 More recent evidence, referred to in the current guideline (see section 11.2), points to a potential revision of this position. Translating very strict targets from tightly controlled clinical trials to routine practice presents many challenges, including choice of combination therapy, dose titration, more frequent supervision, and monitoring for patient safety, not to mention patient engagement. In order to balance current evidence for benefit and harm within the context of feasible service delivery, the guideline development group has adopted a reasonably conservative approach, recognising that even with the targets recommended here, the control of about half of all patients with hypertension may remain suboptimal. RIndividuals with uncomplicated hypertension should be supported to achieve a BP target of <140/90 mm Hg (clinic measurement). RFor individuals with established CVD and diabetes, chronic renal disease or target organ damage a lower blood pressure target of <135/85 mm Hg (clinic measurement) should be considered. RLowering BP below 130/80 mm Hg is not routinely recommended as this brings limited additional benefits and causes significant adverse effects. 99 T hese target figures are a general guide, and may be adapted in the light of medicines tolerance, and in particular in the frail or elderly, who may be more susceptible to adverse effects of treatment. In such patients, more modest reductions in blood pressure may still be beneficial. 11.3 SELECTION OF ANTIHYPERTENSIVE THERAPY The weight of evidence suggests that blood pressure lowering, rather than pharmacological action, confers almost all the benefit in preventing cardiovascular events.307 There are four major classes of antihypertensive drug (thiazides, ACE inhibitors, angiotensin receptor blockers (ARB, also known as angiotensin-II receptor antagonists) and calcium channel blockers) which are equally ++ 1 effective, and more effective than beta-blockers, at reducing cardiovascular morbidity and mortality per unit fall in blood pressure. There are some important cautions and contraindications for all of the antihypertensive drug classes.318,328,329 In a meta-analysis, all classes of blood pressure-lowering drugs significantly reduced blood pressure from all pretreatment levels. The extent of blood-pressure reduction increased with pretreatment blood pressure. The reductions were similar at standard dose for each class; the average reduction was 9.1 mm Hg systolic and 5 mm Hg diastolic. The effect of combinations of two drugs on blood pressure was additive.306 The adverse 1++ effect profiles of drugs could be minimised by using half-standard or standard doses, rather than titrating any given drug to higher doses. This does not apply to ACE inhibitors or ARBs, where the adverse effects are present or absent, regardless of dose. The meta-analysis presents a rationale for polypharmacy, utilising modest doses of more than one antihypertensive agent in order to maximise control whilst minimising adverse effects. 64 | 11 • Blood pressure lowering The ASCOT-BPLA study recruited 19,257 patients, including many from Scotland, to treatment with two combinations of antihypertensive drugs.330 The study tested whether a newer antihypertensive combination treatment, comprising the calcium channel blocker (CCB) amlodipine and the ACE inhibitor perindopril, was more effective than an older combination regimen of the beta blocker atenolol and the diuretic 1++ bendroflumethiazide. The trial was terminated early because of a large difference in mortality between the older drugs and the newer ones, favouring the amlodipine+perindopril combination. The trial showed that amlodipine+perindopril were significantly more effective at reducing strokes (327 v 422; unadjusted HR 0.77, 95% CI 0.66 to 0.89, p=0.0003), total cardiovascular events (1,362 v 1,602; HR 0.84, 95% CI 0.78 to 0.90, p<0.0001) and all-cause mortality (738 v 820; HR 0.89, 95% CI 0.81 to 0.99, p=0.025) than atenolol with bendroflumethiazide. A large RCT of 33,357 patients reported on blood pressure lowering in individuals with high global risk and hypertension. A significant proportion of the participants had overt vascular disease as indicated by previous cardiovascular events (MI, stroke), or ongoing symptoms (angina, intermittent claudication). All had moderate hypertension, whether on therapy or untreated. Extensive analysis of this trial and data subsets shows evidence of reduced event rate regardless of starting blood pressure, within the parameters 1++ of trial inclusion.331 Participants were randomised to receive a thiazide-like diuretic (chlorthalidone, 12.5 to 25 mg daily); a CCB (amlodipine, 2.5 to 10 mg daily); or an ACE inhibitor (lisinopril, 10 to 40 mg daily). There was no significant difference between groups in combined fatal CHD or non-fatal MI. Five-year SBP was significantly higher in the amlodipine (0.8 mm Hg, p=0.03) and lisinopril (2 mm Hg, p<0.001) groups compared with chlorthalidone, and five-year DBP was significantly lower with amlodipine (0.8 mm Hg, p<0.001). For amlodipine versus chlorthalidone, outcomes were similar except for a higher six-year rate of heart failure with amlodipine (10.2% v 7.7%; RR, 1.38, 95% CI 1.25 to 1.52). 99 In any individual with hypertension, consideration should be given to using two or more antihypertensive agents, in half to standard doses, to achieve additive blood pressure lowering whilst minimising the adverse effect profile. 11.3.1 THE BRITISH HYPERTENSION SOCIETY ALGORITHM The British Hypertension Society A/CD algorithm has been widely adopted for deciding upon drug therapy for an individual. The algorithm was ratified by the ASCOT trial and accepted by The Joint British Societies’ Guidelines as the best method of defining combination drug therapy.30 The algorithm and subsequent adaptations established that initial therapy for primary hypertension should be stratified according to age and ethnicity. In 2011 NICE and the BHS released jointly a revised guideline that updated the clinical evidence base to include recent RCTs and included a cost-effectiveness analysis comparing the various blood pressure-lowering drug classes.42 The results showed that: yy beta blockers are the least clinically and cost-effective drug at preventing major cardiovascular events yy calcium channel blockers are the most clinically and cost-effective choice for the majority of people aged over 55 years but thiazide-type diuretics represent an alternative for those with heart failure or the very elderly who are intolerant of calcium channel blockers yy when choosing a thiazide-like diuretic chlortalidone or indapamide may be more effective than bendroflumethiazide yy for people under the age of 55, drugs affecting the renin-angiotensin system are recommended. The recommendations based on this evidence are summarised in the A/CD algorithm shown in Figure 1. It incorporates the recommended classes of antihypertensive drugs. Although not specifically validated by a clinical trial, the recommended drug combinations and sequencing are similar to those used in many clinical trials of blood pressure-lowering drugs. | 65 Risk estimation and the prevention of cardiovascular disease Figure 1: The NICE/British Hypertension Society A/CD algorithm for blood pressure Aged under 55 Aged over 55 years, or black years person of African or Caribbean family origin of any age Step 1 A C* Step 2 A + C* Step 3 A+C+D Resistant hypertension A + C + D + consider further diuretic†,‡ or Step 4 alpha blocker¶ or beta blocker¶ Consider seeking expert advice A = ACE inhibitor or low cost ARB, C = calcium channel blocker, D = thiazide-type diuretic. * A CCB is preferred but consider a thiazide-like diuretic if a CCB is not tolerated or the person has oedema, evidence of heart failure or a high risk of heart failure. † Consider a low dose of spironolactone‡ or higher doses of thiazide-type diuretic. ‡ At the time of publication of this NICE/BHS guideline (August 2011), spironolactone did not have a UK marketing authorisation for this indication. Informed consent should be obtained and documented. ¶ Consider an alpha or beta blocker if further diuretic therapy is not tolerated, or is contraindicated or ineffective. National Institute for Health and Clinical Excellence (2011) Hypertension: the clinical management of primary hypertension in adults. Methods, evidence, and recommendations (CG127). Available from: www.nice.org. uk/guidance/cg127. NICE has not checked the use of its content in this guideline to confirm that it accurately reflects the NICE publication from which it is taken. This material is provided under the terms of NICE’s Open Content licence (www.nice.org.uk/re-using-our-content/uk-open-content-licence). 66 | 11 • Blood pressure lowering 11.4 MULTIPLE RISK INTERVENTIONS One Cochrane review of 55 trials, including 163,471 participants, investigated the effects of interventions which used counselling and education to facilitate behaviour change that aimed to reduce more than one risk factor (multiple risk-factor interventions) in people without evidence of cardiovascular disease.332 Pooled effects suggested that multiple risk-factor interventions had no effect on mortality (RR 1.00, 95% CI 0.96 to 1.05) but yielded small reductions in blood pressure and cholesterol. Significant reductions in total mortality 1+ and combined fatal and non-fatal cardiovascular events were reported from results of trials involving people with hypertension (16 trials) and diabetes (five trials): OR 0.78 (95% CI 0.68 to 0.89) and OR 0.71 (95% CI 0.61 to 0.83), respectively. The authors note that multiple risk-factor interventions appear to be more effective in high-risk populations who may be more highly motivated to act on counselling and education and may also benefit because they were more likely to adhere to their drug medications. Treating large numbers of individuals in low-risk populations may result in small treatment benefits being outweighed by small treatment risks.333,334 Evidence suggests that health promotion interventions achieve 1+ limited benefits in general populations at relatively low cardiovascular risk and the high costs of such approaches may be better used in people at higher cardiovascular risk. | 67 Risk estimation and the prevention of cardiovascular disease 12 Psychological issues 12.1 THE IMPACT OF PSYCHOLOGICAL WELLBEING ON CARDIOVASCULAR RISK Stress is perceived by the majority of cardiac patients to have been an important cause of their heart disease. This belief is also common among the general public, and confusion exists among health professionals as to its role in the development of and outcome with CHD. Stress is a commonly used global term which has different interpretations making accurate measurement problematic. Social isolation or lack of social support, work stress, and acute and chronic life events can serve as stressors, with resulting psychological outcomes such as depression and anxiety. A review of systematic reviews undertaken by an Expert Working Group of the National Heart Foundation of Australia identified 15 reviews showing strong and consistent evidence that depression and social isolation or lack of quality social support are independent risk factors for the development of CHD and subsequent prognosis.335 The largest of these reviews provides strong and consistent evidence for both of these factors but also evidence that aspects of work-related stress may be associated with increased risk.336 The review 2 ++ concluded that depression, social isolation and lack of social support are significant risk factors for CHD and are independent of conventional risk factors such as smoking, hypercholesterolaemia and hypertension with a similar strength of association (one to two-fold increased risk of developing CHD with minor depression and three to five-fold increase with major depression). Social isolation/lack of quality social support is also of a clinically significant magnitude (two to three-fold increased risk of developing CHD and three to five-fold increased risk of death in patients with CHD). There is no clear evidence to suggest that treating depression is effective in reducing risk. Increased attention to conventional risk factors in patients with depression may be appropriate.337 Further research is necessary to determine the underlying mechanisms accounting for this increased risk and to determine which interventions are effective in treating it. There is evidence that anxiety is an independent risk factor for CVD.338 A systematic review and meta-analysis of 37 prospective population studies (including 1,565,699 participants), with mean follow up of 1–24 years, suggested that anxiety (defined as anxiety disorder or increased anxiety symptoms) was associated with new onset of atherosclerotic CVD, relative to no anxiety in people free from CVD at baseline. There was a high likelihood of publication bias in the studies but, when this was adjusted for, there remained an increased 2++ incidence of CVD associated with anxiety (HR 1.41, 95% CI 1.26 to 1.57). This risk estimate might be an overestimation because confounders were insufficiently accounted for, for example only a third of studies adjusted for comorbid depression and only a minority of studies adjusted for psychotropic medication, which has been associated with increased cardiovascular risk. Nevertheless, risk estimates from studies that accounted for depression (14 comparisons, HR 1.57, 95% CI 1.29 to 1.90) or multiple CVD risk factors (34 comparisons, HR 1.50, 95% CI 1.33 to 1.71) were comparable with the overall pooled HR, reinforcing the suggestion that anxiety may be an independent risk factor for CVD. A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in 7,973 patients with CHD found a non-specific association between generalised anxiety disorder and MCE.339 The association was significant in outpatient groups only, mainly referring to people 2+ who have had an MCE and are subsequently discharged from hospital. It was not clear if anxiety had a contributory effect on CHD. It was also not possible to assess the extent of the increase in MCE by anxiety subtypes independent of depression, due to high levels of comorbidity. The studies included were of low quality, included no RCTs and were highly heterogeneous. There is consistent evidence that catastrophic life events of a highly stressful nature such as earthquakes or ++ 2 terrorist attacks and, to a lesser degree, bereavement are associated with increased cardiac risk.335 A systematic review of 26 cohort studies investigating work stress revealed moderate evidence that stress at work is related to cardiovascular morbidity and mortality.340 The association between job stress and cardiovascular disease in women was not clear and associations were weaker in participants above the age of 55. 68 | 12 • Psychological issues A meta-analysis of 13 cohort studies found that job strain was associated with a small increased risk of an incident cardiovascular event.341 However, contrary to the previous review, this study showed broadly similar results for men and women, and for those younger and over 50. There were a number of limiting factors. 2+ The methodological quality of the included studies was not assessed and included unpublished studies. The analysis found a substantial difference between the published and unpublished studies with unpublished studies showing a weaker association between job strain and CHD. The INTERHEART study reported on risk factors, including psychosocial factors, in 11,119 cases of MI and 13,648 controls across 52 countries.342 Composite variables of subjective stress (home, work, and financial stress, low self-efficacy and self-reported retrospective rating of depression) appeared to be associated with increased risk of developing an acute MI across gender, nationality, ethnic groups, and to be independent 2++ of smoking and socioeconomic status. There are some major concerns regarding the methods of measuring stress in this study, which was undertaken in a non-standardised way, and retrospectively relying on patient memory and perception over the previous 12 months. It does indicate that some undefined elements of stress contribute to increased risk of cardiac events across cultures. A precise definition of work stress and consistency of measurement in studies is lacking. Previously, there was some evidence that work-related CHD risk was affected by individual personality factors such as coping styles, availability of support and other psychosocial factors rather than work-specific characteristics. While 2++ early studies suggested that personality traits such as type A behaviour or hostility might be associated with increased cardiovascular risk, there is now clear evidence that this is not the case.336 RDepression, anxiety and social isolation or lack of quality social support are risk factors for the development and prognosis of cardiovascular disease and should be taken into account when assessing individual risk. The National Institute for Health and Care Excellence has published guidelines on recognition and management of depression in adults with and without a chronic physical health problem.343,344 12.2 INTERVENTIONS FOR PSYCHOLOGICAL DISTRESS 12.2.1 PSYCHOLOGICAL INTERVENTIONS Psychological interventions are based on psychological concepts and theory and aim to help people understand and change their thinking, behaviour and relationships to relieve distress and to improve functioning.345 The stepped-care model which organises the provision of services in a structured manner and emphasises offering the least intrusive but most effective intervention first and progressing to further steps only if the patient does not benefit, or declines the intervention, is described in a UK guideline.343 Cognitive behavioural therapy Cognitive behavioural therapy (CBT) is a structured therapy addressing individuals’ core beliefs, assumptions, thinking patterns and behaviour. It has been shown to be effective in patients with a wide range of conditions, 4 including anxiety, depression, post-traumatic stress disorder and medical conditions.346 Some of the following evidence and recommendation is derived from the SIGN guideline on non-pharmaceutical management of depression in adults.347 There is robust and consistent meta-analysis and systematic review evidence that CBT is more effective than either treatment as usual or waiting list control in the treatment of depression in adults and older adults and is at least as effective as antidepressant medication. For those studies where follow up was examined 1++ CBT was at least as effective as antidepressant medication over six months to two years’ follow up. In some studies CBT was more effective than other psychological therapies whilst other studies suggest CBT has similar effectiveness to other systematic therapies such as psychodynamic therapy and interpersonal therapy.348-353 One systematic review included a comparison of group versus individual CBT and found that patients receiving individual CBT were more likely to improve and had fewer symptoms at follow up than patients 1++ receiving group CBT.348 | 69 Risk estimation and the prevention of cardiovascular disease Use of CBT in patients with either cardiac or other physical health problems (chronic fatigue and chronic pain) as part of an educational and rehabilitation programme has addressed beliefs and attributions and 1++ used goal setting and pacing principles to shape the desired behaviour. Studies note positive outcomes in exercise, activities and mood.288-291 The NICE guideline on management of generalised anxiety disorder (GAD) and panic disorder in adults recommends CBT in people with GAD and marked functional impairment, or those whose symptoms have 4 not responded adequately to step 2 interventions (low-intensity psychological interventions, individual non-facilitated self-help and individual guided self-help and psychoeducational groups).354 R Individual CBT is recommended as a treatment option for patients with depression or anxiety disorders. Mixed interventions A Cochrane review of psychological interventions for patients with CHD included 24 studies where the effect of psychological interventions could be distinguished from other components of rehabilitative treatment (for example exercise).355 There was no strong evidence that psychological intervention reduced total deaths, risk of revascularisation, or non-fatal MI. Amongst a smaller group of studies reporting cardiac mortality there was a modest positive effect from the psychological intervention (RR 0.80, 95% CI 0.64 to 1.00), however, there was some evidence of small-study bias. There was evidence that psychological interventions may produce 1++ small to moderate reductions in depression (standardised mean difference (SMD) -0.21, 95% CI -0.35 to -0.08) and anxiety (SMD -0.25, 95% CI -0.48 to 0.03).There was a wide variation in the types of psychological intervention used to treat cardiac patients included in this review which reflects the uncertainty in the literature linking emotion with cardiac outcomes, however all interventions were delivered by healthcare workers with specific training in the particular psychological techniques required. There was substantial clinical heterogeneity observed in the included studies, which was reflected in significant statistical heterogeneity for psychological outcomes. A systematic review examined the effectiveness of psychological interventions for patients with CHD and their partners.356 The review included only seven studies, comprising 673 patients, of which two studies demonstrated modest improvements in depression, anxiety, knowledge of disease and treatment, and 1++ satisfaction with care, and in partners’ anxiety, knowledge and satisfaction. One study showed a beneficial effect on blood pressure. There was no evidence of significant effects on mortality, morbidity or cardiovascular risk factors. The studies were generally of poor methodology and excluded studies were not listed. Lifestyle interventions, including relaxation, are often recommended as initial treatment for mild hypertension, although the efficacy is unclear. A Cochrane review was conducted to clarify the effects of relaxation therapies on cardiovascular outcomes and blood pressure in people with elevated blood pressure. This review included 1++ 25 RCTs with 1,198 participants. It noted that the poor quality of the trials included and the unexplained variation between the trials meant that evidence in favour of causal association between relaxation and blood pressure reduction is weak.357 RPsychological treatments for patients with mood and anxiety disorders and comorbid cardiovascular disease should be considered. 99 atients who present with more complex psychological problems should be considered for referral to P mental health services for assessment and delivery, where appropriate, of high-intensity or specialist treatments. 70 | 12 • Psychological issues Therapist training, skill and competence The effectiveness of any intervention depends on the training and competence of the therapist. NHS Education for Scotland recommends that therapists need to be trained to recognised standards, have the competences 1+ necessary to deliver psychological interventions effectively to the tier of service within which they work; 4 deliver well-articulated therapy, adhering to the appropriate model and; operate within a well-governed system which offers regular high-quality, model-specific clinical supervision, support and relevant CPD.345 99 ractitioners using psychological techniques should receive appropriate training and supervision P from a clinical psychologist or therapist with similar level of expertise. 12.2.2 PHARMACOLOGICAL INTERVENTIONS FOR DEPRESSION Three systematic reviews of selective serotonin reuptake inhibitors (SSRIs) in patients with both CHD and diagnosed depression reported that SSRIs showed a small benefit in reducing depression however they 1++ showed no impact on mortality or cardiac events.358-360 Data on the effect on hospital readmission were inconsistent. A systematic examination of recommendations for drug treatment in 12 NICE guidelines for single disease conditions calculated the potential for interactions between drugs recommended across different guidelines and between drugs and diseases.361 Drug-disease interactions were not common, with the exception of those related to CKD. However 89 potential important drug-drug interactions were identified between drugs recommended in the depression guideline and those recommended in the other 11 guidelines analysed. The authors note that by taking account explicitly of the patient’s comorbidities there is the potential to avoid unnecessary interactions. For example, SSRIs are noted to interact with a number of medications which are commonly prescribed in patients with CHD, such as aspirin, clopidogrel, warfarin and dabigatran, increasing the risk of bleeding. In addition there is a noted interaction between SSRIs and tramadol, which is often used to manage pain. Given that around a quarter of people with depression also suffer painful physical conditions, clinicians may wish to consider alternative treatments for depression in such patients.362 RPharmacological treatment with SSRIs in patients with depression and coronary heart disease should be considered, although caution should be taken over patients receiving polypharmacy in whom bleeding risk may be increased. | 71 Risk estimation and the prevention of cardiovascular disease 13 Provision of information This section reflects the issues likely to be of most concern to patients and their carers. These points are provided for use by health professionals when discussing cardiovascular disease with patients and carers and in guiding the production of locally-produced information materials. 13.1 SOURCES OF FURTHER INFORMATION In addition to the information provided at the time of consultation, both patients and carers may be encouraged to access trusted websites or national third sector provider helplines to answer any non-urgent/ non-emergency enquiries. National helplines help provide clarity to patients and carers on a number topics, most commonly a recent diagnosis or test result and/or providing support in reducing cardiovascular risk. NHS inform Telephone: 0800 22 44 88 (8am–10pm) www.nhsinform.scot NHS inform is the national health and care information service for Scotland. It includes a section on heart conditions with information and links to resources to support patients with heart disease. www.nhsinform.scot/illnesses-and-conditions/heart-and-blood-vessels There is also a section providing advice on healthy living for physical and mental wellbeing www.nhsinform. scot/healthy-living British Heart Foundation Ocean Point 1, 94 Ocean Drive, Edinburgh, EH6 6JH Telephone: 020 7554 0000; Heart Helpline: 0300 330 3311 www.bhf.org.uk • Email: bhfhi@bhf.org.uk The BHF is a national heart charity and the largest independent funder of cardiovascular research in the UK. In addition to fundraising activities and allocating research funding, the BHF provides vital support, information and care for patients and their carers. The BHF is leading the fight to prevent more people from developing cardiovascular disease and helping more people to survive a cardiac arrest or heart attack. It provides forums to listen to, engage and influence both patients and key stakeholders. Chest Heart & Stroke Scotland Third Floor, Rosebery House, 9 Haymarket Terrace, Edinburgh, EH12 5EZ Telephone: 0131 225 6963; Advice Line Nurses - 0808 801 0899. (9.30am–4.00pm, Mon–Fri) www.chss.org.uk • Email:admin@chss.org.uk Chest Heart & Stroke Scotland is a health charity set up to improve the quality of life for people in Scotland affected by chest, heart and stroke illness, through medical research, influencing public policy, advice and information and support in the community. Diabetes UK Careline Scotland, The Venlaw, 349 Bath Street, Glasgow, G2 4AA Telephone: (Careline Scotland) 0141 212 8710 www.diabetes.org.uk • Email: careline.scotland@diabetes.org.uk Diabetes UK provides information, advice and support to help people with diabetes manage the condition well, and bring people together for support when it’s needed most. 72 | 13 • Provision of information Heart UK Cholesterol Helpline: 0345 450 5988 (Mon–Fri 10am–3pm) www.heartuk.org.uk • Email: ask@heartuk.org.uk Heart UK is a national charity which provides support, guidance and education services to healthcare professionals and people and families affected by raised cholesterol or other blood fats. Smokeline Caledonia House, Fifty Pitches Road, Cardonald Park, Glasgow, G51 4EB Telephone: 0800 84 84 84 (8am–10pm) www.canstopsmoking.com • Email: smokeline@nhs24.scot.nhs.uk Smokeline is Scotland’s national smoking cessation helpline; open every day from 8am–10pm 13.2 CHECKLIST FOR PROVISION OF INFORMATION This section gives examples of the information patients/carers may find helpful at the key stages of the patient journey. The checklist was designed by members of the GDG based on their experience and their understanding of the evidence base. The checklist is neither exhaustive nor exclusive. For all patients: yy d iscuss the relevance of non-modifiable risk factors and empower the patient to change modifiable risk factors where feasible, using positive health promotion. Set goals which are both SMART and person centred yy describe and, where appropriate, provide referral to support services, for example smoking cessation, alcohol services and exercise referral schemes yy ensure that the patient understands the importance of any required follow up. In patients without established CVD: yy be aware of the different routes of presentation to primary care for risk estimation, for example: – patient request – at-risk population called by practice – referred by another professional, for example optician, pharmacist or secondary-care clinic (high cholesterol, high BP etc detected) – following work/private medical insurance check up yy c heck the patient’s understanding of the information provided at the beginning and end of the consultation yy explain the purpose of cardiovascular risk estimation using terminology appropriate to the patient yy explain the individual’s specific levels of risk using terminology and visual tools appropriate to the patient, and yy make patients aware of the role of pharmacists in providing advice about avoiding drug interactions and supporting adherence to prescribing. In patients with established CVD: yy be aware of the different routes of presentation to primary care, for example: – following first cardiovascular event – arranged follow up yy p resenting after a first cardiovascular event, explain the purpose of accurate history taking, examination and blood tests and prioritise lifestyle modifications to reduce future risk, and yy arrange a polypharmacy review which should include advice on stopping medications which are no longer required, and raising awareness of possible drug interactions and adverse effects. | 73 Risk estimation and the prevention of cardiovascular disease 14 Implementing the guideline This section provides advice on the resource implications associated with implementing the key clinical recommendations, and advice on audit as a tool to aid implementation. 14.1 IMPLEMENTATION STRATEGY Implementation of national clinical guidelines is the responsibility of each NHS board and is an essential part of clinical governance. Mechanisms should be in place to review care provided against the guideline recommendations. The reasons for any differences should be assessed and addressed where appropriate. Local arrangements should then be made to implement the national guideline in individual hospitals, units and practices. Implementation of this guideline will be encouraged and supported by SIGN. The implementation strategy for this guideline encompasses the following tools and activities. 14.2 RESOURCE IMPLICATIONS OF KEY RECOMMENDATIONS No recommendations are considered likely to reach the £5 million threshold which warrants a resource impact analysis. 14.3 AUDITING CURRENT PRACTICE A first step in implementing a clinical practice guideline is to gain an understanding of current clinical practice. Audit tools designed around guideline recommendations can assist in this process. Audit tools should be comprehensive but not time consuming to use. Successful implementation and audit of guideline recommendations requires good communication between staff and multidisciplinary team working. The GDG has identified the following as key points to audit to assist with the implementation of this guideline: yy t he proportion of patients who discontinue statin treatment due to reported muscle pain or weakness who are rechallenged with either the same statin or a different statin at the same dose yy the proportion of patients who discontinue statin treatment due to reported muscle pain or weakness who are rechallenged with either the same statin or a different statin at the same dose and remain on treatment one year later yy the proportion of patients with familial hypercholesterolaemia receiving statin treatment yy the proportion of individuals prescribed statins who report statin intolerance and are rechallenged on an alternative statin yy the proportion of patients with BP ≥160/100 mm Hg who are on blood pressure-lowering treatment yy The proportion of patients being treated with blood pressure-lowering medication whose last recorded BP result was <140/90 mm Hg, <135/85 mm Hg or <130/80 mm Hg yy the proportion of patients with diagnosed CKD receiving blood pressure-lowering treatment yy the proportion of patients with CVD receiving: – any statin therapy – intensive statin therapy yy the proportion of GP consultation in which moderate physical activity is recommended. 74 | 14 • Implementing the guideline 14.4 HEALTH TECHNOLOGY ASSESSMENT ADVICE FOR NHSSCOTLAND In February 2017 the SMC advised that evolocumab was accepted for restricted use within NHSScotland in adults with primary hypercholesterolaemia (heterozygous familial (HeFH) and non-familial) or mixed dyslipidaemia, as an adjunct to diet: yy in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-cholesterol goals with the maximum tolerated dose of a statin or, yy alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. It is restricted for specialist use only, when administered at a dose of 140 mg every two weeks, in patients at high cardiovascular risk as follows: yy patients with HeFH and LDL cholesterol ≥5.0 mmol/l, for primary prevention of cardiovascular events, or yy patients with HeFH and LDL cholesterol ≥3.5 mmol/l, for secondary prevention of cardiovascular events, or yy patients at high risk due to previous cardiovascular events and LDL cholesterol ≥4.0 mmol/l, or yy patients with recurrent/polyvascular disease and LDL cholesterol ≥3.5 mmol/l. In August 2016 the SMC advised that alirocumab was accepted for restricted use within NHSScotland in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: yy in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-cholesterol goals with the maximum tolerated dose of a statin, or yy alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. It is restricted for specialist use only in patients at high cardiovascular risk as follows: yy patients with HeFH and LDL cholesterol ≥5.0 mmol/l, for primary prevention of cardiovascular events, or yy patients with HeFH and LDL cholesterol ≥3.5 mmol/l, for secondary prevention of cardiovascular events, or yy patients at high risk due to previous cardiovascular events and LDL cholesterol ≥4.0 mmol/l, or yy patients with recurrent/polyvascular disease and LDL cholesterol ≥3.5 mmol/l. In January 2007 the SMC advised that varenicline was accepted for use within NHSScotland for smoking cessation in adults. The benefits of an additional treatment course in those who have stopped smoking after the initial 12 weeks of therapy appear modest. Efficacy and safety in patients with significant comorbidity are uncertain. In October 2005 the SMC advised that atorvastatin calcium was accepted for restricted use in NHSScotland as an adjunct to diet for the reduction of elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides in children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate. It is restricted to initiation by paediatricians or physicians specialising in the management of lipid disorders. In June 2005 the SMC advised that ezetimibe/simvastatin was accepted for restricted use in NHSScotland only for patients who have failed to achieve target cholesterol levels after titration and optimisation of statin monotherapy and where the combination of ezetimibe 10 mg and simvastatin 20 mg, 40 mg or 80 mg is appropriate. This reflects advice on ezetimibe issued by the Scottish Medicines Consortium in September 2003 (61/03) and is based on the combined tablets being priced at approximately the same level as the individual ingredients. In September 2003 the SMC advised that ezetimibe may be considered in combination with a statin for patients who have failed to reach target cholesterol levels despite treatment with titrated/optimised statins alone. It may also be considered as monotherapy where statins are inappropriate or poorly tolerated. | 75 Risk estimation and the prevention of cardiovascular disease 15 The evidence base 15.1 SYSTEMATIC LITERATURE REVIEW The evidence base for this guideline was synthesised in accordance with SIGN methodology. A systematic review of the literature was carried out using an explicit search strategy devised by a SIGN Evidence and Information Scientist. Databases searched included Cochrane Central Register of Controlled Trials (CENTRAL), National Institute for Health Research - Health Technology Assessment (NIHR-HTA), Medline, Medline In- Process, Embase, Cinahl, PsycINFO and the Cochrane Library. The year range covered was 2009–2015. Internet searches were carried out on various websites including the US National Guidelines Clearinghouse. The main searches were supplemented by material identified by individual members of the development group. Each of the selected papers was evaluated by two Evidence and Information Scientists using standard SIGN methodological checklists before conclusions were considered as evidence by the GDG. 15.1.1 LITERATURE SEARCH FOR PATIENT ISSUES At the start of the guideline development process, a SIGN Evidence and Information Scientist conducted a literature search for qualitative and quantitative studies that addressed patient issues of relevance to risk estimation and prevention of CVD. Databases searched included Medline, Embase, Cinahl and PsycINFO and the results were summarised by the SIGN Patient Involvement Officer and presented to the GDG. 15.1.2 LITERATURE SEARCH FOR COST-EFFECTIVENESS EVIDENCE The GDG identified key questions with potential cost-effectiveness implications, based on the following criteria, where it was judged particularly important to gain an understanding of the additional costs and benefits of different treatment strategies: yy treatments which may have a significant resource impact yy opportunities for significant disinvestment or resource release yy the potential need for significant service redesign yy cost-effectiveness evidence could aid implementation of a recommendation. A systematic literature search for economic evidence for these questions was carried out by a SIGN Evidence and Information Scientist covering the years 2009–2015. Databases searched include Medline, Embase, NHS Economic Evaluation Database (NHS EED) and Health Economics Evaluation Database (HEED). Each of the selected papers was evaluated by a Health Economist, and considered for clinical relevance by guideline group members. Interventions are considered to be cost effective if they fall below the commonly-accepted UK threshold of £20,000 per QALY. 76 | 15 • The evidence base 15.2 RECOMMENDATIONS FOR RESEARCH The GDG was not able to identify sufficient evidence to answer all of the key questions asked in this guideline (see Annex 1). The following areas for further research have been identified: yy r obust economic, epidemiological and feasibility analyses of novel age-stratified and/or life-expectancy maximisation risk estimation tools. yy population studies to assess the incidence of statin intolerance reported in primary care. yy adequately powered RCTs to investigate the effects of stopping statin therapy in people aged ≥85, including cardiovascular and QoL primary outcomes. yy studies investigating the causality of association between anxiety and cardiovascular risk. yy randomised controlled trials of interventions to reduce anxiety in people with diagnosed anxiety disorders and CVD. yy randomised controlled trials in patients with established CVD to determine the benefits and harms of initiating blood pressure-lowering treatment at any level of baseline BP. yy randomised controlled trials in patients without established CVD but elevated BP to determine the benefits and harms of initiating blood pressure-lowering treatment at different levels of baseline estimated cardiovascular risk. yy randomised controlled trials in patients with type 2 diabetes to determine the level of baseline BP at which absolute benefit outweighs risks of initiating blood pressure-lowering treatment. yy exploration of the means whereby blood pressure-lowering treatment in the frail elderly may be optimised. yy randomised controlled trials that directly compare the clinical effectiveness of varenicline with combination nicotine-replacement therapy in respect of biochemically-confirmed quit rates at six months post-treatment; also measuring the impact of attendance at group support sessions or individual support. yy randomised controlled trials on the clinical effectiveness of varenicline in diverse populations and settings (such as older people with comorbidities), particularly including investigation of the risk of a significant adverse occurring in a person taking varenicline. yy long-term surveillance studies to consider the potential health impacts of inhaling the contents of e-cigarettes, electronic nicotine delivery systems and vaporisers. yy randomised controlled trials to directly compare the effectiveness of e-cigarettes and electronic nicotine delivery systems with other smoking cessation treatments on biochemically-confirmed quit rates at six months post-treatment. yy large-scale studies to compare carriers of the ADH1B genetic variant with non-carriers, adequately powered to investigate the impact of alcohol consumption on the different sub-types of stroke and the impact of different patterns of alcohol consumption on cardiovascular risk. yy randomised controlled trials in patients at high cardiovascular risk or with CVD who have high triglycerides and low HDL cholesterol investigating the effect of fibrate therapy on CVD events. yy exploration of the putative mechanisms accounting for the association between cardiovascular risk and depression and RCTs to evaluate the efficacy of interventions to treat depression and their impact on cardiovascular risk. yy long-term RCTs of the efficacy and safety of stanol esters and plant sterols for LDL cholesterol lowering and whether this translates into reductions in CVD events. yy long-term RCTs of the efficacy and safety of substitution of soya products into the diet for LDL cholesterol lowering and whether this translates into reductions in CVD events. yy randomised controlled trials in patients with CKD but no CVD of the efficacy and safety of aspirin for primary prevention of cardiovascular disease. | 77 Risk estimation and the prevention of cardiovascular disease 16 Development of the guideline 16.1INTRODUCTION SIGN is a collaborative network of clinicians, other healthcare professionals and patient organisations and is part of Healthcare Improvement Scotland. SIGN guidelines are developed by multidisciplinary groups of practising healthcare professionals using a standard methodology based on a systematic review of the evidence. Further details about SIGN and the guideline development methodology are contained in ‘SIGN 50: A Guideline Developer’s Handbook’, available at www.sign.ac.uk This guideline was developed according to the 2014 edition of SIGN 50. 16.2 THE GUIDELINE DEVELOPMENT GROUP Professor Naveed Sattar Professor of Metabolic Medicine, University of Glasgow (Chair) Dr Lesley Allan Clinical Psychologist, Crosshouse Hospital, Kilmarnock Ms Ann Auld Lead Pharmacist Prescribing Management, NHS Lanarkshire Mr Edward Clifton Senior Health Economist, Healthcare Improvement Scotland Mr Richard Forsyth Health Services Engagement Lead, BHF Scotland Dr Jason Gill Reader in Exercise Sciences, BHF Glasgow Cardiovascular Research Centre Dr Douglas Hamilton General Practitioner, Glasgow Dr Catherine Hankey Senior Lecturer in Human Nutrition, Glasgow Royal Infirmary Miss Jenny Harbour Evidence and Information Scientist, Healthcare Improvement Scotland Mr John Hitchon Lay Representative, Montrose Mr Chris Macnamee Lay Representative, Edinburgh Miss Jan Manson Health Services Researcher, Healthcare Improvement Scotland Professor Jill Morrison Professor of General Practice, University of Glasgow Dr Moray Nairn Programme Manager, SIGN Dr Brian O’Suilleabhain Consultant in Public Health, University Hospital, Ayr Mrs Lynne Smith Evidence and Information Scientist, Healthcare Improvement Scotland Dr David Preiss Associate Professor and Honorary Consultant in Metabolic Medicine, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford Dr Graeme Tait Consultant Cardiologist, Dumfries and Galloway Royal Infirmary Professor John Webster Consultant Physician, Aberdeen Royal Infirmary 78 | 16 • Development of the guideline The membership of the GDG was confirmed following consultation with the member organisations of SIGN. All members of the GDG made declarations of interest. A register of interests is available in the supporting material section for this guideline at www.sign.ac.uk Guideline development and literature review expertise, support and facilitation were provided by SIGN Executive and Healthcare Improvement Scotland staff. All members of the SIGN Executive make yearly declarations of interest A register of interests is available on the contacts page of the SIGN website www.sign.ac.uk Euan Bremner Project Officer, SIGN Executive Julie Calvert Health Services Researcher, Healthcare Improvement Scotland Claire Daly Distribution and Office Co-ordinator, SIGN Executive Karen Graham Patient Involvement Officer, Healthcare Improvement Scotland Karen King Distribution and Office Co-ordinator, SIGN Executive Heather McIntosh Health Services Researcher, Healthcare Improvement Scotland Stuart Neville Publications Designer, SIGN Executive Gaynor Rattray Guideline Co-ordinator, SIGN Executive Emma Riches Health Services Researcher, Healthcare Improvement Scotland Carolyn Sleith Evidence and Information Scientist, Healthcare Improvement Scotland Pei-Ling Choo Health Services Researcher, Healthcare Improvement Scotland 16.2.1ACKNOWLEDGEMENTS SIGN would like to acknowledge the GDG responsible for the development of SIGN 97: Risk estimation and the prevention of cardiovascular disease, on which this guideline is based. SIGN is also grateful to the following who have contributed to the ongoing work in risk estimation. Dr Kathleen Boyd Lecturer, Institute of Health and Wellbeing, University of Glasgow Professor Andrew Briggs Chair in Health Economics, Institute of Health and Wellbeing, University of Glasgow Mr Ewan Gray Health Economist, Healthcare Improvement Scotland Mr Ciaran Kohli-Lynch Research Student, Institute of Health and Wellbeing, University of Glasgow Dr Jim Lewsey Reader in Medical Statistics, Institute of Health and Wellbeing, University of Glasgow 16.3 THE STEERING GROUP A steering group comprising the chairs of the six SIGN CHD guidelines and other invited experts was established to oversee the progress of the guideline development. This group met regularly throughout the development of the guidelines. Professor Sir Lewis Ritchie, OBE Mackenzie Professor and Head of Department, Department of General (Chair) Practice and Primary Care, University of Aberdeen Mrs Corinne Booth Senior Health Economist, Healthcare Improvement Scotland Mr James Cant (until Feb 2017) Director, British Heart Foundation Scotland Dr Derek Connelly Consultant Cardiologist, Golden Jubilee Hospital, Glasgow Dr Nick Cruden Interventional Cardiologist, Royal Infirmary of Edinburgh Ms Lynda Friel (from Feb 2017) Professional Lead North, Health Services Engagement, British Heart Foundation Scotland Mr Steve McGlynn Principal Pharmacist, Department of Pharmaceutical Sciences, Strathclyde Institute for Biomedical Sciences, Glasgow | 79 Risk estimation and the prevention of cardiovascular disease Dr Susan Myles Lead Health Economist, Healthcare Improvement Scotland Professor David Newby British Heart Foundation Professor of Cardiology, University of Edinburgh Dr Morag Osborne Consultant Clinical Psychologist, West Glasgow Ambulatory Care Hospital, Glasgow Professor Naveed Sattar Professor of Metabolic Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow Mr Gordon Snedden Lay representative, Forfar Professor Allan Struthers Professor of Cardiovascular Medicine and Therapeutics, Ninewells Hospital, Dundee Dr Iain Todd Consultant in Cardiovascular Rehabilitation, Astley Ainslie Hospital, Edinburgh 16.4 CONSULTATION AND PEER REVIEW A report of the consultation and peer review comments and responses is available in the supporting material section for this guideline on the SIGN website. All expert referees and other contributors made declarations of interest and further details of these are available on request from the SIGN Executive. 16.4.1 SPECIALIST REVIEWERS This guideline was reviewed in draft form by the following independent expert referees, who were asked to comment primarily on the comprehensiveness and accuracy of interpretation of the evidence base supporting the recommendations in the guideline. The guideline group addresses every comment made by an external reviewer, and must justify any disagreement with the reviewers’ comments. Professor Annie Anderson Professor of Public Health Nutrition, University of Dundee Professor Colin Baigent Professor of Epidemiology and Deputy Director, Clinical Trial Service Unit, University of Oxford Ms Marissa Collins Researcher in Health Economics, Glasgow Caledonian University Dr Andrew Docherty Consultant Cardiologist, Wishaw General Hospital Professor Frank Dunn Consultant Cardiologist, Stobhill Hospital, Glasgow Ms Jennifer Elliott Specialist Nurse Practitioner, Astley Ainslie Hospital, Edinburgh Professor Mark Hamer Chair in Exercise as Medicine, Loughborough University Professor Tony Heagerty Professor of Medicine and Cardiac Centre Lead in the Institute of Cardiovascular Sciences, University of Manchester Dr Andrew Keen Consultant Health Psychologist, NHS Grampian Dr Jim Lewsey Reader in Medical Statistics, Institute of Health and Wellbeing, University of Glasgow Professor Julie Lovegrove Hugh Sinclair Chair in Human Nutrition, University of Reading Dr Isla Mackenzie Consultant Physician, Ninewells Hospital, Dundee Dr Steve McCabe General Practitioner, Isle of Skye Ms Louise McCombie Chief Operating Officer, Counterweight Ltd Professor Zosia Miedzybrodzka Reader in Medical Genetics, University of Aberdeen Professor Marie Murphy Professor of Exercise and Health, University of Ulster Professor Nanette Mutrie Chair in Physical Activity for Health, University of Edinburgh Professor Stuart Pringle Consultant Cardiologist and President, Scottish Cardiac Society, Perth Royal Infirmary 80 | 16 • Development of the guideline Ms Marie-Claire Shankland Programme Director – Psychology, NHS Education Scotland Dr John Sharp Consultant Psychologist, Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow Dr William Simpson Consultant Chemical Pathologist and Chair, Scottish Lipid Forum, University of Dundee Dr Rani Sinnak Consultant Clinical Health Psychologist, Ayrshire Central Hospital, Irvine Dr John Stout General Practitioner, Peterhead Dr Vivien Swanson Reader/Consultant Health Psychologist, University of Stirling Professor Sarah Wild Professor of Epidemiology and Honorary Consultant in Public Health, University of Edinburgh Professor David Williams Consultant in Stroke Medicine, Beaumont Royal College of Surgeons in Ireland Dr Thomas Yates Senior Lecturer in Physical Activity, Sedentary Behaviour and Health, University of Leicester, Division of Clinical Psychology and Division of Health Psychology, The British Psychological Society, Leicester 16.4.2 PUBLIC CONSULTATION The draft guideline was also available on the SIGN website for a month to allow all interested parties to comment. All contributors made declarations of interest and further details of these are available on request from the SIGN Executive. 16.4.3 SIGN EDITORIAL GROUP As a final quality control check, the guideline is reviewed by an editorial group comprising the relevant specialty representatives on SIGN Council to ensure that the specialist reviewers’ comments have been addressed adequately and that any risk of bias in the guideline development process as a whole has been minimised. The editorial group for this guideline was as follows. All members of SIGN Council make yearly declarations of interest. A register of interests is available on the SIGN Council Membership page of the SIGN website www.sign.ac.uk Dr Roberta James SIGN Programme Lead; Co-Editor Professor John Kinsella Chair of SIGN; Co-Editor Dr Jenny Bennison Vice-Chair of SIGN Mr Gary Cook Royal Pharmaceutical Society Professor Gregory Lip Royal College of Physicians of Edinburgh Dr Susan Myles Healthcare Improvement Scotland | 81 Risk estimation and the prevention of cardiovascular disease Abbreviations ABPM ambulatory blood pressure monitoring ACE angiotensin converting enzyme ACS acute coronary syndrome ACCORD-Lipid The Action to Control Cardiovascular Risk in Diabetes-Lipid trial ADH1B alcohol dehydrogenase 1B AHA American Heart Association AIM-HIGH Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes trial ARB angiotensin receptor blocker ARR absolute risk reduction ASCOT-BPLA Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm ASH Action on Smoking and Health ASSIGN Assessing cardiovascular risk using SIGN guidelines to ASSIGN preventive treatment ATT Antithrombotic Trialists’ Collaboration BC behavioural counselling BHF British Heart Foundation BHS British Hypertension Society BMI body mass index BP blood pressure CBT cognitive behavioural therapy CCB calcium channel blocker CENTRAL Cochrane Central Register of Controlled Trials CHD coronary heart disease CI confidence interval CK creatine kinase CKD chronic kidney disease CTT Cholesterol Treatment Trialists’ Collaboration CV cardiovascular CVD cardiovascular disease DBP diastolic blood pressure DM diabetes mellitus ECG electrocardiogram eGFR estimated glomerular filtration rate ENDS electronic nicotine delivery systems ETS environmental tobacco smoke 82 | Abbreviations EVOO extra virgin olive oil FH familial hypercholesterolaemia FIELD Fenofibrate Intervention and Event Lowering in Diabetes trial FOURIER Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk trial GAD generalised anxiety disorder GDG guideline development group GP general practitioner HbA1c glycated haemoglobin HDL high-density lipoprotein HEED Health Economics Evaluation Database HeFH heterozygous familial hypercholesterolaemia HOT Hypertension Optimal Treatment trial HPS2-THRIVE Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events trial HR hazard ratio HRmax maximal heart rate IDF International Diabetes Federation IMPROVE-IT IMProved Reduction of Outcomes: Vytorin Efficacy International Trial IR immediate release JBS Joint British Societies JBS3 Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease JNC Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JUPITER Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin KDIGO Kidney Disease: Improving Global Outcomes LDL low-density lipoprotein LDL-c low-density lipoprotein cholesterol MA marketing authorisation MCE major cardiovascular event METS metabolic equivalents MI myocardial infarction MR modified release MTA multiple technology appraisal NHS National Health Service NHS EED NHS Economic Evaluation Database NICE National Institute for Health and Care Excellence | 83 Risk estimation and the prevention of cardiovascular disease NIHR-HTA National Institute for Health Research - Health Technology Assessment NNH number needed to harm NNT number needed to treat NPC1L1 Niemann-Pick C1-Like 1 NRT nicotine replacement therapy OR odds ratio PAD peripheral arterial disease PCSK9 proprotein convertase subtilisin/kexin type 9 PREDIMED Prevención con DietaMediterránea trial PROGRESSThe perindopril protection against recurrent stroke study PROSPER The Prospective Study of Pravastatin in the Elderly at Risk PTSD post-traumatic stress disorder QALY quality adjusted life year QoL quality of life RA rheumatoid arthritis RCT randomised controlled trial RPE rating of perceived exertion RR risk ratio or relative risk SBP systolic blood pressure SCD sudden cardiac death SHARP Study of Heart and Renal Protection trial SIGN Scottish Intercollegiate Guidelines Network SMC Scottish Medicines Consortium SMD standardised mean difference SPRINT Systolic Blood Pressure Intervention trial SSRI selective serotonin reuptake inhibitor TC total cholesterol TG triglycerides TIA transient ischaemic attack UK United Kingdom US United States VO2max maximal oxygen uptake WOSCOPS West of Scotland Coronary Prevention Study 84 | Annexes Annex 1 Key questions addressed in this update This guideline is based on a series of structured key questions that define the target population, the intervention, diagnostic test, or exposure under investigation, the comparison(s) used and the outcomes used to measure efficacy, effectiveness, or risk. These questions form the basis of the systematic literature search. Guideline Key question section DIET 5.4, 5.5 1. What is the evidence that dietary modifications are effective in reducing cardiovascular events? Population: adults with and without a clinical diagnosis of CVD consider following subgroups, where possible, BMI ≤25, >25, >30 Intervention: yy stanol esters and plant sterols yy folate, vitamin B6 or B12 (homocysteine lowering) yy dietary patterns: Mediterranean diet, low GI/GL, low carbohydrate Comparators: yy usual diet or placebo Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy blood pressure yy adverse events yy QoL | 85 Risk estimation and the prevention of cardiovascular disease 5.1 2. What is the evidence that altering an individual’s dietary fat intake is effective in reducing cardiovascular events? Population: adults with and without a clinical diagnosis of CVD consider following subgroups, where possible, BMI ≤25, >25, >30 Intervention: yy reduction of total fat intake yy modified fat intake (increased unsaturated fat) yy e ssential fatty acids: includes dietary intake (fish and other sources), food supplements, prescription omega-3 fatty acids (Omacor, Maxepa) Comparators: usual diet or placebo Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy blood pressure yy adverse events yy QoL 5.7 3. What is the evidence that losing weight reduces the risk of adverse cardiovascular outcomes? Population: adults with and without a clinical diagnosis of CVD consider following subgroups, where possible, yy BMI ≤25, >25, >30 yy ethnic minorities yy people with hypertension yy people with diabetes Intervention: yy weight loss yy diet (any) yy composite (eg diet and exercise) yy pharmaceutical yy surgical interventions Comparators: yy no weight loss Outcomes: yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy blood pressure yy adverse events yy QoL 86 | Annexes PHYSICAL ACTIVITY 6.2.3 4. What is the evidence that high-intensity physical activity is effective in reducing cardiovascular events? Population: adults with and without a clinical diagnosis of CVD consider following subgroups, where possible, yy BMI ≤25, >25, >30 yy people with hypertension yy people with impaired glucose regulation yy people with high/low baseline activity levels Intervention: high-intensity physical activity (as defined by authors of individual studies) Comparators: moderate-intensity physical activity no physical activity Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy blood pressure yy QoL 6.2.3 5. Is there any evidence that high-intensity physical activity can increase the risk of sudden death or acute cardiovascular events? Population: adults with and without a clinical diagnosis of CVD consider following subgroups, where possible, yy BMI ≤25, >25, >30 yy people with hypertension yy people with impaired glucose regulation yy people with high/low baseline activity levels Intervention: high-intensity physical activity (as defined by authors of individual studies) Comparators: yy moderate-intensity physical activity yy no physical activity Outcomes: yy cardiovascular mortality yy cardiovascular events(occurring during or soon after intervention) | 87 Risk estimation and the prevention of cardiovascular disease 6.2.4 6. Is there any evidence to show that a reduction in sedentary behaviour can decrease the risk of cardiovascular events? Population: sedentary adults with and without a clinical diagnosis of CVD Intervention: reduction in sedentary behaviour (any intervention) Comparators: maintenance of sedentary behaviour Outcomes: yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy blood pressure yy QoL SMOKING 7.2.1 7. What is the evidence that varenicline is clinically and cost effective for smoking cessation? Population: adult smokers Intervention: varenicline Comparators: yy placebo yy nicotine replacement therapy yy buproprion Outcomes: yy quit rate yy adverse events yy cost effectiveness 7.2.2 8. Is there any evidence that e-cigarettes are clinically and cost effective for smoking cessation? Population: adult smokers Intervention: e-cigarettes Comparators: yy placebo yy other nicotine replacement therapy yy buproprion yy varenicline Outcomes: yy quit rate yy adverse events yy cost effectiveness 88 | Annexes ALCOHOL 8.1 9. What is the evidence that light to medium alcohol consumption is protective against adverse cardiovascular outcomes? Population: adults with and without a clinical diagnosis of CVD Intervention: light to moderate alcohol consumption Comparators: abstinence Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy blood pressure ANTIPLATELET THERAPY 9.2 10 What is the clinical and cost effectiveness and safety of antiplatelet agents for the primary prevention of cardiovascular events? Population: yy adults estimated to be at high risk of CVD using formal risk estimation methods yy adults with diabetes yy adults with hypertension Intervention: yy aspirin yy clopidogrel yy dipyridamole yy prasugrel yy ticagrelor Comparators: yy alternative antiplatelet agent yy placebo Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy adverse events yy cost effectiveness | 89 Risk estimation and the prevention of cardiovascular disease LIPID-LOWERING THERAPY 10.6 11 For adults with and without established CVD what is the clinical effectiveness, cost effectiveness and safety of lipid-lowering medicines (excluding statins)? Population: yy adults with a diagnosis of CVD yy adults estimated to be at high risk of CVD Consider following subgroups, where possible: yy adults with diabetes yy adults with hypertension Intervention: yy bile acid sequestrants (anion-exchange resins) yy fibrates yy ezetimibe yy colestyramine yy nicotinic acid yy PCSK9 inhibitors Comparators: yy statin yy placebo Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL-cholesterol levels yy adverse events yy cost effectiveness 90 | Annexes 10.1–10.5 12 For adults with and without established CVD what is the clinical effectiveness, cost effectiveness and safety of statins? Population: yy adults with a diagnosis of CVD yy adults estimated to be at high risk of CVD Consider following subgroups, where possible: yy adults with diabetes yy adults with hypertension Intervention: statin at moderate or intensive dose Comparators: yy statin at moderate or intensive dose yy placebo Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy adverse events yy cost effectiveness 10.4.6 13 In patients who are intolerant to first line statin therapy, what is the evidence that second or third choice statins can be tolerated? Population: patients intolerant to statins Intervention: alternative statin regimen Comparators: N/A Outcomes: yy compliance yy adverse events | 91 Risk estimation and the prevention of cardiovascular disease 10.5.4 14 Is there any evidence to promote the cessation of statins in the very elderly? Population: elderly statin users (≥85 years) Intervention: statin cessation Comparators: continuation of statin therapy Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy total cholesterol levels yy LDL cholesterol levels yy adverse events yy QoL BLOOD PRESSURE-LOWERING THERAPY 11.1.1, 15 Is there evidence for a lower blood pressure treatment threshold for individuals with 11.1.3 established CVD and diabetes or renal disease? Population: adults with a diagnosis of CVD and: yy diabetes, or yy CKD, or yy target organ damage Intervention: initiation of treatment with antihypertensives at <140/90 mm Hg Comparators: initiation of treatment with antihypertensives at ≥140/90 mm Hg Outcomes: yy all-cause mortality yy cardiovascular mortality yy myocardial infarction yy stroke or TIA yy blood pressure levels yy adverse events yy cost effectiveness yy QoL 92 | Annexes 11.1.2 16 Is there evidence that individuals without established CVD but who are estimated to be at high CVD risk gain benefit from antihypertensive treatment at any baseline blood pressure level? Population: adults without a diagnosis of CVD but estimated to be at high risk of CVD and: yy blood pressure ≥140/90 mm Hg yy blood pressure <140/90 mm Hg Intervention: antihypertensive therapy Comparators: placebo Outcomes: yy all-cause mortality yy cardiovascular mortality yy myocardial infarction yy stroke or TIA yy blood pressure levels yy adverse events yy cost effectiveness yy QoL 11.2 17 Is there evidence for an optimal target value for blood pressure lowering? Population: adults receiving antihypertensives Intervention: lowering blood pressure to <145/85 mm Hg Comparators: lowering blood pressure to <130/80 mm Hg Outcomes: yy all-cause mortality yy cardiovascular mortality yy myocardial infarction yy stroke or TIA yy blood pressure levels yy adverse events yy cost effectiveness yy QoL | 93 Risk estimation and the prevention of cardiovascular disease 11.2.1, 18 Is there evidence for an optimal target value for blood pressure lowering? 11.2.2, Population: 11.2.3, 11.2.4 adults with a diagnosis of CVD and: yy diabetes, or yy CKD, or yy target organ damage Intervention: lowering blood pressure with antihypertensive therapy to <130/80 mm Hg Comparators: lowering blood pressure with antihypertensive therapy to ≥130/80 mm Hg Outcomes: yy all-cause mortality yy cardiovascular mortality yy myocardial infarction yy stroke or TIA yy blood pressure levels yy adverse events yy cost effectiveness yy QoL PSYCHOLOGICAL ISSUES 12.1 19 Is there evidence that anxiety and/or stress are independent risk factors for cardiovascular disease? Population: adults with a diagnosis or at risk of CVD and with a clinical diagnosis of anxiety, post- traumatic stress disorder (PTSD) or chronic stress (eg being a carer or multiple life stressors) Intervention: N/A Comparators: N/A Outcomes: yy cardiovascular mortality yy cardiovascular events 94 | Annexes 12.2 20 Is there evidence that interventions to alleviate anxiety and depression influence cardiovascular risk? Population: adults with a diagnosis or at risk of CVD and with a clinical diagnosis of anxiety, PTSD or chronic stress (eg being a carer or multiple life stressors) Intervention: yy pharmacotherapy yy cognitive behavioural therapy yy stress management yy mindfulness yy interpersonal therapy yy acceptance and commitment therapy Comparators: yy placebo yy alternative interventions Outcomes: yy all-cause mortality yy cardiovascular mortality yy cardiovascular events yy reduction in depression/anxiety/PTSD scores yy adverse events yy QoL | 95 96 | Check the label on Eatwell Guide packaged foods Use the Eatwell Guide to help you get a balance of healthier and more sustainable food. Each serving (150g) contains It shows how much of what you eat overall should come from each food group. 6-8 Annex 2 Energy Fat Saturates Sugars Salt 1046kJ a day 3.0g 1.3g 34g 0.9g Choos 250kcal ay LOW LOW HIGH MED e wh ery d oleg 13% 4% 7% 38% 15% bles ev rain eta Pota or h of an adult’s reference intake veg toes igh Water, lower fat d , br er The Eatwell Guide Typical values (as sold) per 100g: 697kJ/ 167kcal an ead fib milk, sugar-free uit , ri re Choose foods lower f fr Raisins ce ve drinks including s ,p rsi tea and coffee in fat, salt and sugars yo ble as ta on riet e ta a s all count. va g Potatoes nd w ve ith fa d ot Limit fruit juice le an he s so and/or smoothies r s it n s u a to a total of io ta Fr dd 150ml a day. ort rch Chopped ed t omatoe s 5p f yc t a at, rbo leas Whole salt Cous hyd grain l cerea Cous Eat at Risk estimation and the prevention of cardiovascular disease rates and su Frozen Bagels peas gar Whole wheat pasta Porridge Rice Lentils Beans lower salt L o w f at and s o f t ch e es e Spaghetti s ugar Tuna n Plain Leaince Chick m nuts peas Veg O il Semi skimmed Soya Lower fatad spre Crisps milk drink Plain Low fat y o g hu r t Sauce Be an es Oil & spreads Ea s, p ulse ativ d altern so t more s, fis h, eg an and Choose unsaturated oils ur b gs, mea Dairy r fat and use in small amounts red ced eans t and other proteins we tions and fish and p ul se lo p ses, 2 por Choo ugar op proc er we ek tions of sustainably s esse lower Eat less often and d mea, one of which is oily. Eat less t in small amounts Per day 2000kcal 2500kcal = ALL FOOD + ALL DRINKS Source: Public Health England in association with the Welsh government, Food Standards Scotland and the Food Standards Agency in Northern Ireland © Crown copyright 2016 Annexes Annex 3 UK physical activity guidelines Start Active, Stay Active is a report on physical activity for health from the four home countries’ Chief Medical Officers.41 It presents recommendations on the volume, duration, frequency and type of physical activity required throughout life to achieve general health benefits. PHYSICAL ACTIVITY INFOGRAPHIC COLOUR_AW_HR.pdf 1 21/08/2015 14:58 Physical activity benefits for adults and older adults REDUCES YOUR CHANCE OF BENEFITS HEALTH IMPROVES SLEEP MAINTAINS HEALTHY WEIGHT MANAGES STRESS IMPROVES QUALITY OF LIFE Cancers (Colon and Breast) What should you do? UK Chief Medical Officers’ Guidelines 2011 Start Active, Stay Active: | 97 Risk estimation and the prevention of cardiovascular disease Annex 4 Alcohol by volume of wine and lager 10 UK Chief Medical Officers’ Low Risk Drinking Guidelines 2016 9 ©Crown Copyright This publication is licensed under the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit http://www.nationalarchives.gov.uk/doc/open-governmentlicence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU. 98 | References References 15 Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndrome. Edinburgh: SIGN; 2016. (148). [cited 05 May 2017]. Available from url: http://www.sign.ac.uk/sign-148-acute- coronary-syndrome.html 1 Brown L, Campbell-Jack D, Gray L, Hovald P, Kirkpatrick G, Knudsen 16 Scottish Intercollegiate Guidelines Network (SIGN). Management L, et al. The Scottish Health Survey. Edinburgh: National Statistics. of stable angina. Edinburgh: SIGN; 2007. (96). [cited 05 May 2017]. The Scottish Government; 2015. (Volume 1). [cited 05 May 2017]. Available from url: http://www.sign.ac.uk/sign-96-management- Available from url: http://www.gov.scot/Resource/0050/00505798. of-stable-angina.html pdf 17 Scottish Intercollegiate Guidelines Network (SIGN). Cardiac 2 National Records of Scotland. Vital Events Reference Tables 2015. rehabilitation. Edinburgh: SIGN; 2017. (SIGN publication number Section 6: Deaths - Causes. [cited 05 May 2017]. Available from 150). (SIGN publication number 150). Available from url: http:// url: http://www.nrscotland.gov.uk/statistics-and-data/statistics/ www.sign.ac.uk/sign-150-cardiac-rehabilitation.html statistics-by-theme/vital-events/general-publications/vital- events-reference-tables/2015/section-6-deaths-causes 18 Joint Formulary Committee. Guidance on Prescribing. British National Formulary. [cited 05 May 2017]. Available from url: 3 Hallqvist J, Lundberg M, Diderichsen F, Ahlbom A. Socioeconomic https://www.medicinescomplete.com/mc/bnf/current/PHP97234- differences in risk of myocardial infarction 1971-1994 in Sweden: guidance-on-prescribing.htm time trends, relative risks and population attributable risks. Int J Epidemiol 1998;27(3):410-5. 19 Medicines and Healthcare Products Regulatory Agency. Off-label or unlicensed use of medicines: prescribers’ responsibilities. Drug 4 Macintyre K, Stewart S, Chalmers J, Pell J, Finlayson A, Boyd J, et Safety Update 2009;2(9):6-7. al. Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. 20 Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect BMJ 2001;322(7295):1152-3. of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control 5 Nyboe J, Jensen G, Appleyard M, Schnohr P. Risk factors for acute study. Lancet 2004;364(9438):937-52. myocardial infarction in Copenhagen. I: Hereditary, educational and socioeconomic factors. Copenhagen City Heart Study. Eur 21 Emberson J, Whincup P, Morris R, Walker M. Re-assessing the Heart J 1989;10(10):910-6. contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: 6 NHS National Services Scotland, ISD Scotland. Scottish Heart impact of regression dilution bias. Eur Heart J 2003;24(19):1719-26. Disease Statistics 2015. Edinburgh: Information Services Division.; 2016. [cited 05 May 2017]. Available from url: https://www. 22 GBD 2015 Risk Factors Collaborators. Global, regional, and national isdscotland.org/Health-Topics/Heart-Disease/Publications/2016- comparative risk assessment of 79 behavioural, environmental and 01-26/2016-01-26-Heart-Disease-Report.pdf occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. 7 Castelli WP. Epidemiology of coronary heart disease: the Lancet 2016;388(10053):1659-724. Framingham study. Am J Med 1984;76(2A):4-12. 23 Rose G. Strategy of prevention: lessons from cardiovascular disease. 8 National Records of Scotland. Scotland’s Census 2011. [cited 05 BMJ 1981;282(6279):1847-51. May 2017]. Available from url: http://www.scotlandscensus.gov. uk/ethnicity-identity-language-and-religion 24 Zhang X-F, Attia J, D’Este C, Yu X-H, Wu X-G. A risk score predicted coronary heart disease and stroke in a Chinese cohort. J Clin 9 NHS National Services Scotland, ISD Scotland. Scottish Stroke Epidemiol 2005;58(9):951-8. Statistics 2015. Edinburgh: Information Services Division.; 2016. [cited 05 May 2017]. Available from url: https://www.isdscotland. 25 Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, org/Health-Topics/Stroke/Publications/2016-01-26/2016-01-26- Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and Stroke-Report.pdf safety of more intensive lowering of LDL cholesterol: a meta- analysis of data from 170,000 participants in 26 randomised trials. 10 Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating Lancet 2010;376(9753):1670-81. the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25(6):484-91. 26 Beswick A, Brindle P. Risk scoring in the assessment of cardiovascular risk. Curr Opin Lipidol 2006;17(4):375-86. 11 Rose G. Sick Individuals and Sick Populations. Int J Epidemiol 1985;14(1):32-8. 27 Dawber TR, Meadors GF, Moore FE. Epidemiological Approaches to Heart Disease: The Framingham Study Am J Public Health Nations 12 Yusuf S. Two decades of progress in preventing vascular disease. Health 1951;41(3):279-86. Lancet 2002;360(9326):2-3. 28 Woodward M, Brindle P, Tunstall-Pedoe H, SIGN group on risk 13 Scottish Intercollegiate Guidelines Network (SIGN). Cardiac estimation. Adding social deprivation and family history to arrhythmias in coronary heart disease. Edinburgh: SIGN; 2007. (94). cardiovascular risk assessment: the ASSIGN score from the Scottish [cited 05 May 2017]. Available from url: http://www.sign.ac.uk/ Heart Health Extended Cohort (SHHEC). Heart 2007;93(2):172-6. sign-94-cardiac-arrhythmias-in-coronary-heart-disease.html 29 de la Iglesia B, Potter JF, Poulter NR, Robins MM, Skinner J. 14 Scottish Intercollegiate Guidelines Network (SIGN). Management Performance of the ASSIGN cardiovascular disease risk score on a of chronic heart failure. Edinburgh: SIGN; 2016. (147). [cited 05 UK cohort of patients from general practice. Heart 2011;97(6):491- May 2017]. Available from url: http://www.sign.ac.uk/sign-147- 9. management-of-chronic-heart-failure.html 30 JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100 Suppl 2:ii1-ii67. | 99 Risk estimation and the prevention of cardiovascular disease 31 National Institute of Health and Care Excellence. Cardiovascular 47 John WG, UK Department of Health Advisory Committee on disease: risk assessment and reduction, including lipid modification. Diabetes. Use of HbA1c in the diagnosis of diabetes mellitus in the London: NICE; 2014. (CG181). [cited 05 May 2017]. Available from UK. The implementation of World Health Organization guidance url: https://www.nice.org.uk/guidance/cg181 2011. Diabet Med 2011;29(11):1350-7. 32 Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe 48 Han C, Robinson DW, Jr., Hackett MV, Paramore LC, Fraeman KH, SM, et al. Pravastatin in elderly individuals at risk of vascular Bala MV. Cardiovascular disease and risk factors in patients with disease (PROSPER): a randomised controlled trial. Lancet rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. 2002;360(9346):1623-30. J Rheumatol 2006;33(11):2167-72. 33 Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and 49 Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Jacobsen SJ, et al. Increased unrecognized coronary heart disease Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary and sudden deaths in rheumatoid arthritis: a population-based Prevention Study. Circulation 2016;133(11):1073-80. cohort study. Arthritis Rheum 2005;52(2):402-11. 34 Marma AK, Lloyd-Jones DM. Systematic examination of the 50 Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas updated Framingham heart study general cardiovascular risk R, Sheikh A, et al. Predicting cardiovascular risk in England and profile. Circulation 2009;120(5):384-90. Wales: prospective derivation and validation of QRISK2. BMJ 2008;336(7659):1475-82. 35 Hong YM. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ J 2010;40(1):1-9. 51 Weiner DE, Tighioart H, Amin AG, Stark PC, MacLeod B, Griffith JL, et al. Chronic Kidney Disease as a Risk Factor for Cardiovascular 36 Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM. Disease and All-Cause Mortality: A Pooled Analysis of Community- LIfetime risk and years lived free of total cardiovascular disease. Based Studies. J Am Soc Nephrol 2004;15(5):1307-15. JAMA 2012;308(17):1795-801. 52 Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, 37 Navar-Boggan AM, Peterson ED, D’Agostino RB, Sr., Pencina MJ, Heerspink HJ, Mann JF, et al. Chronic kidney disease and Sniderman AD. Using age- and sex-specific risk thresholds to cardiovascular risk: epidemiology, mechanisms, and prevention. guide statin therapy: one size may not fit all. J Am Coll Cardiol Lancet 2013;382(9889):339-52. 2015;65(16):1633-9. 53 Durrington P. Risk in cardiovascular disease. Joint British societies 38 Norheim O, Gjelsvik B, Klemsdal T, Madsen S, Meland E, Stein N, et al. recommend their computer program for risk calculations. BMJ Norway’s new principles for primary prevention of cardiovascular 2000;321(7254):174-5. disease: age differentiated risk thresholds. BMJ 2011;343:d3626. 54 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, 39 Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular et al. Guidelines for management of hypertension: report of the disease risk profiles. Am Heart J 1991;121(1 Pt 2):293-8. fourth working party of the British Hypertension Society, 2004— BHS IV. J Hum Hypertens 2004;18(3):139-85. 40 Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and Paternal History of Myocardial Infarction and 55 British Cardiac Society, British Hypertension Society, Diabetes Risk of Cardiovascular Disease in Men and Women. Circulation UK, HEART UK, Primary Care Cardiovascular Society, Stroke 2001;104(4):393-8. Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 41 Department of Health, Physical Activity, Health Improvement 5):v1-52. and Protection. Start Active, Stay Active: A report on physical activity from the four home countries’ Chief Medical Officers. 56 Stamler J, Stamler R, Neaton JD. Blood Pressure, Systolic and 2011. [cited 05 May 2017]. Available from url: http://www.gov. Diastolic, and Cardiovascular Risks. US Population Data. Arch Intern uk/government/uploads/system/uploads/attachment_data/ Med 1993;153(5):598. file/216370/dh_128210.pdf 57 Wrieden WL, Barton KL. Estimation of food and nutrient intakes 42 National Institute of Health and Care Excellence. Hypertension in from food purchase data in Scotland 2001-2012. 2015. (FS424018). adults: diagnosis and management. London: NICE; 2016. (CG127). [cited 08 May 2017]. Available from url: http://www.foodstandards. [cited 05 May 2017]. Available from url: http://www.nice.org.uk/ gov.scot/sites/default/files/Monitoring Scottish Dietary Goals Final guidance/cg127 Report 300415 - with triple graphic.pdf 43 Hamm P, Shekelle RB, Stamler J. Large fluctuations in body weight 58 Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, during young adulthood and twenty-five-year risk of coronary Moore HJ, et al. Reduced or modified dietary fat for preventing death in men. Am J Epidemiol 1989;129(2):312-8. cardiovascular disease. Cochrane Database of Systematic Reviews 2012, Issue 5. 44 Pouliot M-C, Després J-P, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal 59 Panel on Dietary Reference Values. Dietary Reference Values for diameter: best simple anthropometric indexes of abdominal Food Energy and Nutrients for the UK. Report of the Panel on DRVs visceral adipose tissue accumulation and related cardiovascular of the Committee on Medical Aspects of Food Policy. London: The risk in men and women. Am J Cardiol 1994;73(7):460-8. Stationery Office; 1991. (41. Reports on health and social subjects). 45 Abbott RD, Behrens GR, Sharp DS, Rodriguez BL, Burchfiel CM, 60 Chen Q, Cheng LQ, Xiao TH, Zhang YX, Zhu M, Zhang R, et al. Ross GW, et al. Body mass index and thromboembolic stroke Effects of omega-3 fatty acid for sudden cardiac death prevention in nonsmoking men in older middle age. The Honolulu Heart in patients with cardiovascular disease: A contemporary meta- Program. Stroke 1994;25(12):2370-6. analysis of randomized, controlled trials. Cardiovasc Drugs Ther 2011;25(3):259-65. 46 Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. Edinburgh: SIGN; 2010. (116). [cited 05 May 2017]. Available from url: http://www.sign.ac.uk/sign-116-management- of-diabetes.html 100 | References 61 Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 Fatty acids 78 Edwards K, Kwaw I, Matud J, Kurtz I. Effect of Pistachio Nuts on Serum and cardiovascular outcomes: systematic review and meta-analysis. Lipid Levels in Patients with Moderate Hypercholesterolemia. J Am Circ Cardiovasc Qual Outcomes 2012;5(6):808-18. Coll Nutr 1999;18(3):229-32. 62 Food standards agency. Healthy diet:nutrition essentials: fish 79 Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connellly PW, and shellfish. [cited 08 May 2017]. Available from url: http:// Qian W, et al. Dose Response of Almonds on Coronary Heart webarchive.nationalarchives.gov.uk/20060715141954/eatwell. Disease Risk Factors: Blood Lipids, Oxidized Low-Density gov.uk/healthydiet/nutritionessentials/fishandshellfish/ Lipoproteins, Lipoprotein(a), Homocysteine, and Pulmonary Nitric Oxide: A Randomized, Controlled, Crossover Trial. Circulation 63 He FJ, MacGregor GA. Effect of modest salt reduction on blood 2002;106(11):1327-32. pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002;16(11):761-70. 80 Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, 64 Jürgens G, Graudal NA. Effects of low sodium diet versus high oxidized LDL, homocysteine, and blood pressure in hyperlipidemic sodium diet on blood pressure, renin, aldosterone, catecholamines, men and women. Am J Clin Nutr. 2002;76(2):365-72. cholesterols, and triglyceride. Cochrane Database of Systematic Reviews 2004, Issue 1. 81 Sanders TA, Dean TS, Grainger D, Miller GJ, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with 65 Hooper L, Bartlett C, Davey SG, Ebrahim S. Advice to reduce dietary ethanol-extracted soy protein increase HDL but do not influence salt for prevention of cardiovascular disease. Cochrane Database transforming growth factor beta(1) concentrations and hemostatic of Systematic Reviews 2004, Issue 1. risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr. 2002;76(2):373-7. 66 Scientific Advisory Committee on Nutrition. Salt and Health. London: The Stationery Office; 2003. [cited 08 May 2017]. Available 82 Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, et from url: https://www.gov.uk/government/publications/sacn-salt- al. ‘Mediterranean’ dietary pattern for the primary prevention of and-health-report cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 8. 67 Anderson JW, Hanna TJ, Peng X, Kryscio RJ. Whole Grain Foods and Heart Disease Risk. J Am Coll Nutr 2000;19(3 suppl):291S-9S. 83 Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, et al. Meta-analysis comparing Mediterranean to low- 68 Law MR, Morris JK. By how much does fruit and vegetable fat diets for modification of cardiovascular risk factors. Am J Med consumption reduce the risk of ischaemic heart disease? Eur J Clin 2011;124(9):841-51.e2. Nutr 1998;52(8):549-56. 84 Estruch R, Ros E, Salas-Salvado J, Covas M-I, Corella D, Aros F, et al. 69 Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, Tu W, et al. Primary prevention of cardiovascular disease with a Mediterranean Effect of supplemental vitamin E for the prevention and treatment diet. N Engl J Med 2013;368(14):1279-90. of cardiovascular disease. J Gen Intern Med 2004;19(4):380-9. 85 Guasch-Ferre M, Hu FB, Martinez-Gonzalez MA, Fito M, Bullo M, 70 Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Estruch R, et al. Olive oil intake and risk of cardiovascular disease Randomized Trials of Vitamin E in the Treatment and Prevention and mortality in the PREDIMED Study. BMC Med 2014;12:78. of Cardiovascular Disease. Arch Intern Med 2004;164(14):1552-6. 86 Goff LM, Cowland DE, Hooper L, Frost GS. Low glycaemic index 71 Miller E R 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, diets and blood lipids: a systematic review and meta-analysis Guallar EL. Meta-Analysis: High-Dosage Vitamin E Supplementation of randomised controlled trials. Nutr Metab Cardiovasc Dis May Increase All-Cause Mortality. Ann Intern Med 2005;142(1):37- 2013;23(1):1-10. 46. 87 Vestfold Heartcare Study Group. Influence on lifestyle measures 72 Morris CD, Carson S. Routine Vitamin Supplementation To Prevent and five-year coronary risk by a comprehensive lifestyle Cardiovascular Disease: A Summary of the Evidence for the U.S. intervention programme in patients with coronary heart disease. Preventive Services Task Force. Ann Intern Med 2003;139(1):56-70. Eur J Cardiovasc Prev Rehabil 2003;10(6):429-37. 73 Marti-Carvajal AJ, Sola I, Lathyris D, Karakitsiou DE, Simancas- 88 Ness AR, Ashfield-Watt PA, Whiting JM, Smith GD, Hughes J, Burr Racines D. Homocysteine-lowering interventions for preventing ML. The long-term effect of dietary advice on the diet of men with cardiovascular events. Cochrane Database of Systematic Reviews angina: the diet and angina randomized trial. J Hum Nutr Diet 2013, Issue 1. 2004;17(2):117-9. 74 Zhou YH, Tang JY, Wu MJ, Lu J, Wei X, Qin YY, et al. Effect of folic 89 Thompson RL, Summerbell CD, Hooper L, Higgins JPT, Little P, Talbot acid supplementation on cardiovascular outcomes: a systematic D, et al. Dietary advice given by a dietitian versus other health review and meta-analysis. PloS One 2011;6(9):e25142. professional or self-help resources to reduce blood cholesterol. Cochrane Database of Systematic Reviews 2003, Issue 3. 75 Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, et al. Efficacy and Safety of Plant Stanols and Sterols in the Management 90 Dalgard C, Thuroe A, Haastrup B, Haghfelt T, Stender S. Saturated of Blood Cholesterol Levels. Mayo Clin Proc 2003;78(8):965-78. Fat Intake is Reduced in Patients With Ischemic Heart Disease 1 Year After Comprehensive Counseling But Not After Brief Counseling. J 76 Law M. Plant sterol and stanol margarines and health. BMJ Am Diet Assoc 2001;101(12):1420-9. 2000;320(7238):861-4. 91 Masley S, Phillips S, Copeland J. Group office visits change 77 Vasquez-Trespalacios EM, Romero-Palacio J. Efficacy of yogurt dietary habits of patients with coronary artery disease: The drink with added plant stanol esters (Benecol, Colanta) in Dietary Intervention and Evaluation Trial (D.I.E.T.). J Fam Pract reducing total and LDL cholesterol in subjects with moderate 2001;50(3):235-9. hypercholesterolemia: A randomized placebo-controlled crossover trial NCT01461798. Lipids Health Dis 2014;13:125. | 101 Risk estimation and the prevention of cardiovascular disease 92 Vale M, Jelinek M, Best J, Santamaria J. Coaching patients with 107 Lee IM, Sesso HD, Oguma Y, Paffenbarger RS Jr. Relative Intensity coronary heart disease to achieve the target cholesterol:A of Physical Activity and Risk of Coronary Heart Disease. Circulation method to bridge the gap between evidence-based medicine 2003;107(8):1110-6. and the “real world”—randomized controlled trial. J Clin Epidemiol 2002;55(3):245-52. 108 Lee IM, Sesso HD, Paffenbarger RS Jr. Physical Activity and Coronary Heart Disease Risk in Men : Does the Duration of Exercise Episodes 93 Baillot A, Romain AJ, Boisvert-Vigneault K, Audet M, Baillargeon Predict Risk? Circulation 2000;102(9):981-6. JP, Dionne IJ, et al. Effects of Lifestyle Interventions That Include a Physical Activity Component in Class II and III Obese 109 Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Individuals: A Systematic Review and Meta-Analysis. PLoS One Oberman A, et al. Walking Compared with Vigorous Exercise for 2015;10(4):e0119017. the Prevention of Cardiovascular Events in Women. N Engl J Med 2002;347(10):716-25. 94 Dombrowski SU, Avenell A, Sniehott FF. Behavioural interventions for obese adults with additional risk factors for morbidity: 110 Sesso HD, Paffenbarger RS Jr, Lee IM. Physical Activity and systematic review of effects on behaviour, weight and disease risk Coronary Heart Disease in Men : The Harvard Alumni Health Study. factors. Obes Facts 2010;3(6):377-96. Circulation 2000;102(9):975-80. 95 Leblanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. 111 Tanasescu M, Leitzmann M, Rimm E, Willett W, Stampfer M, Hu F. Effectiveness of primary care-relevant treatments for obesity in Exercise type and intensity in relation to coronary heart disease adults: a systematic evidence review for the U.S. Preventive Services in men. JAMA 2002;288(16):1994-2000. Task Force. Ann Intern Med 2011;155(7):434-47. 112 Celis-Morales CA, Lyall DM, Anderson J, Iliodromiti S, Fan Y, Ntuk 96 Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens Lars UE, et al. The association between physical activity and risk of G, Semlitsch T, et al. Long-term effects of weight-reducing diets in mortality is modulated by grip strength and cardiorespiratory hypertensive patients. Cochrane Database of Systematic Reviews fitness: evidence from 498 135 UK-Biobank participants. Eur Heart 2011, Issue 9. J 2017;38(2):116-22. 97 Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint 113 Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. PK, et al. Bariatric surgery and its impact on cardiovascular disease Cardiorespiratory fitness as a quantitative predictor of all-cause and mortality: a systematic review and meta-analysis. Int J Cardiol mortality and cardiovascular events in healthy men and women: 2014;173(1):20-8. a meta-analysis. JAMA 2009;301(19):2024-35. 98 Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, 114 Balducci S, Zanuso S, Cardelli P, Salvi L, Bazuro A, Pugliese L, et et al. Bariatric surgery versus non-surgical treatment for obesity: al. Effect of high- versus low-intensity supervised aerobic and a systematic review and meta-analysis of randomised controlled resistance training on modifiable cardiovascular risk factors in trials. BMJ 2013;347:f5934. type 2 diabetes; the Italian Diabetes and Exercise Study (IDES). PLoS One 2012;7(11):e49297. 99 Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict 115 Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical cardiovascular disease and diabetes? Outcome data from two Outcomes and Cardiovascular Responses to Different Exercise prospective studies. Lancet 2008;371(9628):1927-35. Training Intensities in Patients With Heart Failure. A Systematic Review and Meta-Analysis. JACC Heart Fail 2013;1(6):514-22. 100 Caspersen C, Powell K, Christenson G. Physical activity, exercise and physical fitness: Definitions and distinctions for health-related 116 Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Lovo KT, Gullikstad research. Public Health Rep 1985;100(2):126-31. LR, et al. Aerobic interval training versus continuous moderate exercise after coronary artery bypass surgery: a randomized 101 American College of Sports Medicine. ACSM’s Guidelines for study of cardiovascular effects and quality of life. Am Heart J Exercise Testing and Prescription, Tenth edition. Philidelphia, PA: 2009;158(6):1031-7. Wolters Kluwer Health; 2016. 117 Molmen-Hansen HE, Stolen T, Tjonna AE, Aamot IL, Ekeberg IS, 102 Sedentary Behaviour Research Network. Letter to the editor: Tyldum GA, et al. Aerobic interval training reduces blood pressure standardized use of the terms “sedentary” and “sedentary and improves myocardial function in hypertensive patients. Eur J behaviours”. Appl Physiol Nutr Metab 2012;37(3):540-2. Prev Cardiol 2012;19(2):151-60. 103 Altieri A, Tavani A, Gallus S, La vecchia C. Occupational and leisure 118 Munk PS, Staal EM, Butt N, Isaksen K, Larsen AI. High-intensity interval time physical activity and the risk of nonfatal acute myocardial training may reduce in-stent restenosis following percutaneous infarction in Italy. Ann Epidemiol 2004;14(7):461-6. coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial function 104 Barengo N, Hu G, Lakka T, Pekkarinen H, Nissinen A, Tuomilehto and inflammation. Am Heart J 2009;158(5):734-41. J. Low physical activity as a predictor for total and cardiovascular disease mortality in middle-aged men and women in Finland. Eur 119 Rognmo O, Moholdt T, Bakken H, Hole T, Molstad P, Myhr NE, Heart J 2004;25(24):2204-11. et al. Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation 105 Hakim AA, Curb JD, Petrovitch H, Rodriguez BL, Yano K, Ross GW, et 2012;126(12):1436-40. al. Effects of Walking on Coronary Heart Disease in Elderly Men :The Honolulu Heart Program. Circulation 1999;100(1):9-13. 120 Dahabreh IJ, Paulus JK. Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review 106 Hu G, Tuomilehto J, Silventoinen K, Barengo N, Jousilahti P. Joint and meta-analysis. JAMA 2011;305(12):1225-33. effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease 121 Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, among middle-aged Finnish men and women. Eur Heart J et al. Sedentary time in adults and the association with diabetes, 2004;25(24):2212-9. cardiovascular disease and death: systematic review and meta- analysis. Diabetologia 2012;55(11):2895-905. 102 | References 122 Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, 139 Scottish Health Survey 2015. Supplementary web table SHeS15 Owen N, Powell KE, et al. Does physical activity attenuate, or Part 10 - Smoking. The Scottish Government. National Statistics; even eliminate, the detrimental association of sitting time with 2016. [cited 11 May 2017]. Available from url: http://www.gov.scot/ mortality? A harmonised meta-analysis of data from more than 1 Resource/0050/00505710.xls million men and women. Lancet 2016;388(10051):1302-10. 140 Jacobs EJ, Thun MJ, Apicella LF. Cigar Smoking and Death From 123 van Uffelen JG, Wong J, Chau JY, van der Ploeg HP, Riphagen I, Coronary Heart Disease in a Prospective Study of US Men. Arch Gilson ND, et al. Occupational sitting and health risks: a systematic Intern Med 1999;159(20):2413-18. review. Am J Prev Med 2010;39(4):379-88. 141 Sauer WH, Berlin JA, Strom BL, Miles C, Carson JL, Kimmel SE. 124 Saunders TJ, Larouche R, Colley RC, Tremblay MS. Acute sedentary Cigarette Yield and the Risk of Myocardial Infarction in Smokers. behaviour and markers of cardiometabolic risk: a systematic review Arch Intern Med 2002;162(3):300-6. of intervention studies. J Nutr Metab 2012;2012:712435. 142 Steenland K. Risk assessment for heart disease and workplace 125 Scottish Government. Physical Activity and Sport. [cited 11 ETS exposure among nonsmokers. Environ Health Perspect May 2017]. Available from url: http://www.healthscotland.scot/ 1999;107(Suppl 6):859-63. publications/a-guide-to-smoking-cessation-in-scotland 143 Thun M, Henley J, Apicella L. Epidemiologic studies of fatal and 126 Department of Health. UK Physical Activity Guidelines. [cited 11 nonfatal cardiovascular disease and ETS exposure from spousal May 2017]. Available from url: https://www.gov.uk/government/ smoking. Environ Health Perspect 1999;107(Suppl 6):841-6. publications/uk-physical-activity-guidelines 144 Pitsavos C, Panagiotakos DB, Chrysohoou C, Skoumas J, Tzioumis K, 127 Leon AS, Sanchez OA. Response of blood lipids to exercise training Stefanadis C, et al. Association between exposure to environmental alone or combined with dietary intervention. Med Sci Sports Exerc tobacco smoke and the development of acute coronary syndromes: 2001;33(6 Suppl):S502-S15. the CARDIO2000 case-control study. Tob Control 2002;11(3):220-5. 128 Whelton SP, Chin A, Xin X, He J. Effect of Aerobic Exercise on Blood 145 Pitsavos C, Panagiotakos D, Chrysohoou C, Tzioumis K, Papaioannou Pressure. Ann Intern Med 2002;136(7):493-503. I, Stefanadis C, et al. Association between passive cigarette smoking and the risk of developing acute coronary syndromes: 129 Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to the CARDIO2000 study. Heart Vessels 2002;16(4):127-30. smoking: 50 years’ observations on male British doctors. BMJ 2004;328(7455):1519-33. 146 Rosenlund M, Berglind N, Gustavsson A, Reuterwall C, Hallqvist J, Nyberg F, et al. Environmental Tobacco Smoke and Myocardial 130 Law MR, Morris JK, Wald NJ. Environmental tobacco smoke Infarction among Never-Smokers in the Stockholm Heart exposure and ischaemic heart disease: an evaluation of the Epidemiology Program (SHEEP). Epidemiology 2001;12(5):558-64. evidence. BMJ 1997;315(7114):973-80. 147 NHS Health Scotland and ASH Scotland. A guide to smoking 131 Ockene IS, Miller NH. Cigarette Smoking, Cardiovascular Disease, cessation in Scotland 2010. Helping Smokers to stop. Brief and Stroke : A Statement for Healthcare Professionals From the Interventions. [cited 11 May 2017]. Available from url: http://www. American Heart Association. American Heart Association Task healthscotland.scot/media/1097/web_helping-smokers-to-stop- Force on Risk Reduction. Circulation 1997;96(9):3243-7. smoking_3248.pdf 132 Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking 148 NHS Health Scotland and ASH Scotland. Smoking cessation cessation and the risk of stroke in middle-aged men. JAMA guidelines for Scotland: 2004 update. Edinburgh: NHS Health 1995;274(2):155-60. Scotland; 2005. [cited 1 Dec 2006]. Available from url: http://www. hebs.scot.nhs.uk/services/pubs/pdf/SmokingCessation2005.pdf 133 Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, et al. Smoking Cessation in Relation to Total Mortality 149 NHS Health Scotland and ASH Scotland. Reducing smoking and Rates in Women: A Prospective Cohort Study. Ann Intern Med tobacco related harm. A key to transforming health. Edinburgh: 1993;119(10):992-1000. NHS Health Scotland; 2003. [cited 11 May 2017]. Available from url: http://www.healthscotland.com/uploads/documents/7930- 134 Pirie K, Peto R, Reeves GK, Green J, Beral V, Million Women Study TobaccoReport.pdf Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. 150 Scottish Executive. A breath of fresh air for Scotland. Improving Lancet 2013;381(9861):133-41. Scotland’s health: the challenge. Tobacco control action plan. Edinburgh: Scottish Executive; 2004. [cited 11 May 2017]. Available 135 Scottish Schools Adolescent Lifestyle and Substance Use Survey from url: http://www.gov.scot/Resource/Doc/26487/0013536.pdf (SALSUS): Smoking report 2015. [cited 08 May 2017]. Available from url: http://www.gov.scot/Publications/2016/10/8742 151 Critchley JA, Capewell S. Mortality Risk Reduction Associated With Smoking Cessation in Patients With Coronary Heart Disease. JAMA 136 McNeill AD. The development of dependence on smoking in 2003;290(1):86-7. children. Br J Addict 1991;86(5):589-92. 152 Ellingsen I, Hjermann I, Abdelnoor M, Hjerkinn E, Tonstad S. Dietary 137 Office for National Statistics, Jarvis L. Teenage smoking attitudes in and antismoking advice and ischemic heart disease mortality in 1996: a survey of the smoking behaviour, knowledge, and attitudes men with normal or high fasting triacylglycerol concentrations: a of 11 to 15 year olds in England. London: The Stationery Office; 23-y follow-up study. Am J Clin Nutr. 2003;78(5):935-40. 1997. 153 Cahill K, Stead Lindsay F, Lancaster T. Nicotine receptor partial 138 Marsh A, Mckay S. Poor smokers. London: Policy Studies Institute; agonists for smoking cessation. Cochrane Database of Systematic 1994. (PSI research report 771). Reviews 2012, Issue 4. | 103 Risk estimation and the prevention of cardiovascular disease 154 Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological 170 ASH Scotland. Tobacco and inequalities project. A mapping interventions for smoking cessation: an overview and network exercise and directory of services, resources and training for meta-analysis. Cochrane Database of Systematic Reviews 2013, ethnicity, mental health and older adults. Edinburgh: ASH Issue 5. Scotland; 2005. [cited 1 Dec 2006]. Available from url: http://www. ashscotland.org.uk/ash/files/Service and Resource Directory.pdf 155 Scottish Medicines Consortium. Varenicline 1 mg tablets (Champix). Scotttish Medicines Consortium; 2006. [cited 11 May 2017]. 171 World Health Organization. Alcohol. [cited 11 May 2017]. Available Available from url: https://www.scottishmedicines.org.uk/files/ from url: http://www.who.int/mediacentre/factsheets/fs349/en varenicline_Champix_339_06.pdf 172 Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. 156 Thomas K, Martin R, Knipe D, Higgins J, Gunnell D. Risk of Association of alcohol consumption with selected cardiovascular neuropsychiatric adverse events associated with varenicline: disease outcomes: a systematic review and meta-analysis. BMJ systematic review and meta-analysis. BMJ 2015;350:h1109 2011;342:d671. 157 Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et 173 Zhang C, Qin Y-Y, Chen Q, Jiang H, Chen X-Z, Xu C-L, et al. Alcohol al. Nicotine replacement therapy for smoking cessation. Cochrane intake and risk of stroke: A dose-response meta-analysis of Database of Systematic Reviews 2012, Issue 11. prospective studies. Int J Cardiol 2014;174(3):669-77. 158 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking 174 Cleophas TJ. Wine, beer and spirits and the risk of myocardial cessation. Cochrane Database of Systematic Reviews 2004, Issue infarction: a systematic review. Biomed Pharmacother 4. 1999;53(9):417-23. 159 Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of 175 Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. bupropion (Zyban) for smoking cessation from experience gained Alcohol and coronary heart disease: a meta-analysis. Addiction in general practice use in England in 2000. Eur J Clin Pharmacol 2000;95(10):1505-23. 2003;59(10):767-73. 176 Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, de Gaetano 160 Joint Formulary Committee. British National Formulary (online). G. Meta-Analysis of Wine and Beer Consumption in Relation to London: BMJ Group and Pharmaceutical Press; 2017. [cited 11 May Vascular Risk. Circulation 2002;105(24):2836-44. 2017]. Available from url: https://www.medicinescomplete.com/ mc/bnf/current/index.htm 177 Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta- 161 McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic analysis of effects on lipids and haemostatic factors. BMJ cigarettes for smoking cessation and reduction. Cochrane 1999;319(7224):1523-8. Database of Systematic Reviews 2014, Issue 12. 178 Briasoulis A, Agarwal V, Messerli FH. Alcohol consumption and the 162 Adriaens K, Van Gucht D, Declerck P, Baeyens F. Effectiveness of the risk of hypertension in men and women: a systematic review and electronic cigarette: An eight-week Flemish study with six-month meta-analysis. J Clin Hypertens (Greenwich) 2012;14(11):792-8. follow-up on smoking reduction, craving and experienced benefits and complaints. Int J Environ Res Public Health 2014;11(11):11220- 179 Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. 48. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38(5):1112-7. 163 Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: A meta-analysis. 180 Fillmore KM, Kerr WC, Stockwell T, Chikritzhs T, Bostrom A. J Consult Clin Psychol 2003;71(4):657-63. Moderate alcohol use and reduced mortality risk: Systematic error in prospective studies. Addict Res Theory 2006;14(2):101-32. 164 Covey LS, Glassman AH, Stetner F, Rivelli S, Stage K. A Randomized Trial of Sertraline as a Cessation Aid for Smokers With a History of 181 Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et Major Depression. Am J Psychiatry 2002;159(10):1731-7. al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant 165 Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, Hartz DT, et al. data. BMJ 2014;349:g4164. Nortriptyline and Cognitive-Behavioral Therapy in the Treatment of Cigarette Smoking. Arch Gen Psychiatry 1998;55(8):683-90. 182 Alcohol Guidelines Review- Report from the Guidelines development group to the UK Chief Medical Officers. London: 166 Patten CA, Martin JE, Myers MG, Calfas KJ, Williams CD. Department of Health; 2016. [cited 12 May 2017]. Available from Effectiveness of cognitive-behavioral therapy for smokers with url: https://www.gov.uk/government/uploads/system/uploads/ histories of alcohol dependence and depression. J. Stud. Alcohol attachment_data/file/489797/CMO_Alcohol_Report.pdf 1998;59(3):327-35. 183 Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis 167 Whybrow P, Ramsay J, MacNee K. The Scottish Health Survey: of clinical trials of treatments for alcohol use disorders. Addiction Equality Groups. Topic Report. Edinburgh: The Scottish Government; 2002;97(3):265-77. 2012. [cited 11 May 2017]. Available from url: http://www.gov.scot/ Resource/0040/00406749.pdf 184 Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Kohli H, et al. Prevention of relapse in alcohol dependence. Glasgow: 168 United Kingdom Department of Health. Health survey of England Health Technology Board for Scotland; 2003. (HTA Report 2004: the health of ethnic minorities (headline tables). London: The 3). [cited 12 May 2017]. Available from url: http://www. Department; 2005. [cited 11 May 2017]. Available from url: http:// healthcareimprovementscotland.org/previous_resources/ content.digital.nhs.uk/catalogue/PUB01209/heal-surv-hea-eth- hta_report/hta_3.aspx min-hea-tab-eng-2004-rep.pdf 185 Whitlock EP, Polen MR, Green CA, Orleans T, Klein J, US Preventative 169 Asghar S. Black and minority ethnic views on moking. patterns, Services Task Force. Behavioral Counseling Interventions in Primary prevalence and needs in Glasgow. Edinburgh: ASH Scotland; 2001. Care To Reduce Risky/Harmful Alcohol Use by Adults: A Summary [cited 11 May 2017]. Available from url: http://www.stor.scot.nhs. of the Evidence for the U.S. Preventive Services Task Force. Ann uk/ggc/handle/11289/579508 Intern Med 2004;140(7):557-68. 104 | References 186 Beich A, Thorsen T, Rollnick S. Screening in brief intervention trials 201 Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini targeting excessive drinkers in general practice: systematic review F, et al. Antiplatelet agents for chronic kidney disease. Cochrane and meta-analysis. BMJ 2003;327(7414):536-42. Database of Systematic Reviews 2013, Issue 2. 187 Fleming M, Brown R, Brown D. The efficacy of a brief alcohol 202 Stamler J, Wentworth D, Neaton JD. Is Relationship Between Serum intervention combined with %CDT feedback in patients being Cholesterol and Risk of Premature Death From Coronary Heart treated for type 2 diabetes and/or hypertension. J. Stud. Alcohol Disease Continuous and Graded? Findings in 356,222 primary 2004;65(5):631-7. screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256(20):2823-8. 188 Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke 203 Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, by prolonged antiplatelet therapy in various categories of patients. et al. Serum Cholesterol Level and Mortality Findings for Men Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6921):81-106. Screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 189 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis 1992;152(7):1490-500. of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 204 Neaton JD, Wentworth D. Serum cholesterol, blood pressure, 2002;324(7329):71-86. cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple 190 Weisman SM, Graham DY. Evaluation of the Benefits and Risks of Risk Factor Intervention Trial Research Group. Arch Intern Med Low-Dose Aspirin in the Secondary Prevention of Cardiovascular 1992;152(1):56-64. and Cerebrovascular Events. Arch Intern Med 2002;162(19):2197- 202. 205 Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma Cholesterol Concentration and Mortality. The Whitehall Study. JAMA 191 CAPRIE Steering Committee. A randomised, blinded, trial of 1992;267(1):70-6. clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-39. 206 Keys A, Menotti A, Aravanis C, Blackburn H, Djordevič BS, Buzina R, et al. The seven countries study: 2,289 deaths in 15 years. Prev 192 Chen Z, Sandercock P, Pan H, Counsell C, Collins R, Liu L, et al. Med 1984;13(2):141-54. Indications for Early Aspirin Use in Acute Ischemic Stroke : A Combined Analysis of 40 000 Randomized Patients From the 207 Expert Panel on Detection Evaluation Treatment of High Blood Chinese Acute Stroke Trial and the International Stroke Trial. Stroke Cholesterol in Adults. Executive Summary of the Third Report of 2000;31(6):1240-9. the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol 193 ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstall in Adults (Adult Treatment Panel III). JAMA: The Journal of the PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone American Medical Association 2001;285(19):2486-97. after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367(9523):1665-73. 208 Brown M, Goldstein J. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232(4746):34-47. 194 Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel 209 Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et for recurrent stroke. N Engl J Med 2008;359(12):1238-51. al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart 195 Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala disease: a Mendelian randomization analysis. J Am Coll Cardiol NB, et al. Aspirin for prophylactic use in the primary prevention 2012;60(25):2631-9. of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess 2013;17(43):1-253. 210 Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for 196 Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell ischemic heart disease. J Am Coll Cardiol 2013;61(4):427-36. L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- 211 Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, analysis of individual participant data from randomised trials. Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and Lancet 2009;373(9678):1849-60. risk of vascular disease. JAMA 2009;302(18):1993-2000. 197 Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou 212 Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux S, Sattar N, et al. Effect of aspirin on vascular and nonvascular P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary outcomes: meta-analysis of randomized controlled trials. Arch Syndromes. N Engl J Med 2015;372(25):2387-97. Intern Med 2012;172(3):209-16. 213 The Lipid Research Clinics Coronary Primary Prevention Trial 198 Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the results. I. Reduction in incidence of coronary heart disease. JAMA prevention of cardiovascular events in patients without clinical 1984;251(3):351-64. cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011;162(1):115-24.e2. 214 Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: 199 Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect systematic review and meta-analysis. BMJ 2003;326(7404):1423. of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124(7):621-9. 215 Cholesterol Treatment Trialists (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of 200 Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and lowering LDL cholesterol with statin therapy in people at low anticoagulants for hypertension. Cochrane Database of Systematic risk of vascular disease: Meta-analysis of individual data from 27 Reviews 2011, Issue 12. randomised trials. Lancet 2012;380(9841):581-90. | 105 Risk estimation and the prevention of cardiovascular disease 216 Taylor F, Huffman Mark D, Macedo Ana F, Moore Theresa HM, Burke 232 Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et M, Davey Smith G, et al. Statins for the primary prevention of al. Statins for the prevention of coronary events. Technology cardiovascular disease. Cochrane Database of Systematic Reviews assessment report commissioned by the HTA Programme on 2013, Issue 1. behalf of The National Institute for Clinical Excellence. Sheffield: University of Sheffield, School of Health and Related Research; 217 Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn 2005. [cited 12 May 2017]. Available from url: https://www.nice. B, et al. Efficacy of statins for primary prevention in people at low org.uk/guidance/ta94/documents/assessment-report-coronary- cardiovascular risk: A meta-analysis. CMAJ 2011;183(16):E1189-202. heart-disease-statins2 218 Mills EJ, Oregan C, Eyawo O, Wu P, Mills F, Berwanger O, et al. 233 Cholesterol Treatment Trialists (CTT) Collaborators, Kearney PM, Intensive statin therapy compared with moderate dosing for Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol- prevention of cardiovascular events: A meta-analysis of >40 000 lowering therapy in 18,686 people with diabetes in 14 randomised patients. Eur Heart J 2011;32(11):1409-15. trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25. 219 Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den 234 Gotto AM. Efficacy and safety of statin therapy in children with Hartog F, et al. Statins for acute coronary syndrome. Cochrane familial hypercholesterolemia: A randomized controlled trial. J Database of Systematic Reviews 2014, Issue 9. Pediatr 2005;146(1):144-5. 220 MHRA. Simvastatin: increased risk of myopathy at high dose (80 235 Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller mg). Drug Safety Update. [cited 12 May 2017]. Available from url: HR, et al. Efficacy and Safety of Statin Therapy in Children With https://www.gov.uk/drug-safety-update/simvastatin-increased- Familial Hypercholesterolemia: a randomised controlled trial. JAMA risk-of-myopathy-at-high-dose-80-mg 2004;292(3):331-7. 221 McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid 236 National Institute of Health and Care Excellence. Ezetimibe Association Statin Safety Assessment Task Force. Final Conclusions for treating primary heterozygous-familial and non-familial and Recommendations of the National Lipid Association Statin hypercholesterolaemia. London: NICE 2016. (TA385). [cited 12 May Safety Assessment Task Force. Am J Cardiol 2006;97(8A):89C-94C. 2017]. Available from url: http://www.nice.org.uk/guidance/ta385 222 Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino 237 National Institute of Health and Care Excellence. Familial C, et al. Efficacy and safety of cholesterol-lowering treatment: hypercholesterolaemia: identification and management. London: prospective meta-analysis of data from 90,056 participants in 14 NICE 2008. (CG71). [cited 12 May 2017]. Available from url: https:// randomised trials of statins. Lancet 2005;366(9493):1267-78. www.nice.org.uk/guidance/cg71 223 Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy 238 Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and safety of statin treatment for cardiovascular disease: a network and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 meta-analysis of 170,255 patients from 76 randomized trials. QJM randomized, controlled trials. BMC Med 2015;13:123. 2011;104(2):109-24. 239 Savarese G, Paolillo S, D’Amore C, Losco T, Musella F, Scala O, 224 Committee on Safety of Medicines. Statins and cytochrome P450 et al. Benefits of statins in elderly subjects without established interactions. Current Problems in Pharmacovigilance 2004;30:1-2. cardiovascular disease. a meta-analysis. Eur Heart J 2013;34(suppl 1):163-4. 225 Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of 240 Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson statin therapy. Lancet 2016;388(10059):2532-61. J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 226 Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. participants in 26 randomised trials. Lancet 2010;376(9753):1670- Discontinuation of statins in routine care settings: a cohort study. 81. Ann Intern Med 2013;158(7):526-34. 241 Kutner JS, Blatchford PJ, Taylor DH, Jr., Ritchie CS, Bull JH, Fairclough 227 Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, DL, et al. Safety and benefit of discontinuing statin therapy in the et al. Treatment strategies in patients with statin intolerance: the setting of advanced, life-limiting illness: a randomized clinical trial. Cleveland Clinic experience. Am Heart J 2013;166(3):597-603. JAMA Intern Med 2015;175(5):691-700. 228 Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials 242 Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of and clinical experience. JAMA 2015;313(10):1011-2. gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010;138(1):25-31. 229 Thompson PD, Clarkson P, Karas RH. Statin-Associated Myopathy. JAMA 2003;289(13):1681-90. 243 Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical 230 Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, update from Kidney Disease: Improving Global Outcomes (KDIGO). et al. Tolerability of red yeast rice (2,400 mg twice daily) versus Kidney Int 2011;80(6):572-86. pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105(2):198-204. 244 Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people 231 Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano with chronic kidney disease not requiring dialysis. Cochrane AL, et al. 2016 European Guidelines on cardiovascular disease Database of Systematic Reviews 2014, Issue 5. prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on 245 Cholesterol Treatment Trialists (CTT) Collaboration, Herrington Cardiovascular Disease Prevention in Clinical Practice (constituted WG, Emberson J, Mihaylova B, Blackwell L, Reith C, et al. Impact by representatives of 10 societies and by invited experts)Developed of renal function on the effects of LDL cholesterol lowering with with the special contribution of the European Association for statin-based regimens: a meta-analysis of individual participant Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J data from 28 randomised trials. Lancet Diabetes Endocrinol 2016;37(29):2315-81. 2016;4(10):829-39. 106 | References 246 Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk 262 Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, et al. Effects of EM. Lipid-lowering therapy in persons with chronic kidney fibrates in kidney disease: a systematic review and meta-analysis. disease: a systematic review and meta-analysis. Ann Intern Med J Am Coll Cardiol 2012;60(20):2061-71. 2012;157(4):251-62. 263 Piepho RW. The pharmacokinetics and pharmacodynamics of 247 Holme I. Relation of coronary heart disease incidence and total agents proven to raise high-density lipoprotein cholesterol. Am J mortality to plasma cholesterol reduction in randomised trials: Cardiol 2000;86(12A):35L-40L. use of meta-analysis. Br Heart J 1993;69(1 Suppl):S42-7. 264 McKenney JM, Proctor JD, Harris S, Chinchili VM. A Comparison of 248 Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et the Efficacy and Toxic Effects of Sustained- vs Immediate-Release al. Colesevelam Hydrochloride (Cholestagel): a new, potent bile Niacin in Hypercholesterolemic Patients. JAMA 1994;271(9):672-7. acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159(16):1893-900. 265 Knopp RH, Algona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, et al. Equivalent efficacy of a time-release form of 249 Superko HR, Greenland P, Manchester RA, Andreadis NA, niacin (Niaspan) given once-a-night versus plain niacin in the Schectman G, West NH, et al. Effectiveness of low-dose colestipol management of hyperlipidemia. Metabolism 1998;47(9):1097-104. therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992;70(2):135-40. 266 Clofibrate and Niacin in Coronary Heart Disease. JAMA 1975;231(4):360-81. 250 Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with 267 Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas colesevelam hydrochloride and lovastatin effectively decreases RJ, et al. Fifteen year mortality in Coronary Drug Project patients: low-density lipoprotein cholesterol in patients with primary Long-term benefit with niacin. J Am Coll Cardiol 1986;8(6):1245-55. hypercholesterolemia. Clin Cardiol 2001;24(6):467-74. 268 AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, 251 Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with Efficacy and safety of combination simvastatin and colesevelam low HDL cholesterol levels receiving intensive statin therapy. N in patients with primary hypercholesterolemia. Am J Med Engl J Med. 2011;365(24):2255-67. 2001;110(5):352-60. 269 HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell 252 Shepherd J. Ezetimibe. In: Webb D, Paterson K, Flockhard D, editors. JC, Parish S, Aung T, et al. Effects of extended-release niacin with The year in therapeutics. Oxford: Clinical Publishing; 2005. p.269-91. laropiprant in high-risk patients. N Engl J Med 2014;371(3):203-12. 253 Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh 270 National Insitute of Health and Care Excellence. Alirocumab for R, et al. Efficacy and safety of a potent new selective cholesterol treating primary hypercholesterolaemia and mixed dyslipidaemia. absorption inhibitor, ezetimibe, in patients with primary . London: NICE; 2016. (TA393). [cited 15 May 2017]. Available from hypercholesterolemia. Am J Cardiol 2002;90(10):1092-7. url: https://www.nice.org.uk/guidance/ta393 254 Knopp R. Effects of ezetimibe, a new cholesterol absorption inhibitor, 271 National Insitute of Health and Care Excellence. Evolocumab for on plasma lipids in patients with primary hypercholesterolemia. treating primary hypercholesterolaemia and mixed dyslipidaemia. Eur Heart J 2003;24(8):729-41. . London: NICE; 2016. (TA394). [cited 15 May 2017]. Available from url: https://www.nice.org.uk/guidance/ta394 255 Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin 272 Scottish Medicines Consortium. Alirocumab (Praluent). [cited 15 plus ezetimibe in patients with chronic kidney disease (Study of May 2017]. Available from url: https://www.scottishmedicines. Heart and Renal Protection): a randomised placebo-controlled org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/ trial. Lancet 2011;377(9784):2181-92. alirocumab_Praluent 256 Bezafibrate Infarction Prevention (BIP) Study. Secondary Prevention 273 Scottish Medicines Consortium. Evolocumab (Repatha). [cited 15 by Raising HDL Cholesterol and Reducing Triglycerides in Patients May 2017]. Available from url: https://www.scottishmedicines. With Coronary Artery Disease. Circulation 2000;102(1):21-7. org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/ evolocumab_Repatha_Resub 257 Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in 274 Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Middle-Aged Men with Dyslipidemia. Safety of treatment, changes Y, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 in risk factors, and incidence of coronary heart disease. N Engl J Antibodies in Adults With Hypercholesterolemia: A Systematic Med 1987;317(20):1237-45. Review and Meta-analysis. Ann Intern Med 2015;163(1):40-51. 258 Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et 275 Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, al. Gemfibrozil for the Secondary Prevention of Coronary Heart Lhermusier T, Baker NC, et al. The impact of proprotein convertase Disease in Men with Low Levels of High-Density Lipoprotein subtilisin-kexin type 9 serine protease inhibitors on lipid levels Cholesterol. N Engl J Med 1999;341(6):410-8. and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2016;37(6):536-45. 259 Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The Hypolipidemic Effects of Gemfibrozil in Type V Hyperlipidemia. A 276 Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, double-blind, crossover study. JAMA 1989;262(22):3154-60. Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376(18):1713-22. 260 Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and 277 Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a meta-analysis. Lancet 2010;375(9729):1875-84. Cardiovascular Risk Factor. Am J Cardiol 1998;81(4A):7B-12B. 261 Zhou YH, Ye XF, Yu FF, Zhang X, Qin YY, Lu J, et al. Lipid management 278 Krauss RM. Atherogenicity of Triglyceride-Rich Lipoproteins. Am J in the prevention of stroke: A meta-analysis of fibrates for stroke Cardiol 1998;81(4A):13B-7B. prevention. BMC Neurol 2013;13:1. | 107 Risk estimation and the prevention of cardiovascular disease 279 Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard 293 Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel BG, Tybjaerg-Hansen A. Genetically elevated non-fasting WB, et al. Impact of High-Normal Blood Pressure on the Risk of triglycerides and calculated remnant cholesterol as causal risk Cardiovascular Disease. N Engl J Med 2001;345(18):1291-7. factors for myocardial infarction. Eur Heart J 2013;34(24):1826-33. 294 Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment 280 Triglyceride Coronary Disease Genetics Consortium and Emerging trials of hypertension: improving the estimate of therapeutic Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, benefit. J Hum Hypertens 1996;10(1):1-8. Butterworth AS, Di Angelantonio E, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 295 Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks studies. Lancet 2010;375(9726):1634-9. FM, et al. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. DASH Collaborative Research Group. N Engl J Med 281 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, W Neil 1997;336(16):1117-24. HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative 296 Bao DQ, Mori TA, Burke V, Puddey IB, Beilin LJ. Effects of Dietary Atorvastatin Diabetes Study (CARDS): multicentre randomised Fish and Weight Reduction on Ambulatory Blood Pressure in placebo-controlled trial. Lancet 2004;364(9435):685-96. Overweight Hypertensives. Hypertension 1998;32(4):710-7. 282 Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection 297 Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et Study Collaborative Group. MRC/BHF Heart Protection Study al. Effects on Blood Pressure of Reduced Dietary Sodium and the of cholesterol-lowering with simvastatin in 5963 people Dietary Approaches to Stop Hypertension (DASH) Diet. DASH- with diabetes: a randomised placebo-controlled trial. Lancet Sodium Collaborative Research Group. N Engl J Med 2001;344(1):3- 2003;361(9374):2005-16. 10. 283 Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner 298 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective S, et al. Effect of Lowering LDL Cholesterol Substantially Below Studies Collaboration. Age-specific relevance of usual blood Currently Recommended Levels in Patients With Coronary Heart pressure to vascular mortality: a meta-analysis of individual Disease and Diabetes: The Treating to New Targets (TNT) study. data for one million adults in 61 prospective studies. Lancet Diabetes Care 2006;29(6):1220-6. 2002;360(9349):1903-13. 284 Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen M, et al. Effects 299 Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius of long-term fenofibrate therapy on cardiovascular events in 9795 S, et al. Effects of intensive blood-pressure lowering and low-dose people with type 2 diabetes mellitus (the FIELD study): randomised aspirin in patients with hypertension: principal results of the controlled trial. Lancet 2005;366(9500):1849-61. Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62. 285 Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate 300 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire for combined hyperlipidemia (the SAFARI trial). Am J Cardiol U, et al. Cardiovascular morbidity and mortality in the Losartan 2005;95(4):462-8. Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995- 286 Koh KK, Quon MJ, Han SH, Chung W-J, Ahn JY, Seo Y-H, et al. Additive 1003. Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia. J Am Coll Cardiol 301 PROGRESS Collaborative Group. Randomised trial of a perindopril- 2005;45(10):1649-53. based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 287 ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse 2001;358(9287):1033-41. JR, 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-74. 302 Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active 288 Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with treatment for older patients with isolated systolic hypertension. fibrates. Am J Cardiol 2004;94(7):935-8. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350(9080):757-64. 289 VHA Pharmacy Benefits Management-Strategic Healthcare Group, The Medical Advisory Panel. Statin-fibrate report: focus 303 Staessen JA, Wang J. Blood-pressure lowering for the secondary on safety. United States Department of Veterans Affairs. ; 2004. prevention of stroke. Lancet 2001;358(9287):1026-7. [cited 15 May 2017]. Available from url: http://www.pbm.va.gov/ vacenterformedicationsafety/nationalpbmbulletin/87ry38statinf 304 The Heart Outcomes Prevention Evaluation Study Investigators, ibrateFinal.pdf Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on 290 Martin PD, Dane AL, Schneck DW, Warwick MJ. An open- cardiovascular events in high-risk patients. N Engl J Med label, randomized, three-way crossover trial of the effects 2000;342(3):145-53. of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in 305 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs healthy male volunteers. Clin Ther 2003;25(2):459-71. in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective 291 Rosenson RS. Cholesterol lowering in diabetes. New evidence epidemiological studies. BMJ 2009;338:b1665. supports aggressive LDL-C targets. Postgrad Med 2005;117(4):17- 27. 306 Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health 292 Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with Technol Assess 2003;7(31):1-94. fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95(1):120-2. 108 | References 307 Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne 320 SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, AP, et al. The effects of blood pressure reduction and of different Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus blood pressure-lowering regimens on major cardiovascular events Standard Blood-Pressure Control. N Engl J Med 2015;373(22):2103- according to baseline blood pressure: Meta-analysis of randomized 16. trials. J Hypertens 2011;29(1):4-16. 321 Jonsson B, Hansson L, Stalhammar NO. Health economics in the 308 Thomopoulos C, Parati G, Zanchetti A. Effect of blood pressure Hypertension Optimal Treatment (HOT) study: costs and cost- lowering on outcome incidence in hypertension:2. Effects at effectiveness of intensive blood pressure lowering and low-dose different baseline and achieved blood pressure levels - overview aspirin in patients with hypertension. J Intern Med 2003;253(4):472- and meta-analyses of randomised trials. J Hypertension 80. 2014;32(12):2296-304. 322 Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets 309 Blood Pressure Lowering Treatment Trialists’ Collaboration, in subjects with type 2 diabetes mellitus/impaired fasting glucose: Sundström J, Arima H, Woodward M, Jackson R, Karmali K, et al. Blood observations from traditional and bayesian random-effects meta- pressure-lowering treatment based on cardiovascular risk: a meta- analyses of randomized trials. Circulation 2011;123(24):2799-810. analysis of individual patient data. Lancet 2014;384(9943):591-8. 323 Arguedas Jose A, Leiva V, Wright James M. Blood pressure targets 310 Thomopoulos C, Parati G, Zanchetti A. Effect of blood pressure for hypertension in people with diabetes mellitus. Cochrane lowering on outcome incidence in hypertension. 1. Overview, Database of Systematic Reviews 2013, Issue 10. meta-analyses, and meta-regression analyses of randomised trials. J Hypertens 2014;32(12):2285-95. 324 Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, et al. Blood pressure in chronic kidney disease stage 5D-report 311 Thomopoulos C, Parati G, Zanchetti A. :Effect of blood pressure from a Kidney Disease: Improving Global Outcomes controversies lowering on outcome incidence in hypertension:3. Effects in conference. Kidney Int 2010;77(4):273-84. patients at different levels of cardiovascular risk - overview and meta-analyses of randomised trials. J Hypertens 2014;32(12):2305- 325 Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, 14. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial 312 Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood Hypertension of the European Society of Hypertension (ESH) pressure lowering in type 2 diabetes: a systematic review and and of the European Society of Cardiology (ESC). Eur Heart J meta-analysis. JAMA 2015;313(6):603-15. 2013;34(28):2159-219. 313 Blood Pressure Lowering Treatment Trialists Collaboration, 326 James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood C, Handler J, et al. 2014 evidence-based guideline for the pressure lowering and major cardiovascular events in people with management of high blood pressure in adults: report from the and without chronic kidney disease: meta-analysis of randomised panel members appointed to the Eighth Joint National Committee controlled trials. BMJ 2013;347:f5680. (JNC 8). JAMA 2014;311(5):507-20. 314 Chronic Kidney Disease Prognosis Consortium, Matsushita K, van 327 Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, der Velde M, Astor BC, Woodward M, Levey AS, et al. Association Blumenthal RS, et al. Treatment of Hypertension in Patients With of estimated glomerular filtration rate and albuminuria with all- Coronary Artery Disease: A Scientific Statement from the American cause and cardiovascular mortality in general population cohorts: Heart Association, American College of Cardiology, and American a collaborative meta-analysis. Lancet 2010;375(9731):2073-81. Society of Hypertension. J Am Coll Cardiol 2015;65(18):1998-2038. 315 van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, 328 Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Levey A, et al. Lower estimated glomerular filtration rate and higher Alderman MH, et al. Health Outcomes Associated With Various albuminuria are associated with all-cause and cardiovascular Antihypertensive Therapies Used as First-Line Agents: a network mortality. A collaborative meta-analysis of high-risk population meta-analysis. JAMA 2003;289(19):2534-44. cohorts. Kidney Int 2011;79(12):1341-52. 329 Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood 316 Heerspink HJL, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee pressure reduction: a quantitative overview updated until 1 March DE, Jardine MJ, et al. Effect of lowering blood pressure on 2003. J Hypertens 2003;21(6):1055-76. cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled 330 Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, trials. Lancet 2009;373(9668):1009-15. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus 317 Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu atenolol adding bendroflumethiazide as required, in the Anglo- D, et al. Treatment of hypertension in patients 80 years of age or Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm older. N Engl J Med 2008;358(18):1887-98. (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906. 318 Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering 331 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative regimens on major cardiovascular events: results of Research Group. Major Outcomes in High-Risk Hypertensive prospectively-designed overviews of randomised trials. Lancet Patients Randomized to Angiotensin-Converting Enzyme Inhibitor 2003;362(9395):1527-35. or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 319 Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of JAMA 2002;288(23):2981-97. intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 332 Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith 2016;387(10017):435-43. G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews 2011, Issue 1. | 109 Risk estimation and the prevention of cardiovascular disease 333 Mortality rates after 10.5 years for participants in the Multiple Risk 346 Department of Health. Treatment choice in psychological Factor Intervention Trial. Findings related to a priori hypotheses of therapies and counselling: evidence based clinical practice the trial. The Multiple Risk Factor Intervention Trial Research Group. guideline. London: Department of Health; 2001. [cited 16 May JAMA 1990;263(13):1795-801. 2017]. Available from url: http://webarchive.nationalarchives.gov. uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/ 334 Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarinen VA, Sarna groups/dh_digitalassets/@dh/@en/documents/digitalasset/ SJ, Miettinen TA. Mortality in participants and non-participants dh_4058245.pdf of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study. Heart 347 Scottish Intercollegiate Guidelines Network (SIGN). Non- 1995;74(4):449-54. pharmaceutical management of depression in adults. Edinburgh: SIGN; 2010. (114). [cited 16 May 2017]. Available from url: http:// 335 Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM, www.sign.ac.uk/sign-114-non-pharmaceutical-management-of- et al. “Stress” and coronary heart disease: psychosocial risk factors. depression.html Med J Aust 2003;178(6):272-6. 348 Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, et al. 336 Kuper H, Marmot M, Hemingway H. Systematic Review of A systematic review of controlled trials of the effectiveness and Prospective Cohort Studies of Psychosocial Factors in the Etiology cost-effectiveness of brief psychological treatments for depression. and Prognosis of Coronary Heart Disease. Semin Vasc Med Health Technol Assess 2001;5(35):1-173. 2002;2(3):267-314. 349 Cuijpers P, van Straten A, Smit F. Psychological treatment of late-life 337 Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, depression: a meta-analysis of randomized controlled trials. Int J Burg MM, et al. Depression and Late Mortality After Myocardial Geriatr Psychiatry 2006;21(12):1139-49. Infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) Study. Psychosom Med 2004;66(4):466-74. 350 Hensley PL, Nadiga D, Uhlenhuth EH. Long-term effectiveness of cognitive therapy in major depressive disorder. Depress Anxiety 338 Batelaan NM, Seldenrijk A, Bot M, van Balkom AJLM, Penninx BWJH. 2004;20(1):1-7. Anxiety and new onset of cardiovascular disease: critical review and meta-analysis. Br J Psychiatry 2016;208(3):223-31. 351 Leichsenring F. Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: a 339 Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? meta-analytic approach. Clin Psychol Rev 2001;21(3):401-19. A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in 352 Mackin RS, Arean PA. Evidence-based psychotherapeutic coronary heart disease. J Psychosom Res 2014;77(6):439-48. interventions for geriatric depression. Psychiatr Clin North Am 2005;28(4):805-20. 340 Backe EM, Seidler A, Latza U, Rossnagel K, Schumann B. The role of psychosocial stress at work for the development of cardiovascular 353 Pinquart M, Duberstein PR, Lyness JM. Treatments for later- diseases: A systematic review. Int Arch Occup Environ Health life depressive conditions: a meta-analytic comparison of 2012;85(1):67-79. pharmacotherapy and psychotherapy. Am J Psychiatry 2006;163(9):1493-501. 341 Kivimaki M, Nyberg ST, Batty GD, Fransson EI, Heikkila K, Alfredsson L, et al. Job strain as a risk factor for coronary heart disease: a 354 National Institute of Health and Care Excellence. Generalised collaborative meta-analysis of individual participant data. Lancet anxiety disorder and panic disorder in adults: management. 2012;380(9852):1491-7. London: NICE 2011. (CG113). [cited 16 May 2017]. Available from url: https://www.nice.org.uk/guidance/cg113 342 Rosengren A, Hawken S, Ôunpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute 355 Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, et al. myocardial infarction in 11 119 cases and 13 648 controls from Psychological interventions for coronary heart disease. Cochrane 52 countries (the INTERHEART study): case-control study. Lancet Database of Systematic Reviews 2011, Issue 8. 2004;364(9438):953-62. 356 Reid J, Ski CF, Thompson DR. Psychological interventions for 343 National Institute of Health and Care Excellence. Depression in patients with coronary heart disease and their partners: a adults: recognition and management. London: NICE 2009. (CG90). systematic review. PLoS One 2013;8(9):e73459. [cited 16 May 2017]. Available from url: https://www.nice.org.uk/ guidance/cg90 357 Dickinson HO, Campbell F, Beyer FR, Nicolson DJ, Cook JV, Ford GA, et al. Relaxation therapies for the management of primary 344 National Institute of Health and Care Excellence. Depression in hypertension in adults. Cochrane Database of Systematic Reviews adults with a chronic physical health problem: recognition and 2008, Issue 1. management. London: NICE 2009. (CG91). [cited 16 May 2017]. Available from url: https://www.nice.org.uk/guidance/cg91 358 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery 345 The Scottish Government, NHS Education for Scotland. The Matrix disease. Cochrane Database of Systematic Reviews 2011, Issue 9. (2015) A Guide to Delivering Evidence-Based Psychological Therapies in Scotland. [cited 16 May 2017]. Available from url: 359 Mazza M, Lotrionte M, Biondi-Zoccai G, Abbate A, Sheiban I, http://www.nes.scot.nhs.uk/education-and-training/by-discipline/ Romagnoli E. Selective serotonin reuptake inhibitors provide psychology/the-matrix-(2015)-a-guide-to-delivering-evidence- significant lower re-hospitalization rates in patients recovering based-psychological-therapies-in-scotland/the-matrix-(2015)-a- from acute coronary syndromes: evidence from a meta-analysis. guide-to-delivering-evidence-based-psychological-therapies-in- J Psychopharmacol 2010;24(12):1785-92. scotland.aspx 360 Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 2011;107(7):972-9. 110 | References 361 Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015;350:h949. 362 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380(9836):37-43. | 111 ISBN 978 1 909103 52 8 www.sign.ac.uk www.healthcareimprovementscotland.org Edinburgh Office | Gyle Square |1 South Gyle Crescent | Edinburgh | EH12 9EB Telephone 0131 623 4300 Fax 0131 623 4299 Glasgow Office | Delta House | 50 West Nile Street | Glasgow | G1 2NP Telephone 0141 225 6999 Fax 0141 248 3776 The Healthcare Environment Inspectorate, the Scottish Health Council, the Scottish Health Technologies Group, the Scottish Intercollegiate Guidelines Network (SIGN) and the Scottish Medicines Consortium are key components of our organisation.